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GM1 – monosialoganglioside GM1 (Cer-Glc-Gal(NeuAc)-GalNAc-Gal)  
GM2 – monosialoganglioside GM2 (Cer-Glc-Gal(NeuAc)-GalNAc)  
GM3 - monosialoganglioside GM3 (Cer-Glc-Gal-NeuAc) 
Glc - glucose  
GQ1b – tetrasialoganglioside GQ1b (Cer-Glc-Gal(NeuAc-NeuAc)-GalNAc-Gal-NeuAc-NeuAc) 17 
GSC – ganglioside complex 
GSL – glycosphingolipid 
GT1a - trisialoganglioside GT1a (Cer-Glc-Gal(NeuAc)-GalNAc-Gal-NeuAc-NeuAc) 
GT1b – trisialoganglioside GT1b (Cer-Glc-Gal(NeuAc-NeuAc)-GalNAc-Gal-NeuAc) 
h – hour(s) 
HAT - hypoxanthine-aminopterin-thymidine selection medium 
HGPRT
-/- - hypoxanthine-guanine phosphoribosyltransferase deficient  
HP-TLC – high performance thin layer chromatography 
HRP - horse radish peroxidase 
HT - hypoxanthine-thymidine medium 
Ig - immunoglobulin  
ip - intraperitoneally  
iv – intravenously  
LM1 - sialosyl-neolactotetraosylceramide 
mAb - monoclonal antibody  
MAC - membrane attack complex 
min - minutes 
nAChR - nicotinic acetylcholine receptor 
NeuAc – sialic acid / N-acetylneuraminic acid  
NFL – neurofilament light  
NFL-Tg - GalNAcT GalNAcT 
-/- transgenic (Tg(Nfl-GalNAcT)GalNAcT
-/-)  
NHS - normal human serum 
NMJ – neuromuscular junction 
OD – optical density 
OPD - o-Phenylenediamine dihydrochloride 
PBS - phosphate buffered saline  
PEG - polyethylene glycol  
PS – phosphatidylserine 
pSC - peri-synaptic Schwann cell 
PVDF - polyvinylidene difluoride  
RPMI - Roswell Park Memorial Institute (tissue culture medium) 
SGPG – sulfated glucuronyl paragloboside 
Siglec – sialic acid binding, immunoglobulin like lectin 
TLC - thin layer chromatography  
TRITC - Tetramethyl Rhodamine Isothiocyanate 
TV - tidal volume  
WT - wild type 
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Short summary 
There is plentiful evidence that the pathology of Guillain Barré syndrome (GBS) 
is driven by autoantibodies generated following infection. A number of 
inconsistencies with this theory remain, and in many clinical cases such 
antibodies are not detected. Recent descriptions of ganglioside complex (GSC) 
antibodies suggest a potential explanation for this. This study aimed to further 
investigate GSCs and associated antibodies with a particular focus on GBS. GSCs 
were found to modulate the binding of other lectins such as bacterial toxins, 
immunomodulatory receptors, and monoclonal antibodies. The development of a 
semi-automated array system allowed screening of a large cohort of GBS sera 
against multiple complexes, revealing a greater antibody detection rate 
(particularly in demyelinating forms) than had previously been achieved. Binding 
that was both enhanced and attenuated by complexes was seen, and this varied 
between disease and control sera. Immunisation experiments provided insights 
into the generation of the GSC immune response. A transgenic mouse model of 
GBS was also developed, demonstrating that local axonal expression of 
gangliosides does not induce systemic tolerance. 
The work described in this thesis has thus significantly advanced knowledge in 
the field of glycolipid complexes, particularly with respect to anti-glycolipid 
complex antibodies and their association with inflammatory neuropathies such as 
Guillain-Barré syndrome. 19 
Summary 
Guillain Barré syndrome (GBS) is an acute, acquired peripheral neuropathy 
characterised clinically by ascending weakness and loss of the deep tendon 
reflexes. Since the index case description, various theories regarding its 
pathogenesis have been proposed. Following the first detection in affected 
patients’ sera of antibodies directed against glycolipids, evidence has 
accumulated to suggest that such antibodies arise via a process of molecular 
mimicry following infection, resulting in complement mediated failure of 
neuromuscular transmission and structural nerve damage. However, unresolved 
issues regarding this disease model remain. Anti-GQ1b ganglioside antibodies are 
found in 90-95% of patients with the regional Miller Fisher variant of GBS, and 
the majority of patients with axonal variants are positive for anti-GM1, GD1a or 
related antibodies. However, in the more common demyelinating form of the 
disease (Acute Inflammatory Demyelinating Polyneuropathy, AIDP) no specific 
antibody has been identified. Where antibodies are found, their predilection for 
particular nerves types is unexplained. For example, GD1a antibodies are 
associated with a motor phenotype, yet GD1a is present in roughly equal 
proportions in motor and sensory nerves. There are also unexplained 
discrepancies in the apparent pathogenic potential of different anti-GM1 
antibodies. Furthermore, following infections associated with GBS, the 
mechanism by which self tolerance is overcome in a small proportion of patients, 
but is preserved in the vast majority of others, is unknown.  
It is on this background that the detection of anti-ganglioside complex (GSC) 
antibodies by Japanese researchers proved particularly intriguing. These 
antibodies react with pairs of gangliosides, whilst failing to bind to each 20 
individually. It may be, therefore, that investigators have previously failed to 
identify GBS associated antibodies because the focus has been in assessing 
binding to purified, homogenous preparations of glycolipids in vitro, rather than 
considering the antigenic diversity potentially produced by glycolipid-glycolipid 
inter-combinations occurring in vivo. It can also be envisaged that if GSCs form 
differently on motor and sensory nerves, or fail to form in sites where 
immunological tolerance is generated, then this initial observation may be able 
to be expanded upon to answer some of the additional questions posed above.  
The overall aim of the research described herein was therefore to further 
investigate GSCs with a particular focus on assessing the characteristics of anti-
GSC antibodies associated with GBS.  
Initially existing ganglioside ELISA methodology was expanded to include the 
combinatorial element. This revealed that anti-ganglioside monoclonal 
antibodies (mAbs) frequently demonstrated complex modulated binding. Even 
when an antibody had been generated with specificity against a single, defined, 
ganglioside, cross reactivity was seen towards other complexes. In addition to 
the complex enhanced binding previously described, certain mAbs behaved in a 
different way. These ‘complex attenuated’ antibodies bound well to single 
gangliosides, but were prevented from doing so when certain complex partners 
were additionally present. The most notable example seen was with the anti-
GM1 antibodies DG1 and DG2. DG1 binding is complex attenuated, whereas DG2 
remains able to bind the GM1:GD1a complex. This correlates with the 
pathogenic potential or otherwise of these two antibodies  
The major methodological advance detailed in the thesis is the development of 
the combinatorial glycoarray. The glycoarray allowed screening of numerous 21 
lectins against a large number of different glycolipids and complexes. This 
showed that other lectins, such as bacterial toxins and siglecs (sialic acid binding 
immunoglobulin like lectins), additionally display complex modulated binding. 
The combinatorial glycoarray was then used to look for anti-complex antibodies 
in a large cohort of Western European GBS patients, largely made up of the AIDP 
variant. The application of the array technology increased the antibody 
detection rate in confirmed AIDP cases from 14.3% by ELISA to 62.5% by 
glycoarray. Complex specific antibodies were found in 43.6% of disease 
associated sera, and only 4.1% of controls. When single glycolipid reactive 
antibodies were detected in disease and control sera, they often showed 
divergent patterns of binding with respect to complex enhancement or 
attenuation. Nine antigens showed statistically increased binding in GBS versus 
controls. Particular antibodies were associated with particular clinical features, 
including disease severity and the requirement for mechanical ventilation.  
Immunisation experiments provided important insights into the generation of the 
anti-ganglioside and GSC immune response. This was further investigated using 
newly developed transgenic mice with axonal specific rescue of complex 
ganglioside synthesis. These studies demonstrated that restricted axonal 
ganglioside expression does not generate systemic tolerance, and allowed the 
development of a single animal, mouse model of GBS. 
The work described in this thesis has thus significantly advanced knowledge in 
the field of glycolipid complexes, particularly with respect to anti-glycolipid 
complex antibodies and their association with inflammatory neuropathies such as 
Guillain-Barré syndrome.  22 
1  Introduction 
The overall aim of this study is to evaluate ganglioside complexes (GSC) and GSC 
antibodies with particular focus on their potential role in Guillain-Barré 
syndrome. A more detailed description of these aims is given in section 1.3 
below. This introduction sets this current research in context and is not intended 
to be an all encompassing review of the vast amount of work already performed 
in the wider field. 
1.1  Guillain-Barré syndrome – an acute inflammatory 
disorder of the peripheral nervous system 
1.1.1 Overview 
Guillain-Barré-syndrome (GBS) is a post infectious, monophasic, acute 
inflammatory neuropathy. It was first described by Guillain, Barré and Strohl in 
1916, having been observed in two infantrymen (Guillain et al., 1916). The 
syndrome is characterised by a symmetrical ascending weakness, loss of the 
deep tendon reflexes, and ‘albuminocytological dissociation’ (raised protein with 
normal cell count) on analysis of the cerebrospinal fluid (CSF) (Asbury, 1990). 
Epidemiological studies give an average annual incidence for the disease of 0.4 
to 4.0 per 100,000. The lifetime incidence is around 1 in 1000 (Alter, 1990). 
Diagnosis is largely based on clinical history and physical examination, supported 
by CSF analysis (where appropriate) and neurophysiological assessment (Asbury 
& Cornblath, 1990). Supportive treatment is of paramount importance, and the 
disease course can be positively influenced by immunomodulatory therapy with 
intravenous immunoglobulin, plasmapheresis, or both (Raphael et al., Chapter 1  Introduction     23 
2002;Hughes et al., 2007).  Most patients will make a good recovery, but will 
often require prolonged periods in hospital, and some weeks to months in 
intensive care. Most patients have long term persistent health problems (Bernsen 
et al., 1997;Dornonville & Jakobsen, 2005), and historically 5-15% of patients 
died in the acute phase of the disease. Contemporary studies in countries with 
advanced critical care facilities suggest the mortality rate has fallen to around 
2.5% (Alshekhlee et al., 2008). 
The current, widely accepted, pathological model for the disease is that auto-
reactive antibodies arise following infection, by a process of molecular mimicry, 
and drive complement mediated damage to peripheral nerves (Yuki et al., 
1990;Yuki, 2007a;Yuki & Kuwabara, 2007;Goodyear et al., 1999). There are 
however a number of inconsistencies with this theory, as later discussed.  
1.1.2 Historical aspects 
As noted, GBS takes its name from the 1916 study by Georges Guillain, Jean-
Alexandre Barré, and André Strohl. An earlier case series of ‘ascending paralysis’ 
had been described by Landry in 1859 (Landry, 1879). Landry’s 10 cases included 
a mixture of ascending paralysis with and without ascending sensory loss. CSF 
sampling was not performed, as the technique had not yet been developed. The 
location of the pathology was not identified at autopsy in the three patients that 
died, as the peripheral nerves were not examined.  
Guillain, Barré and Strohl’s paper had the advantage of coming after the 
development of lumbar puncture by Quincke and Wynter in 1891, included a 
relatively accurate speculation on the site of the pathology, and a succinct 
description of the key clinical features; Chapter 1  Introduction     24 
"The syndrome is characterised by motor disorders, abolition of the 
tendon reflexes with preservation of the cutaneous reflexes, 
paraesthesias with slight disturbance of objective sensation, pain on 
pressure of the muscle masses, marked modifications in the electrical 
reactions of the nerves and muscles, and remarkable hyperalbuminosis 
of the cerebrospinal fluid with absence of cytological reaction 
(albuminocytological dissociation).This syndrome seemed to us to 
depend on a concomitant injury of the spinal roots, the nerves, and 
the muscles, probably of infectious or toxic nature." 
There then followed a long lasting debate about the exact nature and boundaries 
of the disorder. Guillain in particular resisted suggestions that GBS was similar to 
Landry’s ascending paralysis, citing the respiratory failure occasionally seen in 
the latter, along with the absence of CSF analysis and suggested that the 
pathology in Landry’s cases was instead bulbar (Guillain, 1936). Three years 
after Guillain, Barré and Strohl’s paper, Bradford, Bashford and Wilson described 
30 further cases under the heading ‘Acute Infective Polyneuritis’ and briefly 
claimed to have indentified an infective pathogen. (Bradford et al., 1919) 
Thereafter, there was a tendency to label any acute lower motor neuron 
paralytic illness GBS or acute infective polyneuritis with the terms seemingly 
being used interchangeably. There was additionally frequent speculation of an 
infective or toxic mechanism.  
In 1949 an attempt was made to define the disease not in terms of the presence 
or absence of specific clinical features, but by the underlying pathological 
process (Haymaker & Kernohan, 1949). Haymaker and Kernohan preformed 
autopsy studies on 50 cases of ‘Landry-Guillain-Barré syndrome,’ some of whom 
had died shortly after the onset of their illness. By comparing tissue obtained at 
different stages of the disease process they hoped to be able to reconstruct the 
temporal sequence of events. Two principle findings were highlighted by the 
authors. The first was that presentations which would previously have been 
variously termed Landry’s ascending paralysis, GBS, or acute (infective) Chapter 1  Introduction     25 
polyneuritis all shared pathological features, and were therefore best considered 
as one disorder. The second was that the initial pathological change was swelling 
of peripheral nerve myelin, before later infiltration of inflammatory cells. The 
authors concluded that neurological dysfunction occurred before lymphocytes 
and macrophages appeared, and speculated that the cells might instead be 
involved in the reparative process. This led others to begin to search for a 
humoral factor in blood or CSF which might be the key pathogenic agent. 
In 1955, rabbits injected with an homogenised preparation of sciatic nerve 
and/or spinal roots and ganglia were observed to develop a flaccid paralysis 
after a two week interval (Waksman & Adams, 1955). Lymphocytic infiltration 
and myelin degradation of the nerve roots, spinal ganglia, and peripheral nerves 
was noted, along with an increase in the total protein content of the spinal fluid 
while cell counts remained normal. This disease model was termed experimental 
allergic neuritis (EAN), and the many similarities to GBS were discussed. 
Refinements to the technique revealed that EAN could be induced by 
immunisation with specific myelin proteins, and that disease activity could be 
transferred along with myelin protein autoreactive T cells (Rostami et al., 
1985;Heininger et al., 1986). Research was therefore focussed along such lines, 
notwithstanding the observations that antibodies to the immunogen were also 
induced and that transfer of such humoral factors also exacerbated disease 
(Archelos et al., 1993;Hahn et al., 1993). 
In the 1980s it was established that in paraproteinaemic neuropathy the protein 
band detected was often autoreactive against myelin associated glycoprotein 
(MAG) or nerve associated glycolipids (Braun et al., 1982). This, coupled with 
the observation that plasma exchange was effective in GBS, reignited interest in Chapter 1  Introduction     26 
circulating, humoral components of the immune system in the disease (Gruener 
et al., 1987;Zerbi et al., 1981;The Guillain-Barré Syndrome Study Group, 
1985;Willison & Yuki, 2002). In 1988, antibodies to gangliosides and related 
glycolipids were first detected in 5 patients with GBS (Ilyas et al., 1988). The 
disease associations, induction and pathogenic effects of anti-ganglioside 
antibodies in GBS have been extensively studied in the intervening period, as 
discussed below (1.1.7). 
1.1.3 Epidemiology 
The incidence of GBS is estimated to be between 0.4 and 4.0 cases per 100,000 
people per year (Alter, 1990;Hughes & Rees, 1997). In Western Europe  the exact 
figure is likely to be around 1.3 to 1.8/100,000 per year (Rees et al., 1998). 
Almost all series show an excess of male over female cases, unusual for a 
presumed autoimmune disease. The annual incidence increases with increasing 
age – from 0.8/100,000 in people less than 18, to 3.2/100,000 in those over 60 in 
one study (Beghi et al., 1985). As this study also highlighted, in GBS, around 60-
70% of patients will have experienced an infection in the previous month. 
Respiratory and gastro-intestinal symptoms have been shown to be statistically 
more common in suffers in the month preceding onset of GBS. A more recent 
prospective case-control study has confirmed this association (Sinha et al., 
2007). In this Indian series, antecedent infection was reported by 49% of patients 
and 4% of controls, with positive serology in 50% and 8% respectively, both highly 
statistically significant differences. On serological testing, Campylobacter jejuni 
is the most frequently identified pathogen, although other infections are 
sometimes identified (Winer et al., 1988;Hadden et al., 2001;van Koningsveld et 
al., 2000). Cases generally have a uniform incidence throughout the year, save Chapter 1  Introduction     27 
for certain GBS variants in Northern China which display seasonal variation (see 
1.1.5 below for further details).  
1.1.4 Clinical features and diagnosis 
Guillain, Barré and Strohl’s 1916 description succinctly captures the key features 
of a typical GBS case. Following the possible link between an increase in GBS 
cases and the 1976/1977 swine flu vaccine, formal diagnostic criteria were 
devised at the behest of the then National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS) (Asbury, 1978). These were 
essentially reaffirmed in 1990, with further refinement of the electrodiagnostic 
criteria (Asbury & Cornblath, 1990). Two features are required for the diagnosis, 
namely progressive motor weakness of more than one limb and areflexia. The 
former ranges from mild weakness of the legs to total paralysis of all 4 limbs, 
and of the facial, bulbar, and respiratory muscles with complete external 
ophthalmoplegia. The areflexia is usually absolute but suppression without total 
absence of proximal reflexes is stated as acceptable if other features are in 
keeping. By definition, the weakness progresses over a maximum of 4 weeks, 
whereas recovery almost always occurs over a much longer period. In around a 
quarter of those affected, involvement of the respiratory muscles leads to the 
requirement for mechanical ventilation on the intensive care unit. Between 4% 
and 15% of patients die, although this may be improving, and up to 20% have not 
fully recovered after 1 year and may never do so (Rees et al., 1998;Hughes et 
al., 2005;Alshekhlee et al., 2008). Clearly, this represents a significant burden 
on both the acute medical and rehabilitation services. Chapter 1  Introduction     28 
Complementary to the core criteria, further features in keeping with the 
diagnosis are provided, in addition to features casting doubt and features 
excluding the diagnosis. These are summarised below (Figure 1.1, Figure 1.2 and 
Figure 1.3). 
 
Figure 1.1 - Features supportive of the diagnosis of GBS 
From Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré 
syndrome. Ann Neurol 1990; 27 (suppl): S21–24. 
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Figure 1.2 - Features casting doubt on the diagnosis of GBS 
From Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré 
syndrome. Ann Neurol 1990; 27 (suppl): S21–24. 
 
Figure 1.3 - Features that rule out the diagnosis of GBS 
From Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré 
syndrome. Ann Neurol 1990; 27 (suppl): S21–24. 
Although the above clinical criteria are widely accepted, the electrodiagnostic 
parameters are more problematic. There are a number of reasons for this. As 
noted above, such studies may remain normal for several weeks following the 
onset of disease.  Furthermore, later in the disease course axonal degeneration 
can complicate an initial demyelinating process, thus altering the 
electrophysiological abnormalities seen. The description of axonal variants of 
GBS in the early to mid-1990s (Acute Motor Axonal Neuropathy, AMAN, and Acute 
Motor-Sensory Axonal Neuropathy, AMSAN) (McKhann et al., 1993), with an Chapter 1  Introduction     30 
entirely separate set of nerve conduction study changes, additionally compounds 
the situation. Essentially, nerve conduction studies can be used to confirm that 
the disease process is due to a peripheral neuropathy and additionally categorise 
this into demyelinating or axonal subtypes. More recent revisions to the 
diagnostic criteria in general, taking into account these variants, have been 
proposed (van der Meche et al., 2001). 
1.1.5 Disease subtypes and variants 
Both axonal and regional variants of GBS exist. The most well known regional 
variant is Miller Fisher syndrome (MFS). First reported in 1956, the striking 
clinical features are ophthalmoplegia, ataxia, and areflexia (Fisher, 1956). 
Formes fruste, with isolated ataxia or ophthalmoplegia, are additionally 
recognised.  The Pharyngeal-Cervical-Brachial (PCB) subtype predominantly 
involves the oropharyngeal, neck and shoulder muscles with facial palsy and 
ptosis but with much less pronounced (or entirely absent) lower limb weakness. 
Likewise, although areflexia is seen in the upper limbs the lower limb reflexes 
may be preserved. Sensory impairment is uncommon. Initially this syndrome was 
speculated to be a GBS variant on the basis of the presence of 
albuminocytological dissociation in the CSF along with electrophysiological 
changes in keeping with the diagnosis and a typical disease course (Ropper, 
1986). More recently, larger case series have further supported the suspicion 
that PCB is part of a spectrum of GBS with clinical features overlapping with all 
of MFS, typical GBS and Bickerstaff’s Brainstem Encephalitis (BBE). BBE itself 
was initially speculated to be similar to ‘infective polyneuritis’ in the 
Birmingham Neurologist’s 1957 paper (Bickerstaff, 1957). This was due to; Chapter 1  Introduction     31 
“the mode of onset and progression, the stationary state at maximal 
disability, and the rapid recovery of gross paralysis with slower final 
extinction of all abnormality. Indeed, several patients had lost all 
tendon reflexes even at a time when neither hypotonia nor paralysis 
of the limbs was marked.” 
Again, further, larger case series in recent years support the concept the BBE 
also lies at one end of a spectrum of GBS and, in particular, MFS, given the 
prominent ophthalmoplegia and ataxia in addition to disturbances of 
consciousness (Ito et al., 2008). 
Historically, the eponym GBS was held widely to be synonymous with the more 
pathologically descriptive term Acute Inflammatory Demyelinating 
Polyradiculoneuropathy (AIDP). However, from the early 1990s onwards, it has 
been increasingly recognised that there are subtypes of the disease which 
appear clinically similar but have a different underlying epidemiology, 
pathology, and presumably aetiology. In a study of patients in China, who mainly 
came form the rural north, it was shown that a syndrome previously diagnosed 
clinically as GBS had a number of unusual features (McKhann et al., 1993). For 
example, seasonal peaks of acute paralysis were observed and the average age 
of patients was 19 years, younger than for AIDP. Furthermore, the progression of 
weakness was somewhat more rapid than for ‘classical’ GBS, with a nadir being 
reached in just under 6 days on average. Bulbar muscles were more commonly 
involved and sensory symptoms rare. However, it was the electrophysiological 
findings and pathology which really set this disease apart as a distinct subtype. 
Nerve conduction studies demonstrated reduced amplitude of action potentials, 
consistent with axonal injury. Pathological studies confirmed the presence of 
motor axonal damage (Figure 1.4) and Wallerian degeneration, and this disease 
was termed Acute Motor Axonal Neuropathy (AMAN), and proposed to be a 
variant of GBS (McKhann et al., 1993). Soon after, another axonal variant, Acute Chapter 1  Introduction     32 
Motor and Sensory Axonal Neuropathy (AMSAN), was described (Griffin et al., 
1996). 
 
Figure 1.4 - Pathological differences between AIDP and AMAN 
Electron micrographs from AIDP (left panel, taken from (Hughes & Cornblath, 2005)) and AMAN 
(right two panels, taken from (Griffin et al., 1996)) are compared. In the former, a macrophage (M) 
can be seen invading the Schwann cell and has stripped myelin from around some of the axons 
(arrows). In contrast, in the AMAN specimens in the right-hand panels, macrophages within an 
intact myelin sheath can be seen to surround the axon (upper panel) and cause axonal granular 
degeneration (lower panel).  
1.1.6 Current treatments 
The only treatment shown to be beneficial as compared to supportive treatment 
alone in GBS is plasma exchange (Zerbi et al., 1981;The Guillain-Barre Syndrome 
Study Group, 1985;McKhann, 1990;Gruener et al., 1987). This technique is 
expensive, requires specialist machinery and intra-venous access, and is only 
partially effective. With treatment, the proportion of patients requiring Chapter 1  Introduction     33 
mechanical ventilation is nearly halved (but still remains at around 14%), 
whereas the percentage who have regained full muscle strength by one year is 
only improved from 55% to 68% (Raphael et al., 2002). Intravenous 
immunoglobulin has been compared to plasma exchange, and found to be 
equivalent (van der Meche & Schmitz, 1992;Hughes et al., 2004). Perhaps 
surprisingly, the effect of corticosteroids in the inflammatory neuropathies is 
variable; deleterious in multifocal motor neuropathy (MMN) (Slee et al., 2007), 
harmful (oral) or equivalent to placebo (intravenous) in GBS (Hughes et al., 
2007), and sometimes beneficial in Chronic Inflammatory Demyelinating 
Polyneuropathy (CIDP) (Toothaker & Brannagan, III, 2007). It is therefore 
hypothesised that steroids might in some cases interfere with the scavenging of 
nerve debris following injury, and hence delay regeneration and recovery, or in 
some other way adversely affect nerve conduction (Hughes et al., 2004;Hughes 
et al., 2006). A range of other immunosuppressants have been investigated in 
the treatment of the GBS and related neuropathies, ranging from long 
established drugs such as azathioprine, methotrexate and ciclosporin, to more 
recently developed monoclonal antibodies such as rituximab and alemtuzumab 
(which deplete B and T lymphocytes respectively). Despite a theoretical basis for 
efficacy, and in some cases supportive data from animal models such as EAN 
(experimental autoimmune neuritis), these approaches lack convincing evidence 
of benefit in humans (zu Horste et al., 2007). 
1.1.7 Pathophysiology 
Pathological studies in GBS typically show an inflammatory, cellular infiltrate 
with macrophages damaging myelin or axons as pictured above (Figure 1.4). It 
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activated T-cells, based on studies of EAN. However, some pathological studies 
demonstrated myelin swelling apparently preceding cellular infiltration 
(Haymaker & Kernohan, 1949). Furthermore, immunological studies showed that 
antibodies directed against gangliosides and related molecules were found in the 
sera of patients with GBS (Ilyas et al., 1988). Both of these studies therefore 
suggest that autoreactive antibodies might first attach to myelin or axolemmal 
antigens, fix complement, and secondarily attract a cellular infiltrate.  
1.1.7.1  Gangliosides and molecular mimicry 
Gangliosides themselves were originally described by Klenk in 1935, who isolated 
what he initially termed ‘substance x’ from the spleens of patients with 
Niemann-Pick and Tay Sachs diseases (Klenk , 1935). He later established that 
this substance was much more enriched in the nervous system, and as the nature 
of this substance was further unravelled the term ganglioside was coined. It is 
now known that gangliosides are membrane incorporated glycosphingolipids 
(GSLs). They are amphipathic molecules, with a long, hydrophobic, lipid tail 
(ceramide) and a much more variable, hydrophilic, charged, sialic-acid-
containing, oligosaccharide head group (Sonnino et al., 2007). It is this 
oligosaccharide head group which gives gangliosides their variability (Figure 1.5) 
and which acts as a target for anti-ganglioside antibodies.  
The widely accepted, abbreviated, ganglioside nomenclature and classification 
was first proposed by Svennerholm, based on the migration pattern of the 
different subtypes on TLC. The initial capital letter (M, D, T, Q) refers to the 
number of sialic acid molecules present (1, 2, 3, 4). The number gives the 
oligosaccharide chain length (1=4, 2=3, 3=2, 4=1). The final lowercase letter (a, Chapter 1  Introduction     35 
b, c) denotes the different isometric arrangements of sialic acid possible. 
(IUPAC-IUB Commission on Biochemical Nomenclature, 1978) 
 
Figure 1.5 - The biosynthetic pathway and structure of gangliosides 
The gangliosides are synthesised by sequential addition of monosaccharide groups and sialic acid 
onto the ceramide tail, producing a large variety of different headgroups, as shown. The first step is 
the addition of glucose, which occurs in the endoplasmic reticulum and is driven by 
glucosylcermaide synthase (GCS). N-acetylgalactosaminyl-transferase knockout (GalNAcT-/-) mice 
lack the GalNAc-transferase (GM2 synthase) enzyme, and hence do not express and are intolerant 
of all gangliosides right of the double vertical line. GD3-/- mice lack the GD3 synthase enzyme, and 
do not express b-series gangliosides (those below the double horizontal line in the above diagram). 
Both of these mutants have previously been used by the Willison group to generate anti-
ganglioside monoclonal antibodies. The box encloses those gangliosides most enriched in the 
nervous system. 
In keeping with the suggestion that prior infection and molecular mimicry is a 
key pathogenic event in GBS, a number of micro-organisms, including C.jejuni, 
have been shown to express ganglioside-like epitopes on their cell surface 
(Aspinall et al., 1994). In addition, extracts of this lipopolysaccharide (LPS) have 
been shown to induce anti-ganglioside antibody production in immunisation 
studies (Goodyear et al., 1999). Evidence supporting the concept that the 
immune response directed against bacterial oligosaccharides can cross react 
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with Campylobacter jejuni infection. Contemporary studies have led some to 
brand this disease induction pathway a ‘true case of molecular mimicry’ (Yuki, 
2007b). By knocking out the waaF gene from C.jejuni, resulting in the 
production of truncated cell surface lipo-oligosaccharide (LOS), Perera et al 
demonstrated that these ganglioside mimicking molecules, and not other cell 
surface components (such as capsular polysaccharide or flagella), are required 
for the production of anti-ganglioside antibodies in the mouse (Perera et al., 
2007).  
Furthermore, analysis of LOS from strains isolated from GBS patients using a 
combination of mass spectrometry and genetic analysis showed that the majority 
bear ganglioside mimics (Godschalk et al., 2007a). However, 6/26 did not; 
whether this indicates that other mechanisms are involved, that antibodies 
directed against non-sialylated oligosaccharides (such as asialo-GM1) may 
sometimes cross react with their sialylated homologues, or merely that there 
was co-infection with two strains or a subsequent mutation in the bacterial 
genes governing LOS synthesis, remains to be seen.  
Strong evidence exists to demonstrate that variability in the activity of the 
C.jejuni sialyltransferase enzyme cstII directs development of the particular 
neuropathy subtype. CstII with α2,3- activity alone results in LOS with GM1 and 
GD1a like mimics, inducing the acute motor axonal neuropathy (AMAN) variant of 
GBS, whereas bifunctional α2,3- and α2,8- cstII activity generates disialosyl 
mimics and leads to Miller Fisher syndrome (MFS) (Figure 1.6) (Koga & Yuki, 
2007;Yuki, 2007a;Yuki & Kuwabara, 2007). Similarly, analysis of a strain of 
Haemophilus influenza from a patient with MFS revealed an homologous 
bifunctional sialyltransferase (Lic3B) producing a disialosyl group linked to the Chapter 1  Introduction     37 
terminal galactose of the LOS (Houliston et al., 2007a). One mechanism by 
which cross reactivity can occur between gangliosides which share such groups, 
such as bacterial GD1c and host GQ1b, GT1a and/or GD3, has been 
demonstrated by epitope mapping using saturation transfer difference NMR 
spectroscopy (Houliston et al., 2007b). For one monoclonal antibody (mAb), only 
a tightly confined area on the terminal sialic acid, common to all the above 
molecules, was required for binding.  
 
Figure 1.6 - Campylobacter jejuni sialyltransferase activity directs neuropathy subtype 
C.jejuni with the cstII allele Thr51 have α2,3 activity alone and produce GM1 and GD1a like LOS, 
resulting in AMAN via the induction of anti-GM1 and anti-GD1a antibodies. Those possessing the 
Asn51 allele have bifunctional enzyme activity. GT1a and GD1c LOS with terminal disialosyl 
groups induce anti-GQ1b, GD3 and GT1a antibodies. (Chen et al., 2009) = ganglioside mimicking 
structure of LOS. *presence of second glucose on core LOS structure is serotype dependent. 
(Diagram from Rinaldi and Willison, Anti-ganglioside Antibodies and Neuropathy, Current Opinion 
in Neurology, 2008) 
Despite these observations, the bacterial factors governing whether infection 
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(if they indeed exist). Taboada and colleagues analysed 1712 genes in 56 
neuropathogenic strains and 56 from cases of uncomplicated enteritis (Taboada 
et al., 2007). Despite the finding of differing absence rates for 6 genes, 4 
involved in LOS biosynthesis and sialylation, the neuropathogenic and enteritis 
groups were remarkably similar. In a PCR-restriction fragment length 
polymorphism approach, only one gene was found to be statistically associated 
with neuropathogenic strains, yet was also present in 39% of enteritis controls 
(Godschalk et al., 2007b), highlighting the crucial importance of other 
contributing factors. 
1.1.7.2  Host susceptibility factors 
As discussed, it can be seen that the genetic diversity of the infective organism 
does not seem to adequately explain why only a small proportion of infected 
individuals go on to develop neuropathy (Tam et al., 2007). Likewise, 
investigation of a number of factors which might explain this response, such as 
HLA associations, T-cell receptor, CD14 and Toll-like receptor 4 typing, has 
failed to reveal any consistent pattern (Geleijns et al., 2004;Ma et al., 1998). 
Particular polymorphisms in CD1 genes have been associated with an increase 
risk of developing GBS (Caporale et al., 2006). This study revealed that those 
with the CD1E*01/01 genotype are 2.5 times more likely to develop GBS, 
whereas those with CD1A*01/02 or CD1E*01/02 genotypes have a reduced risk. 
This makes some theoretical sense, as these molecules are thought to be 
involved in glycolipid antigen presentation to T cells, which could then induce a 
pro-inflammatory response or provide help to auto-reactive, anti-glycolipid B 
cells. (Caporale et al., 2006;De Libero et al., 2002;Shamshiev et al., 2000). Anti-
glycolipid antibody responses were previously felt to be T-cell independent, Chapter 1  Introduction     39 
however, and no such association has been found for chronic inflammatory 
demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy (MMN) (De 
Angelis et al., 2007), suggesting differences in the immune dysregulation 
distinguish acute versus chronic inflammatory neuropathies. Contrary to this, 
IgG1 and IgG3 are the predominant subclasses of GM1 and GQ1b antibodies found 
in MFS and AMAN. These subclasses are capable of complement fixation, and 
generally felt to be T-cell dependent and to arise following class switching from 
IgM (Willison & Veitch, 1994;Ogino et al., 1995). Furthermore, it has been shown 
that only CD1d molecules can bind bacterial LOS, yet CD1d knockout mice 
produced identical concentrations of each subclass of IgG anti-ganglioside 
antibody, as compared with their wild-type equivalents, suggesting T cell help is 
not required in this model (or occurs via another pathway) (Matsumoto et al., 
2008). Differing from the initial observation in GBS patients, a follow up study 
did not find differences in single nucleotide polymorphisms (SNPs) of CD1A and 
CD1E genes in GBS patients versus controls (Kuijf et al., 2008). The description 
of MFS and positive anti-GQ1b antibodies in a patient with advanced AIDS further 
highlights the uncertainty over the relative involvement and interactions of T 
and B-lymphocytes in the different inflammatory neuropathies, and the exact 
immunological pathways involved in these diseases have clearly not been fully 
characterised. (Hiraga et al., 2007) 
There is recent case report of severe GBS complicating Charcot-Marie-Tooth 
disease, and inherited motor and sensory neuropathy with numerous subtypes. In 
this instance the association was with type 1A (CMT1A) which is caused by a 
17p11.2-12 chromosomal duplication, resulting in an overproduction of PMP22 
protein, early excess myelin production and subsequent loss of myelinated 
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genes out with the immune system might also modulate the risk of developing 
inflammatory neuropathy (Munch et al., 2008). This genetic abnormality, along 
with the MPZ mutation which causes a different subtype of CMT also associated 
with co-existing inflammatory neuropathy (Ginsberg et al., 2004), affects myelin 
proteins. It is possible that the resultant deranged myelin production exposes 
otherwise sequestered antigen, be this protein or glycolipid, to immune 
surveillance and attack. As yet unrecognised variability in the way in which 
gangliosides are displayed on the surface of neuronal cells in patients without 
additional inherited neuropathies may similarly modify the risk of developing 
inflammatory neuropathy.  
Recent immunization experiments with GM1 ganglioside in rats, attempting to 
model motor axonal neuropathy, failed to produce any clinical disease or 
pathological nerve injury, despite inducing anti-GM1 IgM antibodies (Ilyas & 
Chen, 2007). In contrast, similar studies in rabbits did induce axonal GBS (Yuki, 
2007a). This might be explained by differences in the fine specificity, titre, 
class, affinity or pro-inflammatory characteristics of the antibodies, as discussed 
in the following section. Alternatively, species variability in the potency of local 
complement inhibitors, involvement of a concurrent process that affects blood 
nerve barrier permeability, or some other discrepancy in antigen accessibility, 
could be influential. 
1.1.7.3  The pathogenic potential of anti-ganglioside antibodies 
In the simplest model of neuronal injury by anti-ganglioside antibodies, 
antibodies bind to their target antigen, fix complement, and cause cell death via 
the formation of MAC (membrane attack complex) pores. However, several 
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some cases of AMAN, recovery of neurophysiological abnormalities occurs much 
more rapidly than could be explained by regenerating nerve fibres (Tamura et 
al., 2007). Likewise, pathological studies in affected subjects sometimes fail to 
demonstrate any evidence of nerve fibre degeneration (Buchwald et al., 2007). 
A recent small case series also showed a similar prompt recovery in patients with 
acute sensory ataxic neuropathy and anti-GD1b antibodies. Sensory nerve action 
potentials improved from undetectable to normal within 3 months, having shown 
initial signs of recovery as early as week one (Notturno et al., 2008).  
The Willison group has previously demonstrated that anti-GQ1b antibodies bind 
to motor nerve terminals in ex vivo preparations of mouse hemi-diaphragm, and 
subsequently activate complement. MAC pore formation leads to unregulated 
calcium influx, which induces massive acetylcholine release followed by 
neuromuscular transmission block (Halstead et al., 2004b;Plomp et al., 
1999;Roberts et al., 1994). This has been dubbed an α-latrotoxin like effect, in 
recognition of the similarity of this process to the paralytic pathology induced by 
the neurotoxin of the black widow spider (genus Latrodectus). A recent study of 
seven patients positive for anti-GQ1b antibody alone (but without limb 
weakness) found no evidence of endplate transmission block by single fibre 
electromyography of limb muscles (Kuwabara et al., 2007). This apparent 
difference might represent species-type or regional differences in the 
distribution of GQ1b or the effects of its antibody, but clearly it would be most 
informative to see whether neuromuscular conduction is impaired in muscles 
primarily affected in MFS. 
Returning to the rabbit model of AMAN, Susuki et al demonstrated absent F-
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deposition, suggesting a more proximal site of injury (Susuki et al., 2007). A 
progressive disruption of the nodal architecture was observed, with the clusters 
of voltage gated sodium channels being dispersed and disruption of cell adhesion 
molecules critical to the axoglial junction as the inflammatory lesion extended 
towards the juxtaparanodal region. These early changes demonstrate how nerve 
function can be impaired without axonal degeneration. They also suggest that 
multiple sites along the neural axis can be disturbed by anti-ganglioside 
antibodies (Figure 1.7), echoing the speculation in the seminal 1916 paper 
(Guillain et al., 1916). 
 
Figure 1.7 - Possible sites of action of anti-ganglioside antibodies 
[1] Brainstem. [2] Dorsal root ganglion. [3] Oculomotor nerve. [4] Node of Ranvier. [5] Spinal nerve 
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Recently, other investigators have assessed the effects of different anti-
ganglioside antibodies on neuromuscular transmission in the mouse hemi-
diaphragm. Anti-GM1 and anti-GD1a antibodies, associated with AMAN, were 
able to suppress pre-synaptic evoked quantal release in the absence of 
complement. This was correlated with the ability of the same antibodies to 
reduce calcium influx in a model of depolarization in neuronal cell cultures 
(Buchwald et al., 2007). Once again, these observations provide a mechanism by 
which a functional impairment in nerve activity can occur in the absence of 
structural damage. 
Interestingly, significant variability has been described in the ability of anti-
ganglioside antibodies to induce inflammation. In rabbits immunized with GM1 
from whom anti-GM1 antibodies were isolated, only the antibodies from subjects 
who developed paralysis were able to cause leukocyte degranulation and 
activate complement. This difference was independent of antibody titre, 
suggesting that this characteristic is essential to induce disease (van Sorge et 
al., 2007). Conversely, in the rabbit model of GD1b induced sensory ataxic 
neuropathy, apoptotic neurons were observed in the dorsal root ganglia without 
any cellular infiltration (Takada et al., 2008).  
It seems likely that the severity of injury induced by anti-ganglioside antibodies 
can vary from reversible functional impairment, through partial axonal injury, to 
complete axonal transection with subsequent Wallerian degeneration. The 
degree (and pattern) of damage sustained is presumably reflected in the 
variability of disease severity and in the tempo of the subsequent recovery. It 
has also been demonstrated that some anti-ganglioside antibodies can impair 
axonal regeneration (Lehmann et al., 2007). An anti-GD1a antibody caused Chapter 1  Introduction     44 
dystrophic nerve sprouting and appearances consistent with stalled growth 
cones. This effect was not observed in mice lacking longer chain gangliosides, 
and was at most partially dependent on complement. This suggests direct 
binding of the antibody to membrane associated gangliosides as the likely 
mechanism, and suggests one explanation for the poor prognosis associated with 
anti-GD1a antibodies.  
1.1.7.4  Clinical-serological associations 
As can be partly inferred from the prior introduction, the spectrum of antibodies 
associated with GBS has expanded since their initial detection. Furthermore, 
particular antibodies have been found to map onto specific disease subtypes 
(Table 1.1).  
Disease subtype  Antibodies 
AIDP  Unknown 
AMSAN  GM1, GM1b, GD1a 
AMAN  GM1, GM1b, GD1a, GalNAc-GD1a 
Acute sensory neuronopathy  GD1b 
Acute pandysautonomia  nAChR (nicotinic acetylcholine receptor) 
Regional variants   
MFS  GQ1b, GT1a 
Oropharyngeal  GT1a 
Overlap   
MFS/GBS overlap  GQ1b, GM1, GM1b, GD1a, GalNAc-GD1a 
Table 1.1 - Antibody-disease associations in GBS subtypes 
From (Hughes & Cornblath, 2005) 
It is in the MFS variant of GBS that the association with anti-ganglioside 
antibodies holds most strong. Over 90% of patients will have anti-GQ1b 
antibodies, which are absent from control groups (Yuki et al., 1993;Willison et 
al., 1993;Chiba et al., 1992). In the axonal subtypes between 30 and 70% of 
cases are positive for antibodies to a number of different gangliosides. However, 
the associations are not absolute. In AIDP, the most common subtype of GBS in 
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galactocerebroside, sulphated-glucuronyl-paragloboside, and LM1 are 
occasionally recognised as antigens (Willison & Yuki, 2002;Hughes & Cornblath, 
2005). Considerable effort continues to be focused on identifying other antibody 
markers directed towards myelin or Schwann cell membrane antigens (Willison & 
Yuki, 2002;Hughes & Cornblath, 2005). There is an expectation, based on 
epidemiological and treatment-related data, that such antibodies are present 
and are likely to be directed towards unknown membrane glycans. Other 
problems are unresolved: for example, it is not understood why the clinical 
phenotype associated with anti-GM1 antibodies can be purely motor, when GM1 
antigen is also present in sensory nerves; the implication being that GM1 is not 
always ‘visible’ to pathogenic autoantibodies. Likewise, although GQ1b is 
relatively enriched in the nerves affected in MFS, its distribution is much more 
widespread than might be suspected from the restricted clinical features usually 
seen (Svennerholm et al., 1994;Chiba et al., 1997). 
1.2 Ganglioside complexes 
It is in light of these unresolved issues in the pathogenesis of GBS that the 
description of ganglioside complexes (GSC) and related antibodies proves 
particularly intriguing. Previously, as discussed, research has focused on 
assessing purified, single glycosphingolipids as potential antigenic targets. These 
more recent observations cast doubt on the validity of this as the sole approach.  
The concepts that there may be some lateral order to glycolipid distribution in 
the living membrane, and that carbohydrate-carbohydrate interactions occur, 
are not new. Originally, however, the fluid mosaic hypothesis proposed that the 
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proteins were randomly distributed and free to move (Singer & Nicolson, 1972). 
Much evidence now exists to suggest that clusters of cholesterol and 
glycosphingolipids form, which act as platforms for proteins, and are involved in 
signal transduction (Simons & Ikonen, 1997). It was hypothesised previously that 
oligosaccharides from different glycans might form a ‘clustered saccharide 
patch’ which could act as a distinct epitope for lectin binding (Varki, 1994).  
Furthermore, the chemical structure of GSLs, containing hydroxyl and acetamide 
groups, allows these molecules to act as both hydrogen bond donors and 
acceptors, and is postulated as the explanation behind their ability to form 
clusters (Todeschini & Hakomori, 2008). Trans carbohydrate-carbohydrate 
interactions (i.e. between two neighbouring cells) were initially described over 
20 years ago, having been shown to be of critical importance in compaction of 
the early mouse embryo (Eggens et al., 1989;Fenderson et al., 1984). There is 
now an increasing realisation that cis interactions (i.e. ‘side to side’ within the 
same membrane) may also be functionally important, as recently shown for the 
gangliosides GM2 and GM3 in the anti-metastasis factor CD82 mediated control 
of cell motility (Todeschini et al., 2008). Furthermore, the ability of anti-
ganglioside monoclonal antibodies to bind to their targets has previously been 
shown to be inhibited by the presence of other ganglioside species. In different 
melanoma cell lines, anti-GM3 antibodies were only able to bind when GM3 was 
the sole surface ganglioside. Even in cells expressing 50% GM3, if a longer chain 
ganglioside, such as GM2, was also present, anti-GM3 binding was abolished 
(Lloyd et al., 1992).  
More recently, interactions between pairs of gangliosides have been shown to be 
of importance in determining antibody binding in GBS associated sera. Chapter 1  Introduction     47 
Researchers found that, in a proportion of GBS patients, antibodies exist which 
bind to pairs of gangliosides, but fail to bind either component ganglioside in 
isolation. These have been termed anti-ganglioside complex (GSC) antibodies 
(Kaida et al., 2004;Kaida et al., 2006;Kaida et al., 2007). In the initial study, it 
was noted that on a crude preparation of bovine brain ganglioside run on a thin 
layer chromatography plate that one neuropathy serum demonstrated binding 
just below the level of GD1a ganglioside following immuno-overlay. This 
appeared to correspond to the overlapping portion between GD1a and GD1b. By 
additionally running lanes of GD1a, GD1b and both GD1a and GD1b, this 
speculation was confirmed (Figure 1.8). 
 
Figure 1.8 - The first TLC demonstration of GSC binding antibodies in GBS 
From (Kaida et al., 2004). In (A), the left hand panels (1-4) are stained with orcinol to reveal the 
location of the ganglioside, and the right hand panels (5-8) have been overlain with sera then an 
IgG secondary antibody. Lane A1 is whole brain ganglioside, A2 GD1a, A3 GD1b, and A4 GD1a 
and GD1b. As can be seen from the overlay, the antibody only binds when both GD1a and GD1b 
are present, and then only to the overlapping, incompletely separated portion. Likewise, if the TLC 
running buffer is changed (B), so that the gangliosides are further separated when applied together 
(lane B3), binding is again abolished (lane B6). (C) confirms the impression drawn from (A), 
demonstrating that the band seen on immuno-overlay (TLC-IM, lower line) corresponds to the 
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Subsequent ELISA analysis backed up these observations, whereby binding was 
only detected in wells coated with a mixture of GD1a and GD1b, and not in wells 
in which one or other of GD1a or GD1b was coated alone. Using this technique, 8 
of 100 consecutive GBS patients were found to have similar antibodies in their 
sera, albeit with lesser degrees of binding to the individual gangliosides in some 
cases.  
Subsequently, a lager series of 234 GBS patients was analysed looking for 
reactivity to 1:1 complexes formed by the different combinations of GM1, GD1b, 
GD1b and GT1b. αGSC antibodies were detected by ELISA in 39 (17%) of these 
patients by ELISA (Figure 1.9A). The presence of anti-GD1a:GD1b or GD1b:GT1b 
antibodies was found to be associated with more severe disease and the 
requirement for mechanical ventilation (Kaida et al., 2007). In 12 patients with 
MFS, GM1:GQ1b complex antibodies were found in the sera of 5, and GD1a:GQ1b 
in 2 (Figure 1.9B) (Kaida et al., 2006). Chapter 1  Introduction     49 
 
Figure 1.9 - GSC antibodies in GBS and MFS detected by ELISA. 
From (Kaida et al., 2007) and (Kaida et al., 2006). (A) GBS. (B) MFS. In the above examples, 
single gangliosides are coated in the leftmost column and uppermost row of the plates. The 1:1 
complexes are to the right and below, the complex at each location derived by combining the 
column and row labels. A line of methanol only coated wells runs from top left to bottom right 
(dotted line) and acts as a negative control. The GBS serum in (A) binds to single GD1a, but also 
to complexes of GT1b:GD1b and GT1b:GM1, yet not GD1a:GT1b. The MFS serum (B) does not 
bind any gangliosides in isolation, yet there is a strong signal with GM1:GT1a, GM1:GQ1b, 
GD1b:GT1a and GD1b:GQ1b. 
These findings have implications for all aspects of the pathogenic process in GBS, 
and potentially for the wider field of membrane glycobiology and cell signalling. 
Existing studies of GSC antibodies come from Japan, where axonal forms of GBS 
are more common. It is intriguing to speculate that the presumed elusive 
antibody specificity in AIDP, the predominant GBS subtype in the Western world, 
will be directed against a complex. This would potentially have major diagnostic 
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While such conjecture is exciting, this is blunted somewhat by realisation that 
the level of complexity of any investigation is dramatically increased by these 
combinatorial possibilities. From 20 individual glycosphingolipids, 190 distinct 
pairs can be formed. Furthermore, significant technical concerns are raised, and 
it is unclear how GSL interactions in the artificial systems of enzyme linked 
immunosorbent assay (ELISA) and thin layer chromatography (TLC) relate to their 
behaviour in the dynamic membrane environment. 
The relationship between the presence of anti-GSC antibodies and clinical 
features suggests a pathological potential for these antibodies, but this has yet 
to be demonstrated experimentally. It remains possible that anti-ganglioside and 
anti-GSC antibodies are merely epiphenomena and not key players in the 
pathological process. Similarly, it is at present uncertain whether gangliosides 
form complexes in the living membrane, and if so whether these are transient or 
more longer lasting structures. It has been suggested that micro-organisms such 
as C.jejuni might also display complexes of gangliosides on their cell surface, 
which would then induce anti-GSC antibody production in the host. There are, 
however, two other possibilities. It could equally be argued that bacterial cell 
surfaces coated with complexes might more effectively evade immune detection 
by more exactly mimicking self. Conversely, given the difference in size between 
the lipid a tail of C.jejuni LPS and the ceramide tail of gangliosides, if 
complexes are formed in the bacterial membrane they may be dissimilar to 
those of the infected host – the ability to distinguish between self and non-self 
complexes could thus be viewed as an advantage in the host/pathogen ‘arms 
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The only existing study into the origin of anti-GSC antibodies could be 
potentially interpreted to support any of these views. Only a small proportion of 
those infected with Campylobacter jejuni bearing multiple gangliosides 
developed anti-complex antibodies, and in two cases such antibodies were 
detected in subjects who had been infected by a C.jejuni strain expressing only 
a single ganglioside species (Kuijf et al., 2007). 
The existence of ganglioside complexes might also be evoked in an attempt to 
explain the apparent nerve type specificity of certain anti-ganglioside 
antibodies, despite the presence of significant proportions of target antigen in 
unaffected nerves. It may be that a particular interaction with neighbouring 
GSLs is required for the target ganglioside to become accessible to antibody. As 
such, the relative amounts of membrane bound molecules, together with the 
way these interact, may be more important than the crude percentage 
composition in determining antigenicity.  
A conceptually similar observation was also recently made by the Willison group. 
Two anti-GM1 antibodies (designated DG1 and DG2) with essentially identical 
binding to isolated GM1 on ELISA showed entirely different patterns of reactivity 
in the living membrane. In these ex vivo studies, DG2 bound and caused 
compliment activation, whereas DG1 did not. This difference was abolished by 
pre-treatment with neuraminidase, which strips sialic acid groups from more 
complex gangliosides and converts them to GM1. The conclusion was that 
another ganglioside, felt to be GD1a, was normally in complex with GM1. In this 
situation, DG1 was unable to bind. This may help to explain why not all anti-GM1 
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expanded by a portion of the following work, and has since been published) 
(Greenshields et al., 2009). 
A greater understanding of anti-GSC antibodies might also impact on current 
attempts to develop novel therapeutic techniques. Glycan conjugated Sepharose 
columns have been developed in an attempt to specifically immuno-adsorb 
pathogenic anti-ganglioside antibodies (Townson et al., 2007). These contain 
highly pure, synthetic ganglioside-GM1, and bind monospecific, monoclonal 
antibodies strongly. However, anti-GM1 antibodies from human serum are not as 
effectively captured (Townson, personal communication). This raises the 
possibility that the antibodies in human sera bind poorly because no complexes 
are formed by the synthetic ganglioside in the column. In contrast, the 
impurities found in extracted preparations used for ELISA may enhance binding, 
perhaps via the formation of ganglioside-ganglioside complexes. Alternatively, as 
previously discussed, it may be that the orientation or accessibility of the target 
antigen in such solid phase detection systems is not consistent with, and not 
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1.3 Aims 
The aim of this thesis is therefore to further investigate glycolipid complexes, 
building on the work already described, and focusing on anti-complex antibodies 
in inflammatory neuropathies typified by Guillain-Barré syndrome. This 
overarching aim can be expanded into five sub-aims, as listed; 
1.  To develop a robust system for assessing anti-GSC binding. 
2.  To use this system to investigate the potential importance of GSCs on the 
binding of other lectins including anti-ganglioside monoclonal antibodies. 
3.  To investigate the sera from Western European case series of GBS, 
predominantly comprising the AIDP variant, for anti-GSC antibodies. 
4.  To assess the immune response to GSCs. 
5.  To establish the pathogenic potential of anti-GSC antibodies in ex vivo 
and in vivo systems.54 
2  Methods 
2.1 Materials and solutions 
2.1.1 Gangliosides and other lipids 
GM1, asialo-GM1, GM2, GM3, GD1a, GD1b, GD2, GD3, and GT1b gangliosides 
were bovine brain derived products obtained from Sigma, Poole, UK. GT1a and 
GQ1b bovine brain derived gangliosides were obtained from Accurate Chemical & 
Scientific, Westbury, USA. Sulfatides, sphingomyelin, cholesterol, 
dicetylphosphate, phosphatidylserine, and dimyristoylphosphatidylcholine 
(DMPC) were also obtained from Sigma. Glactocerebroside (galactosylceramide), 
globoside (Gb4; globotetrahexosylceramide), and trihexosylceramide (CTH, 
ceramide trihexosides, Gb3, globotriaosylceramide) were obtained from Matreya, 
Pleasant Gap, USA. GalNAc-GD1a was prepared and analysed by Professor Sandro 
Sonnino, University of Milan, Italy. LM1 (sialosyl-neolactotetraosylceramide) and 
SGPG (sulfated glucuronyl paragloboside) were gifts from Dr. Robert K. Yu 
(Institute of Molecular Medicine and Genetics, Medical College of Georgia, 
Augusta, USA).  
2.1.2 Secondary antibodies 
2.1.2.1  Peroxidase conjugated 
Anti-mouse IgM (µ chain specific), anti-mouse IgG (heavy and light chain), and 
anti-human IgG (Fc specific), horse radish peroxidase conjugated secondary 
antibodies, all raised in goats, were obtained from Sigma. Rabbit anti-human IgG 
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2.1.2.2  Fluorescent labelled antibodies and markers 
Alpha-Bungarotoxin conjugated to Tetramethyl Rhodamine Iso-Thiocyanate 
fluorophore (αBTx-TRITC) was obtained from Molecular Probes, Oregon. 
Fluorescein isothiocyanate (FITC) conjugated anti-mouse IgG (total), and anti-
mouse IgM subclass specific (1, 2b and 3), as well as anti-human IgG(total) 
secondary antibodies were all obtained from Southern Biotech, Alabama, USA. 
FITC–goat anti-rabbit IgG came from the same supplier. FITC–goat anti–human C3 
came from Dako, Glostrup, Denmark. The neurofilament 1211 antibody was 
purchased from Affinity BioReagents, Colorado, USA. 
2.2 Methods 
2.2.1 Combinatorial PVDF glycoarray 
Single gangliosides and lipids were purchased or obtained as detailed above. 
Stock solutions of each of were prepared in a 50:50 (v/v) chloroform:methanol 
mixture, at 1 to 10mg/ml. Working solutions were made by further dilution in 
methanol to 0.1mg/ml. For single samples, 200µl of the working solution was 
added to a 300µl capacity micro-sampling vial (Chromacol, UK). To create 
complexes, 100µl of each constituent glycosphingolipid (GSL), glycolipid or 
phospholipid was added to a vial. For the larger 28 by 10 grid used to screen the 
Dutch Guillain-Barré syndrome (GBS) sera, the final volume of each sample was 
reduced to 80µl. A test print run using methylene blue demonstrated that the 
needle of the thin layer chromatography (TLC) autosampler was able to reach 
down below 20µl, giving 60µl effective volume (sufficient for up to 300 slides) 
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insert (Chromacol, UK), allowing puncture by the autosampler needle. All 
samples were then sonicated for 3 minutes prior to use. 
Sheets of polyvinylidene difluoride (PVDF) membrane (Sigma, UK) were cut into 
20x25mm (65x25mm for the larger array) squares using a scalpel. These were 
then affixed 12mm from the left hand edge of a plain glass slide (VWR 
International, UK) using UHU glue (UHU GmbH, Germany), and allowed to air dry 
for 10 minutes. A metal grid was used to hold 12 slides in predefined and 
consistent positions on the application plate of a Camag Automatic TLC Sampler 
4 (Figure 2.1, ATS4, Camag, Switzerland). The winCATS planer chromatography 
management software (Camag, Switzerland) was used to write programmes 
which result in the application of duplicate spots of 0.1µl of 100µg/ml glycolipid 
or glycolipid complex over a predefined 0.4µm
2 area. The programmes used and 
the arrays they produced are shown in appendix. Printed membranes were 
outlined with an hydrophobic barrier pen (Vector Laboratories, UK) and allowed 
to air dry for 20 minutes. They were then stored overnight at 4ºC before use.  Chapter 2  Methods     57 
 
Figure 2.1 - The ATS4 autosampler and slide guide 
(A) Dosing syringe and application needle. (B) Sample rack and microvials. (C) Application 
platform with bespoke slide guide loaded with 12 slides. (D) Wash and rinse bottles. (E) Close up 
of slide guide and slides. (F) PVDF membrane affixed to glass slide. (G) Membrane outlined with 
hydrophobic pen. 
Membranes were blocked by immersion in 20-60ml/cm
2 of 2% bovine serum 
albumin/phosphate buffered saline (BSA/PBS) for 1h at 4ºC. Serum samples, 
cerebrospinal fluid (CSF), monoclonal antibodies (mAbs), siglec-Fc fusion 
proteins (preconjugated to horse radish peroxidase (HRP) linked anti-Fc 
antibody), or HRP-bacterial toxin conjugates were diluted in 1% BSA/PBS. 250µl 
/ 500µl / 1ml (depending on membrane size) of this diluted sample was then 
applied to a pre-printed membrane and incubated at 4ºC. After 2h, the sample 
was tipped form the membrane and the slides were briefly placed back in the 2% 
BSA/PBS blocking solution. Probes requiring a secondary antibody underwent a 
primary wash phase. These membranes were transferred to 20-60ml/cm
2 of 1% 
BSA/PBS for 15 minutes of washing on a shaker set at 100rpm. This process was 
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appropriate HRP linked secondary antibody was applied (diluted in 1% BSA/PBS, 
typically to 1 in 30k), and incubated for 30min at 4ºC. All membranes then 
entered a wash phase. For probes not requiring a secondary antibody (siglecs 
and HRP-conjugated bacterial toxins) this immediately followed the primary 
incubation.  
This wash phase consisted of two changes of 1% BSA and three changes of PBS, 
again each of at least 20-60ml/ cm
2. BSA washes were of 30min duration, PBS for 
5min, both on a shaker set at 100rpm. Slides were then briefly dipped in two 
changes of distilled water (20-60ml/cm
2). A chemiluminescent detection 
reaction was then performed using ECL plus (Enhanced chemiluminescence, 
Amersham/GE Healthcare, UK), made up according to manufacturer’s 
instructions. 450µl / 1ml of this detection solution was then applied to the 
membranes and left for 3 minutes at room temperature. The solution was tipped 
from the membranes and signal was detected on radiographic film. Exposure 
time was 15s for siglecs, mAbs, and bacterial toxins. For sera, a range of 
different exposure times were used, typically 5s, 15s, 1min, 5min and 10min. 
Films were digitised by flatbed scanning and the images analysed and quantified 
by the array analysis component of ImageQuant TL software (Amersham 
Biosciences, UK). Raw intensity readings were corrected for background in a two 
step process. Firstly, the spot edge average function of the software was used to 
correct for the local background level around the edges of the defined spot. 
Secondly, the average value for the negative control spots (methanol only) was 
subtracted from all other spots. When comparing the relative binding of one 
lectin to gangliosides and GSCs, a relative intensity reading created by 
normalising all other spots to the value of the most intense (set as 100), was Chapter 2  Methods     59 
used in subsequent analysis. When comparing between different lectins, the non 
normalised corrected arbitrary intensity value was used.  
2.2.2 Ganglioside and glycolipid complex ELISA 
Working solutions for ELISA (enzyme linked immunosorbent assay) were made by 
further dilution of stock gangliosides and glycolipids in methanol to 2µg/ml. For 
complexes, equal volumes of the two component gangliosides were combined in 
a glass vial and sonicated for 3 minutes prior to use. As a negative control, 100µl 
of methanol only was added to a number of wells per ELISA plate. Immunolon 
2HB plates were used for all ELISA assays. Subsequently, 100µl of the single or 
complex ganglioside solution was added per well, and allowed to air dry for 40 
hours (h) in the fume hood. Although the plates were visibly dry at 16h or less, 
the longer drying time seemed to improve the consistency of the assay. 
Typically, single gangliosides and complexes were applied in a grid like pattern, 
with a line of methanol only coated wells running from top left to bottom right, 
and acting as a line of symmetry for duplicate spots within the same plate. 
Plates were kept at 4ºC for at least 1h prior to further use.  
Plates were blocked with 200µl/well of 2% BSA/PBS for 1h at 4ºC. Primary 
samples were diluted as for PVDF glycoarray. 100µl of the diluted solution was 
then applied to each coated well of the ELISA plate. Incubation was for 2h 
(mAbs, siglecs, sera) or 2 minutes (cholera toxin B-subunit) at 4ºC.  
The primary solution was tipped and shaken off, and the plates plunged into cold 
PBS then emptied five times. For bacterial toxins and siglecs, the next step was 
to apply detection buffer. For mAbs and sera, 100µl of the appropriate 
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incubated for 1h at 4ºC. The plates then underwent the same wash protocol as 
for the primary. Detection was performed with 50µl/well of an o-
Phenylenediamine dihydrochloride solution (see appendix). The reaction was 
terminated with 25µl of 4M H2SO4. Optical density at 492nm was detected by an 
automated plate reader (Ascent Multiscan, Labsystems, GMI, USA).  
2.2.3 Ganglioside liposome ELISA 
Dimyristoylphosphatidylcholine (DMPC, 200µl of a 5mg/ml solution) and 10µl of 
ganglioside from 1mg/ml stock in 1:1 (v:v) chloroform:methanol solvent were 
mixed in a 15ml tube. To make ganglioside complex liposomes for ELISA, 10µg of 
each constituent ganglioside was added. Blank liposomes containing no 
ganglioside were also produced. The mixture was then briefly vortexed and 
sonicated for 3 minutes. This solution was dried under a steady stream of N2 in 
the fume hood to leave a thin film on the inside of the tube. Subsequently, 1ml 
of PBS was added and the tube alternately vortexed and sonicated for 15 
minutes, until all of the dried lipid was removed from the walls of the tube and 
the solution had turned a uniformly milky colour. This mixture was then freeze-
thawed 5 times by immersion in liquid N2 followed by thawing in a water bath 
set to 37ºC. Unilamellar liposomes were then created by repeated extrusion (11 
times) through a 0.4µm-pore size membrane using a hand driven extruder. This 
was followed by 1h of ultra-centrifugation using a Ti70 rotor (Beckman Coulter, 
Brea, California, USA) at 38500rpm and 22ºC. The resulting pellet was 
resuspended in 5ml of PBS to give a final ganglioside concentration of 2µg/ml. 
These liposomes were added at 100µl/well to an Immunolon 2HB ELISA plate and 
incubated overnight at 4ºC. The liposome solution was then discarded and the 
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From this point, blocking, primary and secondary incubation, washes, and the 
detection reaction were performed as for Ganglioside and Glycolipid Complex 
ELISA above (2.2.2). 
2.2.4 TLC immuno-overlay 
Thin layer chromatography (TLC) with immuno-overlay was used to assess the 
binding of antibodies to the overlapping and non-overlapping portions of 
different gangliosides migrated by organic solvents. Silica backed TLC plates, 
previously dried by gentle heating on a hot plate to 100ºC, were first cut in half, 
before 3 to 5µl of 1mg/ml ganglioside solution was applied in 0.5cm wide bands 
1cm apart using the ATS4 autosampler. In lanes where two different gangliosides 
were applied, their starting positions were adjusted empirically to alter the 
degree of overlap produced when the plate was run. The pattern of ganglioside 
application was repeated at least once across each plate. This allows the 
migration of glycolipids on one half to be assessed using an orcinol solution, 
which can then be compared with the pattern of immuno-staining seen on the 
other. While the plate was allowed to dry, a running solution of 
chloroform:methanol:0.2% CaCl2 was prepared. For standard development, a 
50:45:10 (v/v/v) mixture of the above was made. To achieve greater separation 
of the individual glycolipids, the ratio was altered to 30:65:10, the greater 
excess of methanol over chloroform producing a more polar solvent. 
One half length and one full length strip of blotting paper were then placed 
reclining against opposite inside walls of a glass TLC tank. The running solution 
was poured down either wall of tank, soaking the blotting paper. The lid was Chapter 2  Methods     62 
replaced, sealed with petroleum jelly, and weighted down. The tank was then 
left overnight to allow the internal atmosphere to become saturated.    
The following day, the prepared TLC plate was quickly placed inside the tank, 
leaning against the wall above the half height blotting paper. The lid was 
replaced and resealed, and the solvent allowed to migrate along the silica 
coated face of the plate until it was around 1cm from the topmost edge. This 
typically took around 25 to 30 minutes. At this point, the plate was removed 
from the tank and allowed to dry in the hood for 1h.  
The plate was then divided further into strips containing identical patterns of 
applied ganglioside. One half was sprayed with orcinol or resorcinol solution (see 
appendix), before being heated to 150ºC for 5 minutes on a hot plate, to allow 
visualisation of the ganglioside migration pattern.  The other half was then used 
for the immuno-overlay. 
The half plate to be used for immuno-overlay was first coated with 0.4% 
polyisobutlymethacrylate (PIBM). This was made up by first dissolving PIBM 
granules in chloroform to 2.5%, before further dilution to 0.4% in n-hexane (see 
appendix). The plate was then dipped into the 0.4% solution for 1 minute, and 
allowed to subsequently air dry for a further 30 minutes in the fume hood. 
Immuno-overlay using TLC plates then followed similar steps to those used in the 
ganglioside ELISA. To compensate for the increased background staining seen 
using this technique, however, blocking with 2% BSA/PBS was performed for at 
least 16h overnight at 4ºC. Following this, 3ml of appropriately diluted mAb or 
serum was applied for 2 h, also at 4ºC. To keep the reagent on the plate, the 
plate was placed face up on a surface covered with a hydrophobic film 
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then tipped from the plate, and a wash cycle performed. This consisted of 3 
changes of 1% BSA/PBS, followed by 3 changes of PBS, with gentle agitation on a 
slow shaker for 5 minutes between each change. The appropriate secondary 
antibody, diluted as per the ELISA to 1:3000 in 1% BSA/PBS, was then applied for 
1h at 4ºC before the wash cycle was repeated. Detection was performed by using 
the ECL+ system, as for the PVDF glycoarray, with the ECL solution applied for 3 
minutes before 15s to 1 minute exposure on x-ray film. 
2.2.5 Monoclonal antibody production and purification from 
existing cell lines 
All cell culture procedures were carried out in sterile conditions, as maintained 
by a Class II hood, using standard sterile practice. All incubations were 
performed in a Class II incubator, set to 37ºc and 5% CO2. Media for culture were 
prepared several days in advance, with a 10ml aliquot being retained and 
incubated separately to confirm sterility. Culture media were warmed to 37ºC in 
a water bath prior to use.  
Frozen aliquots from previously generated hybridoma cell lines were retrieved 
from liquid nitrogen storage and quickly thawed at room temperature. The cells 
were then suspended in 50ml of RPMI and spun down for 5 minutes at 200g 
(1000rpm) in a Centaur 2 bench-top centrifuge (MSE, London, UK). The 
supernatant was discarded and cells resuspended in 14ml of 20% complete 
medium (see appendix) in a T25 (25cm
2 surface area) tissue culture flask 
(Corning, Amsterdam, The Netherlands). 
The cells were incubated at 37ºC and their growth assessed regularly. Initially 
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down and resuspended in a volume of 10% complete medium suitable for the 
particular flask used.  Cells were then split between several different T175 
flasks as appropriate. The supernatant was collected at regular intervals and 
replaced with fresh 10% complete medium. The supernatant was periodically 
checked in a standard ganglioside ELISA, as above, to ensure continued antibody 
production. Aliquots of supernatant were stored at 4ºC prior to purification. 
When the required volume of supernatant had been collected, the monoclonal 
antibodies were purified by passage over a HiTrap Protein A affinity column (for 
IgG3 subclass antibodies) or a HiTrap Protein G column (for IgG1 and Ig2b). 
Initially, the supernatants were defrosted, centrifuged for 30mins at 10000rpm, 
and filtered through the 0.22µm membrane of a bottle top filter under vacuum. 
The supernatants were then dialysed overnight against 1:10 (v/v) binding buffer 
(see appendix) using size 2 (14.3mm), 12-14000 Dalton molecular weight cut-off 
dialysis tubing (Medicell International, London, UK). 
The following day, peristaltic pump tubing was filled with binding buffer 
(maintained on ice), and then the tubing attached to the affinity column. Ten 
column volumes of binding buffer were then applied to the column at a rate of 1 
column volume per minute, using the peristaltic pump. A fraction of binding 
buffer was retained to act as a blank for subsequent spectrophotometry using a 
Biophotometer (Eppendorf, Hamburg, Germany). Filtered supernatant (again 
maintained on ice) was then passed over the column at the same rate, followed 
by binding buffer, until the optical density of the flow through at 280nm 
returned to within 0.05 units of the binding buffer blank. The entire volume of 
flow through was retained and stored at 4ºC for subsequent testing by ELISA.  Chapter 2  Methods     65 
Next, 10 1.5ml collection tubes were prepared with between 200 and 450µl of 
1M Tris-HCl, pH 9. The exact volume used per tube was determined by adding 
gradually an increasing amount of Tris-HCl to 1ml of the appropriate elution 
buffer, until the solution was neutralised (pH 7), as checked with pH strips. The 
peristaltic tubing was then emptied of binding buffer and filled with elution 
buffer. For protein A columns this was 0.1M citric acid, pH 3. For protein G, 0.1M 
glycine, pH 2.7, was used. The elution buffer was then applied to the column at 
1 column volume per minute, and 1ml fractions collected in the pre-prepared 
tubes. Again an aliquot of elution buffer was preserved to act as a blank for 
spectrophotometric analysis. Fractions were collected until 3 consecutive 
samples returned optical densities (ODs) within 0.05 of the blank. The column 
was then washed with 10 column volumes of binding buffer, collected as the 
wash fraction, followed by 10 column volumes of 20% ethanol. The tubing was 
washed with 0.5mM NaOCl in 0.5M NaOH and rinsed with distilled water before 
use with another antibody. Each affinity column was retained for use only with a 
specific monoclonal antibody to prevent cross contamination.  
The starting material (supernatant), flow through, elution fractions and washes 
were all tested on ganglioside ELISA (as above, 2.2.2) against the single 
ganglioside previously identified as being the major target of the monoclonal 
antibody in question. Elution fractions showing binding, defined as a corrected 
OD of >0.1, were pooled, desalted using a Sephadex PD-10 column (Amersham 
Biosciences, Uppsala, Sweden), and returned to PBS. Concentration was 
calculated from OD at 280nm (A280) using the formula; 
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If required, the final concentration of the antibody was adjusted by centrifugal 
filtration using an Amicon Ultra tube filter device (Millipore Corporation, 
Bedford, USA). Antibodies were aliquoted and stored at -80ºC prior to use. 
2.2.6 Liposome production for immunisation 
Liposomes for immunisation were manufactured using a sequential sonication, 
freeze-thaw, extrusion method, similar to that used for liposomes produced for 
ELISA. Cholesterol, sphingomyelin, dicetylphosphate and gangliosides were 
dissolved in a 1:1 mixture of chloroform:methanol to 10µg/ml. These lipids were 
mixed in a 5:4:1:1 molar ratio respectively, or 5:4:1:1:1 where a second 
ganglioside was included. The lipid mixture was dried down under a steady 
stream of nitrogen to form a film on the wall of a 15ml tube. The lipids were 
then resuspended in 1ml of PBS (containing ova at 5mg/ml) by vortexing and 
sonication alternately for at least 15 minutes. The mixture was subjected to a 
freeze thaw cycle by plunging into liquid nitrogen then thawing in a water bath 
at 37ºC. This process was repeated 5 times. The resulting suspension of multi-
lamellar liposomes was clarified by centrifugation at 600g (1800rpm in a B4 
centrifuge, Jouan, Saint-Herblain, France). Unilamellar liposomes were then 
created by repeated extrusion (11 times) through a 0.4µm-pore size membrane 
using a hand driven extruder. This was again followed by 1h of ultra-
centrifugation using a Ti70 rotor (Beckman Coulter, Brea, California, USA) at 
38500rpm and 22ºC. The resultant pellet was resuspended in sterile Dulbecco’s 
phosphate buffered saline (Invitrogen, Paisley, UK) to give a final ganglioside 
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2.2.7 Immunisation protocol 
The immunisation protocol used was based on that previously employed in the 
Willison laboratory (Bowes et al., 2002). N-acetylgalactosaminyl-transferase 
knockout (GalNAcT
-/-), neurofilament light-GalNAcT GalNAcT 
-/- transgenic 
(Tg(Nfl-GalNAcT)GalNAcT
-/-, subsequently abbreviated to NFL-Tg), GD3 synthase 
knockout (GD3s
-/-) and wild type (WT) mice were housed under standard 
conditions with food and water provided ad libitum. Mice aged 6 to 10 weeks 
were used in immunisation experiments.  
On day 0, mice were injected intraperitoneally (ip) with 100µl of ova-alum 
(6mg/ml, 60mg of ova in 100ml of 2% aluminium hydroxide gel, Sigma, UK). This 
was to prime them to react against the ova-ganglioside containing liposomes. On 
days 7, 14 and 21 mice were injected ip with 100µl of 1mg/ml ganglioside 
containing liposomes prepared as above. On days 25, 26 and 27 mice were 
injected intravenously (iv) via the tail vein with 50µl of the same liposomes 
diluted to 200µg/ml (i.e. to give 10µg ganglioside per injection). Blood samples 
were taken from superficial tail veins on days 0, 14, 21 and 28 initially. When 
preliminary experiments revealed that anti-ganglioside antibodies were only 
being detected at day 21 and beyond, the blood sampling point at day 14 was 
omitted.  
2.2.8 Monoclonal antibody generation from immunised animals 
The blood sampled at day 28 from immunised animals was used to confirm a 
serum response to the immunogen and to select animals from which to create 
monoclonal antibody secreting hybridomas. In view of problems obtaining a 
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media, an alternative technique whereby hybridomas were cloned immediately 
after fusion using a selective semi-solid medium (Stemcell Technologies, 
Vancouver, Canada) was subsequently employed. The traditional method is 
described first, before variations to the method as a result of using a semi-solid 
selection media are detailed. 
2.2.8.1  Using liquid based media 
Mouse myeloma cells (P3X63Ag8.653, subsequently referred to as ‘653s’) were 
defrosted and maintained as for the existing monoclonal cell lines above. The 
day before the planned fusion, the 653s were spun down, counted, and 
resuspended at a density of between 2 and 10 x 10
5 cells/ml. For each spleen to 
be fused, 4 T175 flasks each containing 40ml of 653 cells were prepared.  
On the day of the fusion (day 0), the 653s were spun down twice at 300g 
(1200rpm), pooled, and resuspended in a final 10ml volume of RPMI-1640 cell 
culture medium without additional supplements (0% RPMI, Sigma). This, and all 
other media unless otherwise stated, was prewarmed to 37ºC in a water bath. 
While the 653s were being prepared, the animal selected for use in the fusion 
was killed with a rising concentration of CO2, as per Home Office guidelines. The 
spleen was removed from the alcohol soaked mouse under aseptic conditions, 
and blood simultaneously collected for testing later. The spleen was then 
transferred into 5-10ml of 20% RPMI-complete medium (see appendix) and 
homogenised using a 2 part glass homogeniser. The liberated splenocytes were 
then passed through a Falcon 70µm cell strainer (BD Biosciences, Mississauga, 
Ontario, Canada). The homogeniser was then rinsed with a further 20ml of 0% 
RPMI which was then also passed through the strainer. Like the 653s, the 
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in a final 10ml volume of 0% RPMI. Both the 653s and splenocytes were counted 
using a haemocytometer and a light microscope set at 10x magnification. The 
volumes of resuspended cells which would yield 1x10
8 splenocytes and 1x10
7 
653s (i.e. a ratio of 10 spleen :1 myeloma) were calculated and these volumes 
were mixed together in a single 50ml vial. The mixed cells were then spun down 
as before and every last drop of media removed.  
A water bath filled with sterile distilled water was placed in the tissue culture 
hood and used to maintain the cells and media at 37ºC during the fusion. 1ml of 
polyethylene glycol solution (PEG, 50% w/v, Sigma) was then added carefully 
over 1 minute using a 1ml pipette, which was also used to gently stir the cells 
during this process. Stirring was continued for a further 90s after all of the PEG 
had been added. Next, 2ml of 0% RPMI was added over 2 minutes, running the 
medium down the side of the tube while gently shaking the mixture. A further 
20ml of 0% RPMI was then added in an identical fashion over 5 minutes. The 
resulting cell suspension was spun down for 15 minutes at 900rpm, then 
resuspended in 60ml of 20% RPMI containing 1x hypoxanthine-aminopterin-
thymidine mixture (HAT, Sigma, final working concentration: 100µM 
hypoxanthine, 0.4µM aminopterin, 16µM thymidine). The unfused myeloma cells 
are hypoxanthine-guanine phosphoribosyltransferase deficient (HGPRT
-/-) and 
hence cannot survive the aminopterin induced blockage of the purine synthesis 
pathway driven by dihydrofolate reductase (DHFR). In contrast, fused cells will 
have regained the HGPRT enzyme from the splenocytes, and can use this salvage 
pathway to synthesise purines. This media therefore selects out only the 
successfully fused cells for survival. The cell suspension was plated out at 150µl 
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prevent drying out of the cell containing wells) and the last two rows were filled 
with unfused splenocytes and 653s as negative controls. 
After 7 days a further 100µl of 20% RPMI/1x HAT was added to each well. After 
14 days the supernatant was aspirated from each well and replaced with 150µl 
of 20% RPMI with 1x hypoxanthine-thymidine supplement (HT, Sigma, final 
working concentration: 100µM hypoxanthine, 16µM thymidine). The aspirated 
supernatant was screened using the ganglioside complex ELISA technique, as 
described above. Positive wells were expanded by transferring ⅔ of the total 
volume into 2 further wells of a 96 well plate, using tips with the ends cut off to 
prevent fragmentation of the colonies. A further 100µl of 20% RPMI was added to 
all 3 wells of each expansion. On day 21 the cells were fed with a further 100µl 
of 20% RPMI per well. The supernatants from the expanded wells were again 
screened by ganglioside complex ELISA, and the positives cloned by limiting 
dilution. To achieve this, the cells were aspirated, spun down at 300g 
(1200rpm), and resuspended at 2000 cells/ml in 20% RPMI. This cell suspension 
was added to two rows of a 96 well plate (avoiding the outside columns) at 
250µl/well, giving 500 cells/well. Aliquots of the remaining cell suspension were 
diluted 1 in 10 and 1 in 100, and plated out as before, giving two rows with 50 
cells/well and two rows with 5 cells/well. The remaining cell suspension was 
added to a 24 well plate. This was grown until confluent and the cells frozen 
down, at -80ºC overnight in 10% dimethyl sulfoxide / foetal bovine serum 
(DMSO/FBS) with 2x10
6 cells per vial, before storage in liquid nitrogen. These 
polyclonal fused cells could then be returned to at a later date if required.  
Wells were screened at interval using ganglioside complex ELISA and positives 
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wells were produced. These were sequentially expanded into larger wells then 
flasks, with antibody being produced and purified as for existing cell lines above. 
In addition, aliquots of cells were preserved by freezing down in 10% dimethyl 
sulfoxide / foetal bovine serum (DMSO/FBS) at 2x10
6 cells per vial and storing in 
liquid nitrogen. 
2.2.8.2  Using semi-solid selection media 
Using this variation, animals were prepared, and 653s defrosted, as for the 
traditional technique. All media were obtained from Stemcell Technologies. For 
one week prior to fusion, 653s were grown in the supplied ‘medium A,’ 
containing Dulbecco’s Modified Eagle’s Medium (DMEM), pre-selected serum, 
gentamicin, and additional supplements. Cell density was maintained at 
between 1 and 8 x 10
5 cells/ml. If cells grew beyond this density they were 
passaged at least twice to return them to the early-mid log phase of growth. The 
target density at the time of fusion was 2 x 10
5 / ml, and 100ml of medium 
containing 2 x 10
7 cells was required per fusion. On the day of fusion the 
myeloma 653 cells were harvested by centrifugation in 2 x 50 ml tubes. They 
were then washed 3 times in 30ml of serum free ‘medium B’ (containing DMEM 
and gentamicin only). Simultaneously, the spleen from the immunised animal 
was harvested and prepared as before. The liberated splenocytes were then 
themselves washed 3 times in 30ml of medium B, before both the splenocytes 
and the 653s were resuspended in a final volume of 25ml. The myeloma 653s 
were then stained with trypan blue, and the number and percentage of viable 
cells calculated. Similarly, a diluted sample of splenocytes 1 in 10 with 3% acetic 
acid and methylene blue was also prepared (resulting in lysis of the red cells and 
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haemocytometer. The volume of media than contained 1 x 10
8 splenocytes and 2 
x 10
7 653s was then calculated and added to a fresh 50ml conical tube.  
The cell mixture was spun down at 400g for 10 minutes, and every last drop of 
supernatant aspirated off, to ensure the greatest fusion efficiency. The resultant 
pellet was disrupted by gentle tapping of the tube, before 1ml of PEG solution 
was slowly added over 1 minute, without stirring. The cells were then gently 
stirred with the pipette tip for a further minute. Next, 4ml of medium B was 
added over 4 minutes, then a further 10ml over 4 minutes. The tube was topped 
up with 30ml of medium A and spun for 7 minutes at 400g. The supernatant was 
discarded, and cells washed in a further 40ml of medium A to ensure complete 
removal of the PEG. They were then slowly resuspended in 10ml of ‘medium C’ 
(‘recovery medium’ - containing DMEM, serum, gentamicin and supplements) and 
added to a T75 tissue culture flask already containing 20ml of medium C. This 
was incubated overnight at 37ºC, 5% CO2. 
The semi-solid, methylcellulose based, selection medium (‘D’) was removed 
from storage at -20ºC and defrosted overnight. The following day, the fused cells 
were transferred to a 50ml tube, spun down at 400g, and resuspended to a total 
volume of 10ml in medium C. This was then added in to 90ml of medium D, and 
mixed by gentle inversion. The mixture was allowed to rest for 15 minutes until 
the introduced bubbles had risen to the top. Using a 10ml syringe and 16g blunt 
end needles, 9.5ml of the cell suspension was added into ten 100mm diameter, 
sterile, petri dishes (Cornig) and the plates tilted to distribute the medium 
evenly. The petri dishes were then placed in a sealed, plastic container, along 
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moisture content, and incubated at 37ºC, 5% CO2, without disruption, for 10-14 
days. 
After 10-14 days, then plates were examined for the presence of colonies visible 
to the naked eye. Around 500 to 1000 were expected over 10 plates. Several 96 
well tissue culture plates were prepared, with 200µl of recovery ‘medium E’ 
(DMEM, serum, gentamicin and supplements) added per well to sufficient wells 
to accept all of the colonies to be harvested. Using a pipette set to 10µl and 
sterile tips, individual colonies were plucked form the semi-solid medium and 
added to separate wells of the prepared 96 well plate. Once all colonies had 
been transferred, they were resuspended using a multi-channel pipette set to 
150µl. A separate sterile tip was used for each well to maintain clonality.  
Following 4-7 days incubation, by which time the cell density had increased and 
the medium had begun to turn yellow, 150µl of supernatant was aspirated and 
tested for antibody production using the ganglioside complex ELISA technique. 
The supernatant was replaced with a further 150µl of fresh medium E. The 
hybridomas which showed a positive response on ELISA were then expanded by 
transferring 100µl to each of 2 wells of a 24 well tissue culture plate, each 
already containing 1ml of medium E. When the cell density had improved to 
around 4 x 10
5/ml, the cells from one well were frozen down as before, and the 
other expanded in a T75 flask with 5ml each of media A and E. The cells were 
then progressively expanded and transferred to 100% medium A, with further 
aliquots frozen down as required. Chapter 2  Methods     74 
2.2.9 Ex vivo hemidiaphragm preparations 
Diaphragms from NFL-Tg, GalNAcT
-/- and WT mice with attached phrenic nerves 
were dissected out (as described in 2.2.14 below) and pinned under tension in 
Sylgard (silicone) lined dishes containing oxygenated Ringer’s medium (see 
appendix). Whole diaphragms were excised along with the surrounding ribcage, 
by cutting away from spine as posteriorly as possible. Excess tissue was trimmed 
and the diaphragm pinned out through a small remaining portion of the ribcage 
and the central tendon to an underlying medallion of Sylgard. The diaphragms 
were then divided in half, each half retaining its supplying phrenic nerve. A 
small dorsal portion was removed from each resulting hemi-diaphragm and 
quickly snap-frozen. These were later used for baseline immunohistological 
measurements. The remainder of the hemidiaphragms were placed in a 25ml 
tube, still attached under tension to their semi-circular base of Sylgard, before 
being incubated with either Ringer’s (as a control) or mAbs (100µg/ml, diluted in 
Ringer’s) for 2h at 32°C, followed by 30 minutes at 4°C and 10 minutes at room 
temperature. The mAb solutions were then removed and retained for subsequent 
testing on ELISA. 
NHS (normal human serum) diluted to 40% in Ringer’s was then added as a source 
of complement. After 1h at room temperature, the NHS was rinsed off. The 
hemi-diaphragm was further divided, with the section of tissue attached to the 
phrenic nerve snap-frozen before being later processed for analysis of 
immunoglobulin binding, C3-complement, membrane attack complex (MAC) 
deposition and neurofilament loss. Chapter 2  Methods     75 
The remaining portion of hemi-diaphragm was incubated in 2µM ethidium 
homodimer, as a marker of peri-synaptic Schwann cell (pSC) death, for 1h at 
room temperature in the dark. The tissue was then rinsed in Ringer’s solution 
before and after fixation in 0.1% parafomaldehyde in Ringer’s, applied for a 
further hour at room temperature. This fraction of hemi-diaphragm was cryo-
sectioned at 25µm and transferred onto 3-aminopropyltriethoxysilane (APES)-
coated slides.  Fluorescein isothiocyanate conjugated alpha-Bungarotoxin (FITC-
αBTx, Molecular Probes, Oregon, USA) was then applied for 1h at room 
temperature, to counter stain the post-synaptic neuromuscular junction (NMJ), 
before sections were rinsed in PBS and mounted in Citifluor (Citifluor Ltd, 
London, UK). 
For immunoglobulin (Ig), C3-complement, MAC, and neurofilament staining, the 
previously snap-frozen diaphragm tissue was cryostat cut at 8 and 20µm 
thickness and transferred onto APES-coated slides (thicker sections were 
designated for neurofilament staining). All solutions were made up in PBS and 
incubations performed at 4°C. For each incubation, alpha-Bungarotoxin 
conjugated to Tetramethyl Rhodamine Iso-Thiocyanate fluorophore (αBTx-TRITC, 
Molecular Probes, Oregon, USA), was included at 1.3µg/ml (1:1000) to locate 
and outline the NMJs in each section, as αBTx binds to the post-synaptic 
acetylcholine receptor.  To detect mAb binding, Fluorescein isothiocyanate 
(FITC) conjugated subtype-specific anti-immunoglobulin antibody of the required 
species, class and subtype (Southern Biotech, Alabama, USA) was applied at 
3.3µg/ml (1:300) for 3h For detection of the activated complement component 
C3, slides were incubated in FITC–goat anti–human C3 (33µg/ml, 1:200; Dako, 
Glostrup, Denmark) for 2h. Mouse anti–human C5b-9 (363µg/ml, 1in 50; Dako), 
applied for 3.5h, was used to detect membrane attack complex (MAC) Chapter 2  Methods     76 
deposition. This procedure required a separate fluorophore labelled secondary 
antibody, and after rinsing in PBS, FITC–goat anti-mouse IgG2a (Southern 
Biotech) applied at 5µg/ml (1:300) for 3.5h. For neurofilament analysis, 
sectioned tissue was stained for 1h with αBTx-TRITC, rinsed in PBS, and then 
kept for 20 minutes in freezing ethanol (–20°C) prior to incubation overnight 
with 1211 antibody (Affinity BioReagents, Colorado, USA) at 1:750.  Slides were 
rinsed and incubated in FITC–goat anti-rabbit IgG (Southern Biotech, 3.3 µg/ml, 
1:300) for 3.5h. In advance of assessment by confocal microscopy (2.2.15), slides 
were rinsed and mounted under a coverslip in Citifluor (Citifluor Ltd, London, 
UK). 
2.2.10  Disease modelling by passive transfer 
GalNAcT
-/-, NFL-Tg, and wild type (WT) mice were used at 6 to 10 weeks of age 
(15-30g). Baseline respiratory and neurological function was assessed using the 
plethysmography and behavioural testing protocols detailed below. Purified 
monoclonal antibody (mAb) was prepared as previously detailed, and the 
concentration adjusted to 1mg/ml. Each animal was then injected with 1ml of 
the mAb intraperitoneally (ip). After 16h, 1ml of normal human serum (NHS), as 
a source of complement, was injected ip. The animals were then returned to the 
plethysmography chambers for a further 3h of continuous monitoring of 
respiratory function. Following this, the behavioural tests were repeated, and 
the animals briefly returned to the plethysmography chambers to measure 
maximal tidal volume.  
Following completion of the tests, the animals were killed with a rising 
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muscles were quickly dissected out and snap frozen on dry ice, before storage at 
-80ºC and later immunohistochemical analysis, as described below.  
2.2.11  Disease modelling by active immunisation 
This experiment also employed NFL-Tg mice, with GalNAcT
-/- and WT as controls, 
aged 6-8 weeks at the start of the procedure. The immunisation protocol was as 
previously described. On day 0, mice were injected intraperitoneally (ip) with 
100µl of ova-alum (6mg/ml), and baseline respiratory and neurological function 
data was obtained. On days 7, 14 and 21 mice were injected ip with 100µl of 
1mg/ml ganglioside containing liposomes prepared as above. On days 25, 26 and 
27 mice were injected intravenously via the tail vein with 50µl of the same 
liposomes diluted to 200µg/ml (i.e. to give 10µg ganglioside per injection). 
The mice were bled via the tail vein on day 28, and the serum obtained used to 
check the antibody response and titre on ganglioside ELISA. Once this had been 
established, the mice were retested by plethysmography and behavioural testing 
on day 32-36, both pre- and post- 1ml of NHS injected ip. Following this, the 
mice were killed with a rising concentration of CO2, and their diaphragm and 
soleus muscles harvested as before, and processed and analysed as described 
below. In addition, a terminal blood sample was taken to confirm the anti-
ganglioside antibody titre at this time.  
2.2.12  Behavioural testing 
This involved a battery of different tests of strength, balance, co-ordination and 
stamina. Chapter 2  Methods     78 
2.2.12.1  Balance bar 
Each mouse was lowered onto the centre of a wooden bar (60-cm length, 2-cm 
diameter) suspended 60 cm above a foam pillow. The platforms at either end 
were blocked off. The latency to fall (up to 120s) was recorded for three 
consecutive trials. 
2.2.12.2  Forelimb grip strength 
A thin, triangular, metal bar was attached to a force meter (Ugo Basil, Italy). 
The meter was secured to the table and set to record the maximum tensile force 
generated. Each mouse, suspended by the tail, was allowed to grip onto the 
longest aspect of the metal bar. The mouse was then gently pulled back, parallel 
to the force meter’s plane of recording, until its grip on the bar was released. 
This process was repeated three times and the mean force generated calculated. 
2.2.12.3  Total grip strength 
This was recorded as for forelimb grip strength above. The only difference was 
that the metal bar was replaced by a metal grid (10 x 5cm) which allowed the 
mouse to grip on with all 4 limbs simultaneously.  
2.2.12.4  Hindlimb reflex extension  
Mice were suspended by the tail for 10s, a score given as per the table below. 
Score  Reflex 
0  one or both hindlimbs paralysed 
1  loss of reflex and hindlimbs and paws held close to the body with clasping toes 
2  loss of reflex with flexion of hindlimbs 
3  hindlimbs extended to form <90° angle 
4  hindlimbs extended to form >90° angle 
Table 2.1 - Scoring system for hindlimb reflex extension Chapter 2  Methods     79 
2.2.12.5  Platform 
Each mouse was lowered onto the centre of a wooden bar (60-cm length, 2-cm 
diameter) suspended 60cm above a foam pillow and facing one of the platforms 
at either end. The time to reach either platform with four paws (up to 60s) was 
registered in three consecutive trials. In each trial the mouse faced alternate 
platforms and a score of 60s was given to the animal that did not reach either 
platform or fell from the bar. 
2.2.12.6  Rotarod 
A rotarod (Ugo Basil, Italy) was used in both a fixed speed and accelerating 
modes.  
Fixed speed  
Each mouse was placed on a separate portion of the rotating cylinder (5 cm 
diameter) set at 5rpm.  
Accelerating mode 
The mouse was placed on a stopped rod. Rotation was commenced at 5rpm and 
increased in increments of 0.2rpm every second.  
For each mode, the latency to fall from the rod was recorded (to a maximum of 
300s) by a timer stopped automatically by the weight of the mouse triggering a 
break in the circuit when falling onto a lever under the rod. Each mouse was 
tested three times with each mode and a mean time taken. Chapter 2  Methods     80 
2.2.12.7  Open field activity 
Each mouse was placed in the middle of a walled off area (1m
2) with the floor 
divided into 42 squares. The latency to leave the central area, frequency of 
locomotion (number of squares entered with all four paws), rearing (number of 
times the mouse stood on its hindlimbs), and grooming (face or body grooming) 
were recorded over 300s. The floor of the arena was washed with 70% ethanol 
between mice. 
2.2.13  Plethysmography 
Non-invasive whole body plethysmography using a four-chamber system (EMMS, 
Hants, UK), set up and calibrated according to manufacturer’s instructions, was 
used to assess respiration in the passive transfer and active immunisation 
experiments detailed above. Mice were initially acclimatised to the apparatus 
over a 30 minute period. The supplied eDacq software was then used to 
continuously monitor respiratory rate and tidal volume (TV) over the next 3h. 
The software records time stamped data in a spreadsheet, averaging 25 
accepted breaths for each time point and reporting a mean. If the TV falls below 
0.1ml or the inspiratory to expiratory ratio exceeds 60%, the breath is either not 
detected or rejected. The respiratory parameters were recorded every 30 
minutes by taking the next 25 readings from each time point and calculating the 
mean. If individual animals showed respiratory embarrassment to such an extent 
that their tidal volume was persistently below the threshold detectable by the 
apparatus, resulting in fewer than 25 readings over the 30 minute period, the TV 
was recorded as being at the threshold of detection (0.1ml). Furthermore, 
representative flow rate traces were also collected. In recording runs where NHS Chapter 2  Methods     81 
was to be injected, baseline data was recorded for 30 minutes before this source 
of complement was injected.  
2.2.14  Diaphragm and soleus dissection and staining 
Mice from active or passive immunisation experiments, or previously unused 
animals, were killed by a rising concentration of CO2 as per Home Office 
guidelines. Once death was confirmed, a small window was made into the 
thoracic cavity and the internal organs removed. Subsequently, the abdominal 
cavity was opened and the liver, stomach and bowels pulled away from the 
diaphragm, leaving it free on both sides. Whilst holding the central tendon with 
forceps, the diaphragm was cut away from the overlying ribcage in one piece, 
placed in a 1.5ml tube, and snap frozen on dry ice. To dissect out the soleus, the 
animal was turned prone, and the right foot pinned in plantar flexion. Overlying 
fur and skin was dissected away, following soaking with 70% ethanol, to reveal 
the underlying calf muscles and Achilles’ tendon (calcaneal tendon). The 
Achilles’ was then cut through just proximal to the calcaneus, and the proximal 
portion remaining attached to the gastrocnemius grabbed with forceps. Whilst 
maintaining upward lift on the tendon, the gastrocnemius was freed from the 
underlying tissue by dissection along its medial and lateral aspects, before being 
removed entirely by cutting across the proximal aspect. The muscle was then 
removed from the animal and flipped over, to reveal the underlying, more darkly 
coloured soleus. This was then carefully dissected away from the overlying 
muscle bulk and likewise snap frozen in a 0.5ml tube.  
The muscles were subsequently processed, sectioned and stained as per the 
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serum or mAb binding ex vivo, having not previously been exposed to a passive 
transfer or active immunisation protocol, serum or mAb was applied first, prior 
to detection of binding with a FITC-conjugated subtype-specific anti-
immunoglobulin antibody and αBTx-TRITC double stain.  
2.2.15  Imaging and analysis of neuromuscular sections 
Stained sections were imaged using an upright, scanning, confocal microscope 
(Carl Ziess, UK). To assess antibody binding, C3 complement and MAC deposition, 
numerous NMJs in each section were sequentially centred in the field of view at 
40x magnification using an oil immersion lens and the red (TRITC) channel. For 
each NMJ digitised pictures from both the red (TRITC) and green (FITC) channels 
were taken for use in later analysis. The microscope operator was blinded as to 
the identity of the tissue. Between 60 and 90 images were typically obtained for 
each experimental condition. When images had been collected from all sections, 
they were analysed using ImageJ software (NIH, USA, obtained from 
http://rsb.info.nih.gov/ij/). Using an analysis ‘plugin’ (written in house by Dr 
Peter Humphreys) the number of green pixels (of antibody, C3 or MAC) 
overlapping the red, TRITC-αBTx stained NMJ was counted for each image. As 
the data generated followed a non-parametric distribution, the Mann-Whitney 
test was used to make statistical comparisons between the different 
experimental conditions. 
The procedure for analysing peri-synaptic Schwann cell (pSC) death was slightly 
different, and could only be performed with ex vivo living tissue and not on 
frozen section. NMJs stained with FITC-αBTx were located using the green 
channel, and, for each NMJ, the number of nuclei stained red with ethidium Chapter 2  Methods     83 
were counted. This stain is only able to penetrate the cell membrane following 
cell death. The number of dead pSCs per NMJ ranged from zero to four, and the 
frequency counts were recorded in a contingency table, typically 6x5, as shown 
later. Statistical analysis was performed using the Chi-squared test.  84 
3  The ganglioside complex binding properties of 
monoclonal antibodies 
3.1 Introduction 
As already discussed, the concept of ganglioside complexes (GSCs) and 
antibodies targeted against these structures has the potential to address many 
of the as yet unanswered questions regarding the pathogenesis of Guillain Barré 
syndrome (GBS). In particular, the incomplete nature of serological-pathological 
relationships, the variability in pathogenic potential between apparently similar 
antibodies, questions of tolerance, and the incongruous nerve type specificity of 
certain antibodies, could all be theoretically resolved by considering the further 
level of complexity introduced by GSCs. For example, the incomplete 
serological-pathological relationships, exemplified by the acute inflammatory 
demyelinating polyradiculoneuropathy (AIDP) variant of GBS, where no dominant 
antibody association is found, could be addressed by the idea that antibodies 
have not been previously detected because investigators have historically 
focussed on detecting binding towards purified, homogenous preparations of 
glycosphingolipid (GSL) antigens, rather than considering the potentially unique 
epitopes formed in vivo by interactions between different molecules. Likewise, 
differential expression of GSCs in the peripheral nervous system as compared 
with the immune system, where tolerance is initially controlled, might partly 
explain the breakdown in self-tolerance required for the generation of 
pathogenic auto-antibodies. Additionally, sensory and motor nerves contain 
almost identical proportions of the gangliosides GM1, GD1a, and GD1b, yet 
antibodies specifically directed against these antigens, as assessed by solid Chapter 3  Results     85 
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phase in vitro assays, will often bind exclusively to their target antigen in motor 
nerve, whilst failing to bind sensory nerves, or vice versa. It can be envisaged 
that differing interactions in the two nerve types between the apparent target 
ganglioside and its partnering glycolipids could either facilitate or block antibody 
binding. 
To begin to address and investigate these hypotheses, a number of preliminary 
steps are required to be taken. First of all, a reliable, reproducible system for 
assessing binding to GSCs is obligatory. As the initial descriptions of αGSC 
antibodies used thin layer chromatography (TLC) and enzyme linked 
immunosorbent assay (ELISA) techniques, these were employed for first round 
investigations. Secondly, reagents which bound preferentially, or ideally 
exclusively, to GSCs would be required to investigate the pathogenic potential of 
αGSC antibodies, and the tissue distribution of GSCs. The Willison laboratory 
holds an extensive library of previously generated anti-ganglioside monoclonal 
antibodies (mAbs). These were widely employed in this research, both as tools 
for developing αGSC assays, as well as being investigated as potential reagents 
for in vivo pathogenesis and antigen distribution studies.  Chapter 3  Results     86 
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3.2 Results 
3.2.1 Development of ganglioside complex ELISA and initial 
analysis of mAb binding 
The initial reports detailing the presence of αGSC antibodies in neuropathy sera 
relied largely on an ELISA based detection protocol, in addition to TLC with 
immuno-overlay. An established protocol for anti-ganglioside antibody detection 
was already in use in the laboratory. These together provided a starting point for 
the detection of GSC binding, and the existing protocol was subtly modified to 
include GSCs, as detailed in the methods section. Instead of rows of different 
antigens being plated out a grid based layout was used, with single gangliosides 
applied in the first rows and columns, and the resulting 1:1 complexes to the 
right and below, as shown (Table 3.1). 
x  GM1  GM2  GD1a  GD1b  GA1  GT1b  GQ1b 
GM1  x            GM1: 
GQ1b 
GM2    x           
GD1a      x  GD1a:
GD1b 
     
GD1b      GD1a:
GD1b  x       
GA1          x     
GT1b            x   
GQ1b  GM1:
GQ1b            x 
Table 3.1 - GSC ELISA layout 
Single ganglioside antigens were applied in the first row and column (shaded green in the example 
above). The resulting 1:1 complexes were applied to the plate in the wells to the right of and below 
the single antigens (shaded white). The complex applied at each location is determined by 
combining the column and row headings. The location of GD1a:GD1b and GM1:GQ1b complexes 
are shown above as an example. A line of negative control wells were included, running from top 
left to bottom right, shaded orange above. These also act as a line of symmetry for duplicate wells 
within the same plate.  Chapter 3  Results     87 
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In order to develop the technique, and also to screen for hitherto unsuspected 
anti-ganglioside complex reactivity, existing monoclonal anti-ganglioside 
antibodies were assessed using this ELISA technique. Initially, these were 
examined on 8x8 grids against 7 single gangliosides and their 21 associated two 
species complexes. 
There was at first no indication which of the existing mAbs might display 
complex reactivity and so the initial selection of mAbs to screen was based 
mainly on availability and familiarity with the antibodies in the laboratory. CGM3 
is an IgM mouse monoclonal generated previously by immunisation of C3H/HeN 
mice with LPS extracted from the OH4382 isolate of Campylobacter jejuni 
(C.jejuni). Its single ganglioside reactivity had already been established, showing 
CGM3 to be an anti-terminal-disialosyl antibody (binding GD3, GQ1b and GT1a). 
(Goodyear and others 1999) It has been extensively used in the generation of a 
mouse model of Miller Fisher syndrome (MFS), where it binds to the 
neuromuscular junction, fixes complement, induces massive quantal release of 
acetylcholine and block neuromuscular conduction. (Plomp and others 1999; 
Halstead S.K. and others 2008) The initial mAb concentration used in these GSC 
assays was chosen by reference to the previously established half-maximal 
binding concentrations with respect to the single ganglioside antigen. Figure 
3.1A demonstrates that the binding of this monoclonal to gangliosides on ELISA is 
influenced by complex formation. At a concentration of 1.5µg/ml, the average 
optical density reading (OD) for GQ1b alone was 0.51, whereas that seen for 
complexes containing GQ1b ranged from 1.06 to 1.47, although higher levels of 
non-specific background binding were seen with complexes, as later discussed. 
Furthermore, for the complexes GD1a:GT1b and GD1b:GT1b reactivity was 
equivalent to that seen for GQ1b if the differing background signal was Chapter 3  Results     88 
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discounted, and returning about half the OD reading following background 
correction. Never the less, this suggests that a neo-epitope had been formed by 
these complexes and was a novel target for CGM3 binding.  
 
Figure 3.1 - Ganglioside complex ELISA with IgM and IgG monoclonal antibodies 
Histogram of mAb CGM3 (A, IgM) and EG1 (B, IgG) binding intensity against a limited panel of 
seven gangliosides and their potential two-component complexes. EG1 results are derived from the 
average of three independent experiments. Chapter 3  Results     89 
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Unfortunately, as discussed, this interpretation is somewhat confounded by the 
increased background signal to GSCs seen with the anti-mouse IgM secondary 
antibody – which appears to react to most GSCs included in the panel (Figure 
3.1A, blue bars, secondary antibody only applied). As such, a monoclonal IgG 
antibody with similar single ganglioside reactivity, EG1, was also investigated. 
Whilst this demonstrated (Figure 3.1B) that the background signal was much 
reduced with the anti-mouse IgG secondary antibody, ganglioside complexes did 
not enhance or attenuate the binding of this monoclonal. A similar observation 
was seen with the anti-GD1a monoclonal MOG35, which retained its ability to 
bind GD1a in complex with other gangliosides without any attenuation or 
enhancement of signal.  
3.2.2 The effect of premixing by sonication on GSC formation and 
antibody binding 
One of the first IgG mAbs to be indentified which displayed GSC binding was 
TBG2. This antibody was previously generated by the immunisation of GalNAcT
-/- 
mice with lipopolysaccharide (LPS) extracted from the O4 strain of 
Campylobacter jejuni. The predominant target of the antibody is the GD1a 
ganglioside, with minor reactivity towards GM1 and GT1b also having been noted 
previously. Initial GSC ELISA screening of this antibody revealed enhanced 
reactivity towards the GM1:GT1b complex as compared with the individual 
gangliosides in isolation. This allowed some of the underlying concepts of GSC 
reactivity to be addressed. It could be envisaged that the reactivity seen 
towards GSCs might simply reflect a summation of lesser degrees of interaction 
with each constituent ganglioside. Likewise, given that each GSC contains only 
half of the mass amount of each of the single gangliosides, it could be argued Chapter 3  Results     90 
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that this difference alone accounts for modulated binding seen with GSCs. 
Similarly, it may be that the presence of a second ganglioside simply enhances 
the binding of the first to the ELISA plate, resulting in more antigen being 
available for binding and thus an increased signal.  
To begin to tackle some of these issues, a simple experiment was envisaged. 
Focussing on the TBG2 antibody and GM1 and GT1b, these single gangliosides 
were applied to an ELISA plate both at the standard single ganglioside 
concentration (100µl of 2µg/ml, giving 0.2µg/well) and at the concentration 
obtained when the gangliosides were present in a 1:1 GSC (by 50:50 dilution with 
methanol to 1µg/ml, giving 0.1µg/well). Furthermore, 50µl of each ganglioside 
at the standard concentration were applied sequentially in both orders (GM1 
then GT1b, GT1b then GM1). Finally, GSCs were created and applied in the usual 
way by premixing equal volumes of 2µg/ml single ganglioside solutions and then 
sonicating for 3 minutes. As the initial reported protocol employed premixing for 
30 minutes, this was also included. (Kaida et al., 2004) 
As can be seen (Figure 3.2A), the binding to gangliosides which had been 
premixed by sonication was significantly increased in comparison with that seen 
to the individual gangliosides, or when these were added sequentially (General 
Linear Model ANOVA with Bonferroni correction, n=4, p<0.0001 for each 
comparison). 
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Figure 3.2 - Effect of premixing and differing ganglioside ratios on ganglioside complex formation and binding 
(A) Comparison of TBG2 ELISA binding intensity towards non-premixed, premixed GM1 and GT1b and to each ganglioside alone. The solid horizontal line reflects the 
conventional OD value used to define positive binding. * = significant difference in OD compared with all non-premixed wells. (B) Variation in TBG2 ELISA binding 
intensity with differing ratios of GM1:GT1b in the complex mixture..  Chapter 3  Results     92 
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There was no significant difference when comparing premixing for 3 or 30 
minutes, and the shorter time was subsequently adopted as standard. Minor 
increases in OD were observed between 0.2µg and 0.1µg of single ganglioside per 
well. The absolute ODs here fell below the traditional threshold to define 
positivity, although the ODs for GT1b (0.2µg), GM1 then GT1b, and GT1b then 
GM1, are all significantly above zero. In either case, the change in OD does not 
explain the differences seen between single and complex binding, as for GSCs 
the lesser amounts of single ganglioside are combined.  Similar issues are 
returned to later, in light of the observation of complex attenuated binding and 
the development of a new immunoassay. 
Binding to GSCs has previously been observed to be most intense when these are 
created by mixing a 50:50 ratio (w:w) of component gangliosides (Kaida et al., 
2004). A similar pattern was seen when testing TBG2 against varying ratios of 
GM1 and GT1b (Figure 3.2B). Working solutions of both gangliosides were 
prepared at 2µg/ml, and then mixed in the varying proportions shown. For the 
control wells containing GM1 or GT1b alone, the second ganglioside was replaced 
with an equal volume of methanol, such that the amount and concentration of 
the first ganglioside was equal to that found in the two ganglioside mixture.  
3.2.3 Validation of the ganglioside complex ELISA using 
neuropathy sera 
These initial experiments highlighted a number of issues. It was apparent that 
the binding of mAbs could be modified by GSCs, based on the ELISA assay, but 
the amount of data generated even in screening a small number of gangliosides 
and their associated 1:1 complexes was overwhelming. Furthermore, as these Chapter 3  Results     93 
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antibodies had been previously cloned based on their ability to bind single 
ganglioside antigens, it was extremely unlikely that we would detect GSC 
exclusive binding. The opportunity to test some of the sera provided by 
Professor Kusunoki (Kinki University, Osaka, Japan), as detailed in the original 
report into αGSC antibodies (Kaida et al., 2004), not only provided a chance to 
validate our GSC ELISA assay, but also suggested an approach to these other 
problems.  
These sera had been selected for their ability to preferentially bind the 
GM1:GD1a complex, and as such, a more limited ELISA panel, consisting of GM1, 
GD1a, GD1b and their associated GSCs was created. As can been seen (Figure 
3.3), both sera (coded 192 and 194) bound preferentially to GM1:GD1a complex, 
as advertised, with ODs of 2.07 and 2.34 at the same 1 in 40 dilution used in the 
original report. Serum 194 showed a greater degree of ‘complex enhanced’ 
binding as compared to serum 192. The sums of the individual GM1 and GD1a 
ODs for each serum were 1.67 and 0.66, respectively. Furthermore, these results 
were consistent with both of the different criteria stated for establishing GSC 
reactivity as initially defined, namely a corrected absolute OD>0.1 (Kaida et al., 
2004), and an OD for the GSC greater than the sum of the ODs for the two 
constituent gangliosides. (Kaida et al., 2007)  Chapter 3  Results     94 
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Figure 3.3 - ELISA with Japanese neuropathy sera assayed against a limited panel of 
gangliosides 
Sera 192 (upper panel) and 194 (lower panel) were provided as examples of GM1:GD1a binding. 
As can be seen, this was confirmed on our assay, and lesser degrees of binding were also 
detected directed towards the constituent gangliosides, most notably with serum 192 and GM1. In 
addition, both sera bound isolated GD1b with similar ODs to that seen for the GM1:GD1a complex. 
Interestingly, it was also noted that these sera bound to the single ganglioside 
GD1b. Whether this represented a single antibody clone binding to both GD1b 
and the GM1:GD1a GSC, or different antibodies with distinct specificities in a 
polyclonal response, was not determined. Nevertheless, this result suggested 
that the existing stock of in house ‘b-series’ mAbs (i.e. anti-GD1b, GT1b and 
GQ1b) might usefully be investigated for binding to a-series complexes. 
3.2.4 Screening of existing b series monoclonal antibodies 
If such an antibody could be identified, which bound a-series ganglioside 
complexes but only b-series gangliosides in isolation, this would be a suitable 
reagent for the investigation of GSC distribution, and for the assessment of the 
pathogenic potential of αGSC antibodies, in GD3s
-/- mice. As these mice lack b-Chapter 3  Results     95 
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series gangliosides, binding to these species in vitro could be ignored as a 
potential confounding factor in vivo, and any binding seen in vivo attributed to 
interactions with a-series complexes. As such, five mAbs previously generated by 
immunisation with GD1b containing liposomes (MOG1-4 and EG7), and four mAbs 
generated by immunisation with GQ1b-liposomes (MOG26-28 and MOG31), which 
also showed varying degrees of reactivity to isolated GD1b, were investigated. 
Instead of assaying against multiple ganglioside complexes, only those which 
might form in the membrane of a GD3s
-/- mice were prepared. Of the five GD1b 
induced mAbs, two showed equivalent or greater reactivity to the neo-epitope 
formed by GM1:GD1a, as did one from the GQ1b group (Figure 3.4). 
 
Figure 3.4 - The response of anti-b series mAbs to GM1:GD1a complexes 
Average optical density results from two independent experiments performed in duplicate are 
shown for 4 different mAbs, +/-SEM. (A) MOG1 and (B) MOG4, both raised against GD1b 
containing liposomes, also bind the complex of GM1:GD1a, although in the latter binding to the 
complex appears to plateau at a lower concentration than for the single, positive control 
ganglioside. (C) MOG26 and (D) MOG27 were both raised in GalNAcT
-/- mice immunised with 
GQ1b, yet display markedly different behaviours with respect to the ganglioside complex 
GM1:GD1a, as shown. Here, MOG26 (C) binds more strongly to the complex at both 
concentrations tested, whilst showing essentially no binding to either GM1 or GD1a alone. 
Conversely, MOG27 (D) shows some reactivity to isolated GM1, but does not recognise the 
complex GM1:GD1a, and is in effect inhibited from binding GM1 in the presence of GD1a. Chapter 3  Results     96 
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Despite this in vitro ELISA data, none of these antibodies bound in ex vivo 
neuromuscular preparations taken from GD3s
-/- mice, and they all also failed to 
bind to the GM1:GD1a complex when presented in the newly developed PVDF-
glycoarray assay system, as discussed below. 
3.2.5 Impetus for the development of a novel immunoassay for 
investigating ganglioside complex binding 
The results obtained from the investigation of the Japanese neuropathy sera had 
suggested one approach to investigating GSC-lectin interactions – namely 
focussing on a limited panel of gangliosides and their complexes in vitro as a 
prelude to further experimentation in a biological system expressing a similar, 
limited panel of gangliosides. However, it was also felt desirable to be able to 
more efficiently screen for binding against a larger number of GSCs 
simultaneously, for example, when screening collections of disease associated 
serum samples for hitherto unidentified antibody-antigen interactions. It was 
apparent that the use of ELISA for this purpose had several limitations. As the 
number of single gangliosides is increased, the number of unique ganglioside 
complexes increases exponentially (Figure 3.5). When three or four component 
complexes are considered, this problem is further magnified. As can be seen, 
these numbers of complexes would quickly overwhelm the capacity of a single, 
96 well ELISA plate.  Chapter 3  Results     97 
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Figure 3.5 - Relationship between number of single gangliosides and potential number of 
complexes 
(A) Heterodimeric complexes, (B) three and four species complexes. As can be seen, the number 
of potential complexes rises sharply as the number of single gangliosides or glycosphingolipids is 
increased, particularly when larger multimeric structures are considered.  
Furthermore, when dealing with these numbers of potential antigens, the low-
throughput ELISA becomes increasingly impractical, both in terms of the time 
required to prepare and plate out the potential targets, and in its consumption 
of large quantities of scarce reagents. As such, a miniaturised, polyvinylidene 
(PVDF) based, combinatorial glycoarray was developed based on a synthesis of 
previously published methods. (Kaida et al., 2004;Kanter et al., 2006).  
3.2.6 Development of the combinatorial PVDF glycoarray 
A detailed description of the methodology employed in investigating lipid 
autoantibodies in cerebrospinal fluid (CSF) and serum using PVDF membranes 
and an automated TLC spotter was kindly provided by Professor Bill Robinson Chapter 3  Results     98 
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(Stanford University, USA). By adapting this method it was possible to include a 
combinatorial, GSC component and adopt layout similar to that used in the GSC 
ELISA (Table 3.1 and Figure 3.6).  
 
Figure 3.6 - Typical layout for a 10x10 PVDF-glycoarray 
Similarly to the ganglioside complex ELISA, single ganglioside antigens can be found in the 
leftmost column and uppermost row, with complexes spotted in the internal positions. The line of ‘x’ 
running top left to bottom right represents negative control spots of methanol only, and also acts as 
a line of symmetry for duplicate antigens within the same membrane. 
Rather than using the software included with the ATS4 TLC-autospotter to write 
new programmes, as had been done previously, new layouts and protocols could 
be much more quickly established using the ‘fill series’ and formulae 
functionality of Microsoft Excel. This allowed subtle (or indeed major) alteration 
to the layout, spacing and dimensions of the individual spots to be rapidly made 
and investigated. 
Many of the early technical problems with the assay had been addressed by Dr 
Kathryn Brennan, who had investigated different membrane surfaces, secondary 
antibodies and detection systems, and solved the problem of membrane 
detachment from the slide during the wash phase, whilst she was developing a Chapter 3  Results     99 
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similar assay for further investigation of complex lipid antigens in multiple 
sclerosis.  
Further development involved honing the secondary antibody used and the 
detection system employed, assessing the inter- and intra-assay variability, and 
addressing issues raised by the use of ganglioside complexes. Trials of 
fluorescent secondary antibodies were undertaken in an attempt to utilise the 
apparent greater dynamic range of these agents and employ automated scanning 
and detection systems (such as the Storm chemifluorescence imager, GE 
Healthcare, UK). However, shorter wavelength fluorophores, such as an anti-
mouse IgG-FITC conjugate (Southern Biotech, USA), generated a high background 
signal with difficulty differentiating between the presence and absence of 
binding (Figure 3.7A). It was speculated that auto-fluorescence of both the PVDF 
membrane and the gangliosides themselves might be contributing to this, and 
that the issue could be overcome by using longer wavelength probes and filters. 
Unfortunately, use of a TRITC conjugate failed to address the problem, and an 
AlexaFluor-647 conjugated IgG secondary (Molecular Probes, USA) bound non-
specifically to a spectrum of GSCs even in the absence of a primary antibody 
(Figure 3.7B). Neither of these problems could be overcome by altering the 
secondary antibody concentration, incubation period, excitation wavelength and 
voltage, and/or the emission filter settings. Horse-radish peroxidase (HRP) 
conjugated secondaries proved more successful, giving a clear distinction 
between positive and negative spots. Furthermore, reducing the secondary 
antibody concentration from 1:3000 to 1:30000 allowed clearer, individual spot 
definition and reduced non-specific background staining (Figure 3.7C). At 
concentrations below this, binding to some previously positive GSCs was lost.  Chapter 3  Results     100 
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Concerns about the dynamic range of an HRP-ECL (Enhanced 
chemiluminescence, Amersham/GE Healthcare, UK) radiographic detection 
system were addressed by spotting varying concentrations of secondary antibody 
direct onto the PVDF membrane and then processing the slides as normal. This 
revealed a broadly linear signal intensity response across the five secondary 
antibody dilutions used, and demonstrated the signal had not become saturated 
up to the 140000 arbitrary units level obtained by a 1:2000 dilution and 5 
minutes exposure on radiographic film (Figure 3.7D). In the GBS sera series 
screen detailed later, this value was only exceeded on 2 occasions from 288 
assays run, when maximum values of 145000 and 178000 were obtained, using 1 
in 100 serum dilution, secondary antibody at 1:30k, and 1 minute exposure time.     
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Figure 3.7 - Development and initial validation of the PVDF glycoarray 
Use of a FITC conjugated secondary antibody resulted in high auto-fluorescence of the PVDF membrane and a low signal to noise ratio (A). Using the longer 
wavelength AlexaFluor-647 fluorophore, auto-fluorescence of the membrane was reduced, but non-specific binding was seen, as demonstrated by the fact that an 
identical binding pattern was seen with (B, upper panel) and without (B, lower panel) any primary antibody being applied. Furthermore, binding to the negative control 
spots of methanol only was seen with this secondary. Using an HRP-conjugated secondary, the difference between positive and negative spots was distinct, and 
background staining could be reduced by reducing the secondary antibody concentration from 1:3000 to 1:30,000 (C). Plotting a standard curve for this antibody and 
the ECL-radiographic detection system revealed a broadly linear response with no evidence of signal saturation over the range measured. An example of the range of 
intensities rendered on radiographic film following a 15s exposure is shown (D). Example processed grids from the intra- (E) and inter- (F) assay variation experiments 
are also shown.  Chapter 3  Results     102 
 
 
The intra-assay variability was assessed and optimised by applying nine 
independently prepared samples of GM1 ganglioside to the edges of a PVDF array 
in duplicate. Spots around the perimeter of the arrays were chosen as these 
would be expected to show the greatest variability due to edge effects. Using 
the anti-GM1 mAb DG2, the incubation period and volume of secondary antibody 
applied were adjusted and co-efficient of variation (CV, mean of SD of 
duplicates/grand mean of duplicates x100) measured in each case (Figure 3.7E). 
A CV of 8.6% was measured using 500µl of antibody with a 2h incubation period 
(Table 3.2), and this was subsequently used in the standard protocol. Lower 
volumes of antibody had a negative effect on the CV, presumed to be due to 
incomplete covering of the membrane and/or evaporation of the reagent. 
Despite the prior prediction, the intra-assay co-efficient of variation of the 27 
non-edge spots under the same protocol was similar, although slightly higher, at 
9.2%. Following this, five repeats of the assay were run on different days, again 
using DG2 along with the optimum secondary antibody parameters as established 
in the intra-assay experiment. Inter-assay variation was calculated by dividing 
the SD of the individual means by the grand mean, and multiplying by 100 to 
give a percentage. This gave a value of 4.1% (Table 3.3). CVs less than 10% are 
usually considered representative of good reproducibility (Considine et al., 1986) 
and the values obtained for the PVDF array are comparable to the standard, 
ganglioside ELISA (Willison et al., 1999). Chapter 3  Results     103 
 
 
 
Antibody volume (µl)  Incubation Time (h)  Intra-assay CV (%) 
100  1  83.4 
250  1  14.3 
500  1  13.7 
500  2  8.6 
500  4  9.7 
500  16  13.2 
Table 3.2 - Intra-assay variation measurement 
Group mean  92.38 
SD of mean  3.77 
CV  4.1% 
Table 3.3 - Inter-assay variation calculation 
3.2.7 The effect of ganglioside mixing and complex formation on 
adhesion to the PVDF membrane 
As noted for the GSC ELISA above, one potential confounding explanation for the 
modulated binding seen with GSCs as compared with single gangliosides is that 
the presence of the second ganglioside alters the amount of the first which binds 
(or remains bound) to the ELISA plate (or PVDF membrane). The ability to 
measure spot fluorescence using the Storm imager suggested a potential 
experiment to address this. Boron-dipyrromethene (BODIPY-FL) labelled GM1 was 
available commercially (Invitrogen, UK). In this preparation, the BODIPY 
fluorophore is attached to a truncated C5-fatty acid chain, but the sphingosine 
chain length and carbohydrate head groups are unaltered (Figure 3.8). Chapter 3  Results     104 
 
 
 
Figure 3.8 - Structure of BODIPY FL C5-ganglioside GM1 
The fluorophore is present in (and partially replaces) the fatty acid component of the ceramide tail, 
leaving the antibody target formed by the carbohydrate headgroup chemically unaltered. 
(Image taken from manufacturer’s information sheet) 
Using this fluorescent ganglioside, it was first established that differing amounts 
of GM1 per spot could be detected by applying varying concentrations of 
BODIPY-C5-GM1 and measuring the fluorescent intensity using the Storm imager. 
Six concentrations were prepared, to give expected applications of 0, 0.1, 0.2, 
0.5, 1 and 2ng per spot, assuming all of the fluorescent ganglioside became 
attached to the PVDF membrane. These membranes underwent a standard wash 
cycle before spot intensity was measured. As can be seen, the spot intensity 
measured in relative fluorescent units (RFU) was linearly related to the amount 
of fluorescent ganglioside per spot (Figure 3.9A). Regression analysis with a 
fitted line plot gave a formula of: 
Mean RFU = 1.05 + 1.52 (ng of FL-ganglioside applied per spot) 
with an S value of 0.18 (a measure of how far measured points are away from 
the regression line) and an R2 value of 98% (a measure of the proportion of the Chapter 3  Results     105 
 
 
variation in the observed RFU response explained by the predictor – fluorescent 
ganglioside applied per spot). The Pearson correlation co-efficient was 0.968 
(p<0.001), indicating a good correlation. Furthermore, there were significant 
differences between average RFU for 1ng and 0.5ng (n=6, estimated difference 
1.19, p<0.0001) and between 1ng and 2ng (n=6, estimated difference 1.12, 
p=0.0001, both General Linear Model ANOVA with Bonferroni correction). 
 
Figure 3.9 – GD1a in a GM1:GD1a complex does not modulate the amount of GM1 binding to 
the PVDF membrane 
A linear relationship between the amount of BODIPY-C5 GM1-ganglioside spotted and fluorescent 
intensity is shown (A). No difference between the amount of GM1 binding to the membrane was 
observed when comparing a 1:1 mixture of GM1:methanol with a 1:1 mixture of GM1:GD1a (B).  
The second step of the experiment involved comparing the amount of GM1-
ganglioside binding to the membrane in the presence or absence of GD1a. A 
100µg/ml solution of GM1, containing 20% BODIPY FL C5-GM1, was prepared. 
This was then mixed 1:1 (v:v) with either a 100µg/ml solution of GD1a or 
methanol. These two mixtures were then used to apply either GM1 alone, or the 
GM1:GD1a complex, to the same PVDF membrane in duplicate. Assuming GD1a 
made no difference to GM1 binding to the membrane, each 0.1µl spot would be 
expected to contain 5ng of GM1 in total, and 1ng of FL-GM1, with no difference 
in RFU measurement between the two. This was indeed the case, and mean 
observed intensities were 2.18 (GM1 alone) and 2.24 (GM1:GD1a), which was not Chapter 3  Results     106 
 
 
significantly different (n=6, estimate for difference (95% CI) 0.07 (-0.3 to 0.17), 
two sample T-test, p=0.55, Figure 3.9B). Power calculations based on the 
observed standard deviation of 0.18 revealed that the sample size of 6 would be 
sufficient to detect a 0.4 unit difference in RFU with 95% power, should such a 
difference exist. Using the previously determined standard curve regression 
formula, this equates to a difference of 0.26ng of fluorescent ganglioside.  
3.2.8 The differing response of two anti-GM1 antibodies to 
ganglioside complexes  
The anti-GM1 mAb DG2 was used extensively in the development and validation 
of the PVDF glycoarray, as has been discussed. This antibody, along with another 
superficially similar anti-GM1 mAb generated in-house (DG1), had also been 
comprehensively investigated by a previous PhD student (Dr Kay Greenshields). 
This was with a view to gaining a greater understanding of the pathogenic 
potential and mechanism of GM1 antibodies, and generating a murine model of 
anti-GM1 mediated acute motor axonal neuropathy (AMAN). GM1 antibodies have 
long been noted to have apparently inconsistent or contradictory binding 
patterns and effects in biological membranes, which cannot be explained simply 
by the presence, absence or variations in density of the putative target antigen, 
leading some to question their pathological importance.  
Likewise, both of the in-house anti-GM1 monoclonal antibodies DG1 and DG2 
were noted to bind isolated GM1 in solid phase ELISA assays, with very similar 
half maximal binding values of 0.5mg/ml and 0.4mg/ml respectively. (Townson 
et al., 2007) However, when these were investigated by Dr Greenshields in ex 
vivo preparations of mouse neuromuscular tissue, disparate binding patterns Chapter 3  Results     107 
 
 
were noted. In the live motor nerve terminal of GD3s
-/- mice, lacking b-series 
gangliosides but enriched in a-series gangliosides such as GM1 and GD1a, the DG2 
antibody binds to the post-synaptic apparatus of the NMJ and supplying axon and 
fixes complement, leading to the deposition of membrane attack complex (MAC) 
pores and cytoskeletal disruption as evidenced by neurofilament loss. In 
contrast, DG1 fails to bind in such situations and does not fix complement or 
cause tissue damage. (Greenshields et al., 2009) 
It was speculated that DG1 was being prevented from interacting with GM1 in 
the live membrane due to an inhibitory cis interaction with another ganglioside, 
most likely GD1a in the context of the GD3s
-/- mouse. It is of course possible that 
other gangliosides (e.g. GM2, GM3) could mediate similar blocking functions, 
particularly in membranes with other ganglioside compositions. 
Ganglioside complex ELISA and the PVDF glycoarray were used to demonstrate 
that an inhibitory interaction between GM1 and GD1a formed in vitro. In ELISA, 
DG1 was significantly inhibited and DG2 only partially inhibited from binding 
GM1 in the presence of GD1a (Figure 3.10A). The mAbs were used at their GM1 
half-maximal binding concentrations of 0.5µg/ml and 0.4µg/ml. This inhibitory 
effect was not unique to GD1a, and also occurred to a significant extent with 
GM1:GM2 and to a lesser extent (not significant) with GM1:GD1b. In marked 
contrast, complexes of GM1:GM3 and GM1:GD3 did not produce any inhibitory 
effects on DG1 or DG2 binding. This suggests that nonspecific displacement of 
GM1 by a second, nonreactive ganglioside, or simply the further dilution of GM1 
by methanol, does not account for the lower signal seen with the inhibitory 
GM1:ganglioside complexes on ELISA. Chapter 3  Results     108 
 
 
When isolated GM1 was displayed on PVDF membranes in the PVDF glycoarray, 
there was no significant difference in the binding of DG1 and DG2 (Figure 3.10B). 
Paired assays were run, with DG1 and DG2 probed membranes processed and 
developed simultaneously, and binding normalised to the most intense spot 
across both membranes, to allow this comparison to be made. When GM1 was 
complexed with a range of other gangliosides, DG1 was almost completely 
inhibited from binding GM1. In contrast, DG2 binding to GM1 was minimally 
affected, although the difference in binding did reach significance for GM1:GM2 
and GM1:GD1a complexes (Figure 3.10B). Two separate statistical tests were 
used to analyse this data. For comparisons between binding to GM1 alone and to 
GM1 complexes, general linear model analysis of variance (ANOVA), with 
Dunnett’s correction to maintain the family error rate at 0.05 for multiple 
comparisons to the control level, was employed. Differences between DG1 and 
DG2 binding to each complex were assessed by the 2-tailed 2-sample t test. 
Bonferroni’s correction was applied in view of the multiple comparisons being 
made, again to maintain a family error rate of less than 0.05. 
Throughout these PVDF studies, the reduction in complex binding for DG1 was 
substantially and significantly greater than that for DG2. This figure formed part 
of the paper “The neuropathic potential of anti-GM1 autoantibodies is regulated 
by the local glycolipid environment in mice” published in the Journal of Clinical 
Investigation. (Greenshields et al., 2009) Chapter 3  Results     109 
 
 
 
 
Figure 3.10 - Reactivity of anti-GM1 mAbs DG1 and DG2 to ganglioside complexes 
containing GM1 in solid phase 
The ganglioside complex at each location is established by combining the row and column labels. 
Thus, coordinates 1,4 and 4,1 represent GM1:GD1a complex. Wells labelled X are negative 
controls (methanol only). (A) ELISA. DG1 (left) and DG2 (right) both bind GM1 alone, with no 
difference in average OD. DG1 binding to complexes GM1:GM2 and GM1:GD1a was less than that 
of DG2 (*=statistically significant difference in average OD for DG1 versus DG2).The binding of 
both antibodies to complexes of GM1 and GM2 or GD1a is reduced as compared with GM1 alone. 
For clarity, the statistical significance of these comparisons is not marked on the graph. No 
difference was observed with other combinations investigated (GM1:GM3, GM1:GD1b, and 
GM1:GD3). Mean results ± SEM from 3 experiments are shown.  
(B) PVDF glycoarrays. DG1 was the primary antibody on the left membrane, DG2 on the right.. No 
significant difference in GM1 binding was observed for the 2 antibodies. DG1 binding to GM1 
complexes was significantly reduced compared with GM1 alone (P < 0.05, significance level for 
these comparisons again not indicated in graph). DG2 binding GM1 complexes was marginally 
different compared with GM1 alone but statistically significant for GM1:GM2 and GM1:GD1a (not 
marked on graph). The inhibitory effect of complexes on antibody binding is greater for DG1 than 
for DG2. The average absolute reduction in signal intensity for GM1:GD1a complex, compared with 
GM1 alone, is 75.1% for DG1 and 18.2% for DG2 (P < 0.05). Mean results ± SEM for 3 
experiments are shown *P < 0.05, **P < 0.01. 
Key : 1, GM1; 2, GM2; 3, GM3;4, GD1a; 5, GD1b; 6, GD3. Chapter 3  Results     110 
 
 
3.2.9 The disparate binding of mAbs to GSCs on ELISA and PVDF  
The results obtained with DG1 and DG2, above, demonstrated that the binding of 
lectins to GSCs on different surfaces can vary. For example, DG1 was 
significantly inhibited from binding GM1 in the GM1:GM3 complex on the PVDF 
glycoarray, but not by ELISA. In addition to this different inhibitory effect, it was 
also hypothesised that there might be a variation in the enhanced binding to 
complexes between the various assays. The most obvious reagents to test first 
were the anti-b-series mAbs which had displayed GM1:GD1a complex binding on 
ELISA (MOG1, MOG4, and MOG26), but failed to bind to GD3s-/- neuromuscular 
tissue, where such complexes might be expected to be found. 
On PVDF glycoarray, all three of these mAbs failed to display enhanced binding 
to the GM1:GD1a complex, even when they were applied at concentrations 10 
times greater than that used on ELISA. Furthermore, at the 1µg/ml and 7.3µg/ml 
concentrations used in the ELISAs respectively, MOG1 (Figure 3.11A) and MOG4 
(Figure 3.11B) still bound strongly to GD1b (average arbitrary intensities (AI) 
88300 and 72900) in a complex independent fashion. No GSC binding was 
demonstrated by MOG1. MOG4 bound weakly to GD1a (average AI 5500, n=3) but 
this was not enhanced by the GM1:GD1a complex (average AI 1400, n=3). MOG26 
(Figure 3.11C) bound GQ1b, but failed to bind even isolated GD1b, as it had 
done in the ELISA. Additionally, no reactivity was demonstrated towards 
GM1:GD1a complex, although a weak signal was observed with complexes of 
GD1b with GM3, and to a lesser extent with GD1b:GD1a and GD1b:GT1a. Chapter 3  Results     111 
 
 
   
Figure 3.11 - The display platform influences the binding of anti-b-series mAbs to 
GM1:GD1a complex 
MOG1 (A) and MOG4 (B) remain able to bind GD1b on the PVDF glycoarray, but in comparison 
with the ELISA assay (Figure 3.4, above) do not demonstrate binding to the GM1:GD1a complex. 
MOG26 (C) binds GQ1b, but fails to bind even isolated GD1b, as it had done in the ELISA. 
Additionally, no reactivity was demonstrated towards GM1:GD1a complex, although a weak signal 
was observed with complexes of GD1b with GM3, and to a lesser extent with GD1b:GD1a and 
GD1b:GT1a. 
3.2.10  GSC Liposome ELISA 
The disparate results seen between ELISA and PVDF prompted further testing in 
a third assay, a ganglioside complex liposome ELISA. As gangliosides are 
presented in association with a number of accessory lipids in a bilayer, this was 
felt to more accurately represent the living membrane. The GM1 antibodies DG1 
and DG2 were examined, as was MOG4 which binds GM1:GD1a on standard ELISA 
but not on PVDF. The anti-GD1a mAb MOG35 was included as a positive control 
for GD1a containing liposomes. As can be seen, DG1 and DG2 both bound 
isolated GM1 as expected, with no significant difference in OD noted (n=3, 2 
tailed, 2 sample T-test, p=0.19). Both antibodies bound less well to liposomes 
containing the GM1:GD1a complex, but once again DG1 bound significantly less 
well than DG2 to this antigen (n=3, 2 tailed, 2 sample T-test, p=0.01). As 
expected, and as previously seen on standard ELISA, MOG35 recognised GD1a and 
no significant difference in binding was observed as compared with GM1:GD1a 
complex (n=3, 2 tailed, 2 sample T-test, p=0.23). In contrast to the standard Chapter 3  Results     112 
 
 
ELISA, but in keeping with the PVDF array, MOG4 entirely failed to bind the 
GM1:GD1a complex in liposomes (Figure 3.12). 
 
Figure 3.12 - GSC liposome ELISA with GM1:GD1a complex 
Both of the GM1 antibodies DG1 and DG2 bind isolated GM1 liposomes with similar ODs. The 
binding of DG1 to GM1:GD1a containing liposomes is significantly poorer than that seen with DG2. 
MOG35 binds GD1a in GD1a and GM1:GD1a liposomes. MOG4 fails to bind GM1:GD1a complex 
liposomes, in contrast to the pattern seen using standard ELISA, but in keeping with that obtained 
using the PVDF array. (Average OD for 3 independent experiments, +/-SEM, is shown. mAbs were 
used at the same concentrations used in the standard ELISA. Statistical comparisons were made 
using a two-sample two-tailed T-test). 
 
3.2.11  The disparate binding of mAbs to GSCs on TLC, ELISA 
and PVDF  
On reviewing the previous work of the Willison laboratory in generating anti-
ganglioside mAbs, an intriguing observation was noted. When Dr Carl Goodyear 
generated mAbs by immunising mice with GBS associated Campylobacter jejuni 
lipopolysaccharide, these were tested for reactivity against gangliosides by thin Chapter 3  Results     113 
 
 
layer chromatography (Goodyear et al., 1999). For some of the antibodies 
generated, reactivity was; 
“observed with GD1b and an unidentified ganglioside(s) migrating 
between GD1a and GD1b.” 
This has distinct echoes of the comment made in Kaida’s paper (Kaida et al., 
2004) detailing the first description of ganglioside complex antibodies in 
neuropathy sera; 
“an unidentified immunoreactive band [was identified] in the position 
just below GD1a on TLC of a crude ganglioside fraction” 
strongly suggesting that these mAbs might also recognise the GD1a:GD1b 
complex. In fact, looking at the TLC blots themselves suggests most of these 
antibodies do not recognise GD1b alone, with binding corresponding only to the 
overlapping portion with GD1a felt to represent GD1a:GD1b complex. However, 
CGM2, 3, and 5 failed to bind this GSC on the PVDF glycoarray, and only CGM3 
demonstrated some weak binding towards the complex on ELISA (see Figure 3.1 
above).  To address the hypothesis that these antibodies were indeed binding to 
the overlapping portion of GD1a and GD1b in the original TLC assessment, an 
experiment involving three lanes of ganglioside (GD1a, GD1b and both GD1a and 
GD1b), developed by TLC, and then overlaid with the different mAbs, was 
performed. Initially, ganglioside application, the solvent system used, and the 
development time, were optimised to result in a partial overlap of gangliosides 
GD1a and GD1b in lane 3 (Figure 3.13A). Subsequently, sets of these three lane 
panels were applied in triplicate to one TLC plate. After this had been 
developed in solvent and air dried, the left most panel was cut away and the 
distribution of ganglioside revealed by the orcinol reagent.  The remaining two 
panels were split, and each probed with a separate mAb according to the Chapter 3  Results     114 
 
 
protocol already described. By lining up the immunoreactive bands with the 
orcinol processed panel, the ganglioside binding profile can be determined. As 
can be seen, CGM2 binds only to the overlapping portion of GD1a and GD1b in 
lane 3. CGM3 binds very weakly to both individual GD1a and GD1b, but a much 
stronger band is seen again corresponding to the overlapping portion of GD1a 
and GD1b. In fact, in the GD1a only lane it may be that binding is again towards 
GD1a:GD1b complex formed by contaminating GD1b, giving that the 
immunoreactive band corresponds only to the overlapping portion of GD1a and 
GD1b in lane three, rather than the whole extent of GD1a revealed by orcinol. In 
contrast, MOG35 binds GD1a in lane 1, and also recognises the same ganglioside 
in lane 3, with the immunoreactivity appearing to extend into the overlapping 
zone with GD1b (Figure 3.13B).  Chapter 3  Results     115 
 
 
 
 
Figure 3.13 - CGM2 and CGM3 bind GD1a:GD1b complex by TLC with immuno-overlay 
Three lane panels of GD1a, GD1b and both GD1a and GD1b were run in triplicate on silica coated 
TLC plates. These were then divided, and the left most panel developed with the orcinol reagent to 
reveal the distribution of the gangliosides (A). Overlay with CGM2 or CGM3 (B, both at 50µg/ml, 
anti-mouse IgM-HRP secondary at 1:6000, 15s exposure) revealed binding to the overlapping 
portion of GD1a:GD1b in lane 3. In contrast, MOG35 (30µg/ml, secondary at 1:3000, 5s exposure) 
shows binding to GD1a in lane 1, as well as in lane 3, where the immunoreactivity also appears to 
extend into the overlapping region with GD1b. A very faint band in lane 2 at the GD1a level may 
indicate minor contamination of GD1b with GD1a.  Chapter 3  Results     116 
 
 
3.2.12  Antibodies in neuropathy sera bind GM1:GD1a 
complexes on ELISA and PVDF glycoarray 
Provision of further sera containing antibodies purported to bind GM1:GD1a 
complex (again by Professor Susumu Kusunoki of Kinki University, Osaka, Japan) 
allowed binding to be assessed on both ELISA and PVDF glycoarray. Due to the 
limited volumes of sera available, the ELISA assay was limited to GM1, GD1a and 
GM1:GD1a in duplicate. In contrast, a full 10x10 PVDF array was able to be 
processed. Distinct from the disparate GM1:GD1a complex binding seen with the 
b-series mAbs above, both sera 444/17 and 470/23 bound the complex on PVDF 
(Figure 3.14A+B) and in ELISA (Figure 3.14C). Furthermore, the sera remained 
able to bind the complexes on PVDF even when their concentration was reduced 
fivefold (to 1 in 200) as compared with ELISA. Some other discrepancies were 
noted between the two assay systems, however, particularly for serum 470/23. 
On ELISA, this serum bound to GD1a (with a mean OD of 1.55 at 1 in 40 dilution) 
in addition to the GM1:GD1a complex. On PVDF, although binding to this 
complex remained, reactivity to isolated GD1a was not seen. Additionally, 
binding to other complexes of GM1 or GM2 with GD1a, GT1b or GQ1b was also 
noted (Figure 3.14B). There was insufficient 470/23 serum available to 
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Figure 3.14 - Neuropathy sera binding GM1:GD1a complex on PVDF and in ELISA 
In contrast to the findings with the b-series monoclonal antibodies, above, two GM1:GD1a binding 
sera remained able to bind this complex both on PVDF glycoarray (A) and ELISA (B). Binding by 
serum 470/23 to GD1a in isolation, as demonstrated by ELISA, was not replicated on PVDF 
glycoarray, which also demonstrated interaction with a range of other complexes. 
3.2.13  GM1:GD1a anti-sera ex vivo binding assays 
A small number of GBS associated sera were additionally kindly provided by 
Professor Nobuhiro Yuki (Yong Loo Lin School of Medicine, National University of 
Singapore). Two groups had been selected. The first contained 4 sera binding 
GM1:GD1a complex, the second contained 6 sera binding GM1, but not GM1:GD1a 
complex. Unfortunately, these were provided as lyophilised samples and only 2 
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be returned to a gelatinous, semi-solid state unsuitable for use in any sort of 
immunoassay. Nevertheless, 3 of the successfully reconstituted sera showed 
diverse IgG binding patterns on PVDF glycoarray and ELISA, and were selected 
for further study in ex vivo preparations.  
As shown (Figure 3.15), serum A binds most strongly to GM1:GD1a complex, with 
no (on PVDF) or much reduced (ELISA) binding to GM1 and no GD1a reactivity. 
Complex specific binding is also seen towards GA1:GD1a, and to a lesser extent 
GD1a:GD1b. The other two sera would act as near ideal controls in the 
subsequent ex vivo assay. Thus, the faint GA1 binding seen with serum A is 
controlled for by serum B, which binds this single antigen more strongly. Serum 
C shows complex attenuated binding, its interaction with GM1 being blocked by 
other gangliosides including GD1a, but, curiously, only slightly attenuated by 
GalNAc-GD1a. Chapter 3  Results     119 
 
 
 
Figure 3.15 - Glycoarray and ELISA analysis of complex specific, independent and 
attenuated sera used in subsequent ex vivo assay 
PDVF array: (A) serum A, (B) serum B, (C) serum C. All at 1 in 100 dilutions, 5 minutes exposure 
time. (D) Comparative ELISA data (1 in 40 dilution).   
These three sera were then taken forwards for use in an ex vivo assay using 
hemidiaphragm tissue harvested from GD3s
-/- mice. As only 100 to 200µl of each 
serum were available, the ex vivo assay with live hemidiaphragm tissue 
described in 2.2.9 could not be performed. This requires at least 3ml of serum at 
a 1:1 dilution. Instead the harvested diaphragm was snap frozen and processed 
as described (2.2.14), and the sera incubated directly on the frozen sections. In 
this protocol, only 100µl of diluted serum is required per slide. Following 
incubation for 4hrs at 4ºC, the slides were rinsed and an anti-IgG FITC secondary 
antibody applied as previously described. At serum dilution of 1 in 2, 1 in 8, and 
1 in 16, no detectable binding was seen with any of the three sera assayed 
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3.3 Discussion 
The results described in this chapter contribute to the understanding of 
antibody-ganglioside complex interactions in a number of ways. The most 
apparent observation is that the effect of ganglioside complexes on antibody 
binding has now been extended from the setting of neuropathy sera to include 
monoclonal antibodies. Whilst suggesting a wider importance for such 
interactions, this data also allows a number of other conclusions to be drawn. 
For example, data from polyclonal sera where binding is observed directed 
towards both single gangliosides and GSCs does not allow easy ascertainment of 
whether one antibody is able to bind both single gangliosides and complexes, or 
whether the range of binding seen represents a number of distinct antibodies. 
Data from GSC ELISA and TLC-immuno-overlay demonstrates clearly that 
monoclonal antibodies raised against and reactive towards single gangliosides 
can additionally bind GSCs not containing this particular ganglioside, at least in 
certain circumstances. For example, the anti-GD1a antibody TBG2 also 
recognises an epitope formed by GM1:GT1b on ELISA, and the anti-disialosyl 
antibody CGM3 additionally binds GD1a:GD1b on TLC, and to a lesser extent on 
ELISA. This is intriguing but also somewhat disconcerting. It can be easily 
envisaged how, in a family of molecules with different but very much related 
structures, a recognition site on one ganglioside could be replicated by 
component sites on two other gangliosides. For example, a binding site created 
by the terminal Gal-GalNAc disaccharide and internal (attached to the inner 
galactose) disialosyl groups of GD1b might be recreated by the same terminal 
Gal-GalNAc disaccharide present on GM1, plus one internal sialic acid each from 
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explanation. The presence of the second ganglioside may alter the orientation, 
or flexion of the oligosaccharide headgroup with respect to the lipid tail, of the 
first. This may then expose previously cryptic binding sites. Similarly, the 
presence of an additional ganglioside might simply alter the spacing of the first. 
For example, the terminal Gal-GalNAc disaccharide of GD1b would be expected 
to be spaced further apart, both in vitro and in vivo, by the greater volume 
occupied by its two internal sialic acids and hydration water. The terminal Gal-
GalNAc disaccharide of GM1, alternatively, would pack closer together as this 
ganglioside has only one internal sialic acid. (Sonnino et al., 2007) GD1a added 
to GM1 might then act as a spacer, pushing the headgroups of GM1 further apart 
and thus mimicking GD1b (Figure 3.16).  Chapter 3  Results     122 
 
 
 
Figure 3.16 - Potential mechanisms of ganglioside complex mediated binding 
Four different potential mechanisms by which the presence of a second ganglioside might enhance 
the binding of a lectin are illustrated, using GM1 and GD1a as an example. In the first (A) the 
proximity of two different glycolipids in the membrane allows them to occupy two discrete binding 
sites of a lectin, thus synergistically increasing the avidity of the interaction through the combined 
effect of two lower affinity bonds. In this example, the two gangliosides themselves do not 
chemically interact. This model could not be applied to antibodies, but may apply to other lectins 
with multiple glycan binding sites, such as bacterial toxins. In (B), GM1 and GD1a form a 
heterodimer, perhaps via the formation of hydrogen bonds, generating a neo-epitope with 
increased affinity for the lectin in comparison with either solitary ganglioside. In this example, 
monosaccharides from both component gangliosides are involved in the binding site. In (C), the 
binding site of one ganglioside is inaccessible until an interaction with a second ganglioside alters 
the orientation of the first. Only saccharide groups from one ganglioside contribute to the binding 
site. In (D), the spacing between two GD1b molecules is optimum to occupy a binding site. When 
GM1 is present alone (E), the closer packing of the headgroups no longer facilitates binding. When 
GD1a is also present (F), its interdigitation with GM1 alters the spacing of the latter ganglioside to 
resemble that of GD1b, and binding can occur. Chapter 3  Results     123 
 
 
However, given these thoughts and observations, it is not readily apparent 
whether the antigen established by in vitro techniques is the true target in vivo. 
In the case where multiple targets are suggested by solid phase assays, whether 
the antibody recognises one or more of these in the living membrane cannot 
seemingly be easily predicted. 
The other significant finding with respect to ganglioside complexes and antibody 
interactions is the observation of the second ganglioside inhibiting binding of 
antibody to the first. This had been previously speculated to be the reason why 
anti-GM3 antibodies bound well to melanoma cells containing GM3 alone, but not 
to cells also containing more complex gangliosides such as GD2 and GD3, even 
when GM3 formed up to 50% of the total ganglioside content. (Lloyd et al., 1992) 
A similar observation was made in vitro with the anti-DG1 mAb, which binds GM1 
in isolation but not in the presence of GD1a. The fact that an apparently similar 
antibody (DG2) remains able to bind GM1 in such circumstances suggests a 
hitherto unsuspected mechanism whereby the fine specificity of anti-GM1 
antibodies might prove critical to their pathogenic potential. This was born out 
by the elegant series of experiments performed by Dr Greenshields. The initial 
observation was that DG1 failed to bind, whereas DG2 bound strongly, to ex vivo 
neuromuscular preparations from GD3s
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Figure 3.17 - The disparate ex vivo binding patterns of two anti-GM1 monoclonal antibodies 
DG2 binds to the presynaptic apparatus of the NMJ in GD3s
-/- mice, whereas DG1 does not (lower 
panels, kindly supplied by Dr Kay Greenshields). This is compared with the inhibition of DG1 
binding to GM1 by other gangliosides seen on the PVDF glycoarray and the ability of DG2 to bind 
GM1 regardless of the presence or absence of a second ganglioside (upper panels). 
After neuraminidase treatment to unmask GM1 by converting GD1a to GM1, 
binding of DG1 was observed to occur. Of course, in this situation, DG1 might 
simply be binding to de novo GM1 produced by the enzymatic cleavage of the 
terminal sialic acid of GD1a. Pre-blocking native GM1 with cholera toxin B 
subunit (CTB) prior to neuraminidase treatment, however, substantially reduced 
the binding of DG1, indicating only a proportion of the binding seen was to de 
novo GM1. Examination of IgM GM1-antibodies (SM1 and DO1, (Willison et al., 
1994;Paterson et al., 1995)) cloned from patients with multifocal motor 
neuropathy (MMN) showed that they also displayed the same properties as DG1, 
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2009). It is apparent that the interaction of anti-GM1 antibodies with their 
target in solid phase assays does not necessarily imply that they will bind GM1 in 
the living membrane. Such antibodies could become important if the membrane 
is disturbed, for example by neuraminidase or during regeneration, when GM1 is 
then exposed for binding. Additionally, it was shown that the ‘non-pathogenic’ 
DG1 mAb was able to interact with the LOS GM1 mimic on the surface of both 
live and dead C.jejuni even when this was co-expressed in a 50:50 ratio with the 
GD1a mimic. (Greenshields et al., 2009) This implies that certain GM1 antibodies 
might be protective against infection, without compromising self tolerance, at 
least under normal circumstances.  Furthermore, such studies underscore the 
importance of the fine specificity of anti-GM1 antibodies with respect to their 
pathological effects, and provide a potential explanation for the previous 
discrepant results obtained with such antibodies. 
The identification of mAbs with ganglioside complex modulated binding has 
allowed the assessment of factors potentially confounding the hypothesis that 
the interacting presence of the second ganglioside itself is critical. The TBG2 
and DG1 ELISAs demonstrate that simple dilutional effects do not account for 
complex enhanced or attenuated binding. The idea that a straightforward 
summation of affinities towards each single ganglioside is responsible is 
countered by the observation that prior sonication of the two ganglioside 
mixture is required to demonstrate a modulatory effect, at least in some cases. 
It may be that the energy supplied by sonication breaks apart micelles 
containing each single ganglioside and allows them to reform as complex 
mixtures. There is now both direct and indirect evidence that the presence of 
one ganglioside does not significantly enhance or impair binding of the other to 
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both enhanced and attenuated (as well as unaltered) as compared to GM1 alone 
by ELISA, it is difficult to consistently support the argument that the amount of 
GM1 binding to the plate is either increased or decreased. Furthermore, direct 
evidence from the PVDF array shows that the amount of GM1 attached to the 
membrane is not significantly different in the presence or absence of GD1a.  
The above results also expand the concept that lectin-glycolipid interactions can 
be dependent on the surface used for the assay, the presence of accessory 
lipids, and whether or not the glycolipids are applied in aqueous phase. Similar 
observations have been made previously with regard to neuropathy sera binding 
single gangliosides. Here temperature, and whether or not liposomes were 
employed to present the ganglioside, both had profound, but not universal, 
effects on such interactions (Willison & Veitch, 1994). The data presented above 
also highlights the difficulty in predicting the consistency of binding patterns 
across different surfaces and assays, and in confirming the binding observed in 
vitro correlates with that which may or may not occur in the living membrane. 
Differences seen between the TLC, ELISA and PVDF array might simply be due to 
differences in antigen density. However, an estimation involving the well versus 
spot area, and concentrations and volumes of ganglioside applied suggests this 
should be similar between ELISA and PVDF – as was intended when developing 
the new assay- albeit making a number of assumptions, such as total binding of 
all of the applied ganglioside to the surface and no spreading of the solvent 
beyond the contact area on PVDF.  
Another potential explanation is that the interaction of the gangliosides with the 
surface used for the assay (silica for TLC, polystyrene for ELISA, or PVDF) is 
affected by how hydrophilic each material is, and/or by differences in surface Chapter 3  Results     127 
 
 
charge. This might change the orientation of ganglioside attachment, cause 
different flexion of the headgroup with respect to the lipid tail, and variously 
facilitate or inhibit ganglioside-ganglioside interactions. In an extreme example, 
a positively charged surface might bind directly to the negative charge of the 
oligosaccharide headgroup, in which case the ganglioside might be presented 
‘upside down’ as compared with a hydrophobic membrane in which the lipid tail 
would be buried and the headgroup protrude above. As has been discussed, all of 
these factors could potentially modulate antibody accessibility and interaction.  
It is also apparent that there is a further level of fine specificity even within the 
concept of anti-ganglioside complex antibodies defined by ELISA, as 
demonstrated by the observations made with GM1:GD1a. Certain mAbs are able 
to bind this complex on ELISA, but not PVDF, whereas different sera remain able 
to bind in both settings. It may be that some antibodies are more sensitive than 
others to changes in target antigen spacing or orientation. It is therefore 
possible that some mAbs developed for use in in vivo assays are not fully 
representative of the fine specificities of the immunoglobulin found in disease 
associated sera, even when their binding pattern on ELISA appears identical.  
The idea that complex specific, independent and attenuated antibodies have 
different pathological effects in vivo is intriguing. The experiment detailed in 
3.2.13 highlights the pitfalls in attempting to use human sera to address this 
hypothesis. First of all, one cannot be sure that a single monoclonal antibody is 
being investigated, as each sample could potentially contain numerous 
antibodies of differing specificities from multiple expanded antibody producing 
clones of greater or lesser importance. Furthermore, the limited volumes most 
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in solid phase assays. A similar problem is posed by neuromuscular tissue studies. 
Ideally, organ bath preparations with live membranes would be performed, but 
these require more serum than is routinely obtainable. Despite the prior 
hypothesis that ganglioside complexes are disturbed in frozen sections, this was 
the only tissue based assay which could be practicably performed. In this 
context the lack of detectable binding seen with all of the three sera is difficult 
to interpret, and certainly no firm conclusions can be drawn from this, very 
limited, data. The fact that even the complex independent GA1 specific and 
complex attenuated GM1 specific sera (B and C) failed to bind suggests the 
possibility that the assay itself was flawed. The lack of an adequate positive 
control for this assay unfortunately means that even this assertion remains 
speculative. 
The final contribution detailed in this chapter is the newly developed, 
combinatorial, PVDF glycoarray. This has been shown to be a suitable method for 
screening large numbers of lectins for complex modulated binding. The assay 
variability falls within acceptable limits, and is comparable with ganglioside 
ELISA. Furthermore, it is considerably more efficient than the existing 
techniques when considering the antigenic diversity generated by a 
combinatorial approach. This has utility not only in the setting of testing clinical 
series of neuropathy sera, but also in examining other families of lectins, as 
detailed in the subsequent chapter. 129 
4  The ganglioside binding properties of bacterial 
toxins and siglecs 
4.1 Introduction 
Gangliosides are not only important as auto-antibody targets in immune 
neuropathies, as previously discussed. Protein-carbohydrate interactions are also 
involved in a wide variety of other biological processes, including cell-cell 
interactions and signalling, immune system modulation, bacterial toxin binding 
and microbial adherence. It was therefore speculated that ganglioside complex 
(GSC) formation might also influence lectin binding in these other systems. If 
such modulation was found to occur, this would have a profound impact on the 
understanding of all of these processes, potentially forcing a revaluation of 
protein-carbohydrate interactions in a more general sense. The newly developed 
PVDF glycoarray allowed screening of various lectins for binding against a range 
of gangliosides and their 1:1 complexes. 
Recombinant chimeras containing the extracellular region of siglecs fused to the 
Fc domain of human IgG1 were kindly provided by Professor Paul Crocker 
(Dundee, Table 4.1). A horseradish peroxidase conjugated binding fragment of 
tetanus neurotoxin (TENT-HC-HRP) was prepared and provided by Professor 
Giampietro Schiavo (London). This neurotoxin has previously been demonstrated 
to bind GD1b ganglioside (Deinhardt et al., 2006). Cholera toxin B subunit linked 
to HRP is available commercially (Calbiochem, USA) and is known to avidly bind 
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Siglec  Concentration  Previously reported binding pattern 
Sialoadhesin-Fc  0.3mg/ml  GQ1bα>>GD1a=GT1b>>GM3=GM4 
MAG-Fc  0.1mg/ml  GD1a, GT1b 
Siglec-7-Fc  0.6mg/ml  GD3, GQ1b, GT1b 
Siglec-E-Fc  1.5mg/ml  GM3, GD3, GT1b, GQ1b 
Siglec-F-Fc  0.8mg/ml  GQ1b>GT1b 
Siglec-9-Fc  4.5µg/ml   
MAG-Fc  2.9mg/ml  GD1a, GT1b 
Sialoadhesin-1-3-Fc  8.1mg/ml   
 
Table 4.1 - Siglecs provided by Prof. Paul Crocker 
The first 5 siglecs in the list were provided as purified proteins. The last three were provided in a 
second batch as tissue culture supernatants. Sialoadhesin-1-3-Fc is a truncated mouse 
siaoladhesin construct. Siglec-E is a mouse siglec showing overlapping function with human 
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4.2 Results 
4.2.1 Siglec-ganglioside interactions are modulated by 
ganglioside complexes 
Of the provided siglecs, binding to any gangliosides by ELISA and PVDF array was 
only detected for siglecs 7, E and F. Nevertheless, all three of these lectins 
exhibited binding which was modulated by GSCs. Once again, different patterns 
were sometimes seen when ELISA was compared with PVDF. 
Siglec-E-Fc binds to GM2:GT1b on PVDF, while showing no signal for GM2 alone 
and only very weak binding to GT1b. Furthermore, this pattern is repeated on 
ELISA. In contrast, siglec-F-Fc reacts with GM2 alone as assessed by the PVDF 
array, remains able to bind this target in the presence of GT1b (i.e. binds to the 
GM2:GT1b complex), but is inhibited from GM2 binding in the presence of GM1 
(fails to bind to GM1:GM2). On ELISA, siglec-F binding to GM2, GT1b and 
GM2:GT1b is not significantly elevated above background (Figure 4.1). Both of 
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Figure 4.1 - The binding of siglecs E and F is modulated by ganglioside complexes 
Example processed PVDF grids of siglec-E-Fc (A) and siglec-F-Fc (B) are shown. By this method, 
the binding of siglec-E to GM2:GT1b (C) is significantly increased as compared to sum of the 
intensities for GM2 and GT1b alone (an absolute binding intensity increase of 75%, p=0.004). 
Siglec-F Binds to GM2, and to a lesser extent GT1b, but binding to GM2:GT1b is not significantly 
different to the sum of these. In contrast, binding of this siglec to GM2 is significantly impaired by 
the GM1:GM2 complex (D, an average intensity reduction of 45%, p=0.027). On ELISA (E), the 
enhanced binding of siglec-E to GM2:GT1b is also seen, but just fails to reach significance 
(p=0.068). All statistical comparisons used a two-sample, two-tailed T-test, with an α-level of 0.05. Chapter 4  Results     133 
 
 
Siglec-7 is a human cell surface receptor present on natural killer cells and 
monocytes. It has previously been established to bind disialylated gangliosides 
such as GD3, GT1b and GQ1b. 
This binding pattern was confirmed by PVDF glycoarray, but a further level of 
complexity was revealed. Most strikingly, the interaction of siglec-7 with GD3 is 
very significantly attenuated by certain complexes. The interaction with GD3 in 
isolation yields a mean relative signal intensity of 70.3%, yet the intensity seen 
with complexes of GD3 and any of GM1, GM2, GD1a, GD1b and GT1a is reduced 
at between 0.62% and 14.7% (p<0.0001, GLM ANOVA with Dunnett correction, 
family error rate 0.05, n=3). Furthermore, siglec-7 binding was modulated by a 
number of other complexes as compared to the component gangliosides in 
isolation (Figure 4.2A). The inhibitory effect of GM1 on GD3 binding was also 
observed to occur by ganglioside complex ELISA and liposome ELISA (Figure 
4.2B). 
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Figure 4.2 - Siglec-7 and TeNT HC binding is modulated by ganglioside complexes 
(A) Complex mediated binding of siglec -7 to gangliosides as demonstrated by PVDF glycoarray. 
The accompanying graph shows the complex reactivity which significantly differs from the sum of 
the binding intensities of the two component gangliosides, and the magnitude and direction of the 
change. The inhibitory effect of GM1 on siglec-7 interaction with GD3 is also seen on standard and 
liposome ELISA (B). The average absolute values from each set of three independent experiments 
have been normalised to 100% to allow comparison in the same histogram. Uncorrected maximum 
binding values were 0.34, 1.14 and 70.3% for standard ELISA, liposome ELISA and PVDF 
glycoarray respectively. Tetanus toxin (C) also displays complex mediated binding on PVDF. The 
accompanying graph again shows the complex reactivity which significantly differs from the sum of 
the binding intensities of the two component gangliosides, and the magnitude and direction of the 
change. When compared with siglec-7, the opposite effect is seen with respect to GD3 and 
GM1:GD3, with siglec-7 binding being inhibited and TeNT HC enhanced by the complex (D). 
Asterisks denote complexes showing binding levels significantly different from the sum of the two 
individual components. Although some of the non-asterisk marked complex binding intensities are 
significantly different to one or other of the component gangliosides, they are not different to the 
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4.2.2 Certain bacterial toxin-ganglioside interactions are complex 
modulated 
Analogous to siglec-7 and GD3, the sialic acid binding fragment of tetanus toxin 
(TeNT HC) is strongly inhibited from binding GQ1b in the presence of GM2 (Figure 
4.2C, p=0.002, GLM ANOVA with Dunnett correction, family error rate 0.05, 
n=3). The interaction of TeNT HC with GD3 series complexes is in marked 
contrast to siglec-7, however (Figure 4.2D). The toxin does not bind the single 
gangliosides GD3, GM1, GD1a or GT1a, yet reacts strongly with complexes of 
these gangliosides containing GD3. As previously discussed, a confounding factor 
in attributing this effect to the formation of a neo-epitope is that lower degrees 
of binding to individual glycolipids could simply summate. To take into account 
this possibility, the previous ELISA definition (that for true complex reactivity, 
the optical density - OD - for the complex must exceed the sum of the individual 
ODs) (Kaida et al. 2007b) has been expanded to include an additional degree of 
statistical rigor. Complex modulated binding is defined as the state in which the 
signal intensity of the complex minus the sum of the signal intensities of the 
isolated glycolipids (to a maximum of 100%) is significantly different from zero. 
Interactions meeting this definition are marked with an asterisk on the histogram 
(Figure 4.2D). The magnitude of the effect along with confidence intervals is 
depicted in the graphs of Figure 4.2A+C. 
Unlike TeNT HC, cholera toxin B subunit (CTB) binding was not complex 
modulated. There was no significant difference in CTB binding to GM1 as 
compared with any of the GM1 containing complexes at a 1:20,000 dilution (GLM 
ANOVA with Dunnett correction, family error rate 0.05, n=3). Furthermore, to 
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not simply a result of saturation, a higher concentration of 1:10,000 was also 
assayed. The absolute intensity for each complex with the higher concentration 
was increased, showing that the signal is not saturated at the lower 
concentration, and again there was no significant difference in binding to GM1 as 
compared with any of the GM1 containing complexes. Results for the 1:20,000 
dilution have been normalised to the most intense spot at 1:10,000 to reflect 
this (Figure 4.3).  
 
Figure 4.3 - Cholera Toxin B subunit binding to GM1 is unaffected by complexes 
Unlike TeNT HC, CTB’s interaction with GM1 is unaffected by the presence or absence of 
partnering gangliosides. An example membrane following the application of CTB at 1:20000 
dilution for 2 minutes is shown. The accompanying graph shows the signal intensity for GM1 
complexes is not significantly different to that of GM1 alone. The relative intensity for CTB at 
1:20000 has been normalised to the most intense spot on a separate array probed with CTB at 
1:10000, demonstrating the signal seen at 1:20000 is not saturated. The complex independent 
binding of CTB is contrasted with the complex attenuated binding of DG1 and complex enhanced 
binding of serum A. Note that, on this graph, comparisons between the signal intensity obtained for 
the different lectins are not valid, as they have been normalised within their own set of experiments. 
Instead, these other lectins are included merely to compare the different patterns of complex 
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4.3 Discussion 
These results demonstrate that the implications of ligand-enhancing and -
attenuating complexes are wide ranging as illustrated in by the following 
examples. Siglec-7 is a CD33 related human natural killer cell receptor (Avril et 
al. 2006a), and siglecs E and F are mouse lectins found on neutrophils, 
monocytes, dendritic cells, and eosinophils, respectively.  Siglecs are involved in 
self/non-self recognition, yet their ligands are present on host cells an as well as 
on many pathogens (Crocker et al. 2007). The further level of complexity 
introduced by cis interacting glycolipids could allow fine-tuning of siglec-
dependent recognition relevant to host immunity (Avril et al. 2006b).  
TeNT HC initially binds to GD1b on the axonal surface, yet when the toxin is 
internalised, the ganglioside remains on the plasma membrane.(Deinhardt et al. 
2006) During the internalisation at the plasma membrane, GD1b might be 
sequestered by a different complex, reducing its affinity for TeNT HC, and 
allowing the dissociation of the toxin from the ganglioside prior to 
internalisation. Although we have not demonstrated a dramatic on-off effect for 
TeNT HC binding to GD1b series complexes, the statistically significant 
differences in signal intensity between a number of different GD1b complexes 
may have biological relevance. Alternatively, other GD1b-complexes not studied 
in the current array format may prove important in vivo. Conversely, CTB 
displays complex independent binding to GM1 and enters cells bound to GM1 
(Lencer et al. 1999; Lencer 2004), reinforcing the notion that glycolipid 
complexes cannot modulate dissociation of CTB from GM1 prior to 
internalisation. These examples highlight the subtle ways in which differing 
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subsequent functional or pathological effects. Furthermore, many membrane 
proteins are glycosylated, and these oligosaccharides interact with other protein 
and carbohydrate molecules, with functional importance in processes such as 
cell-cell interaction (Hakomori 2002).  It is possible that the heterogeneous 
clustering of oligosaccharides in this paradigm might also influence such 
processes. To date, the only direct evidence for the existence of ganglioside 
complexes in nature is detailed in the studies already discussed (Greenshields et 
al. 2009; Todeschini et al. 2008; Todeschini and Hakomori 2008). In light of the 
observations detailed in this chapter, however, it would seem that looking for 
other potentially pathophysiologically relevant glycolipid complexes and 
assessing their modulatory effects in vivo will prove to be a fruitful area of 
future research.  
Although current considerations of the modulatory effects of ganglioside 
complexes, including this one, have dealt with only heterodimers, it is possible 
that even more intricate interactions, involving three or more glycolipids, might 
prove equally as important. Investigating such situations becomes increasingly 
more difficult as the number of component glycolipids increases, making the 
ability to automatically array ligands described here even more valuable. 
At present, there is a conceptual mismatch between assessing lectin interactions 
in vivo, where many accessory factors in plasma membranes will influence 
binding, and in vitro, where investigations have almost exclusively focussed on 
assessing reactivity to isolated, purified oligosaccharides in artificial systems (for 
example Blixt et al. 2004; Byres et al. 2008).  This concept, and its practical 
demonstration, reveals new horizons in the study of diverse processes including 
cell-cell recognition, toxin binding, autoimmunity and microbial invasion. Chapter 4  Results     140 
 
 
The results detailed in this chapter also further reinforce that concept of three 
distinct patterns of lectin binding with respect to glycolipid complexes. For both 
GM1 and GD3 series complexes in particular, complex enhanced, complex 
independent and complex attenuated binding has been demonstrated (Figure 
4.4). Furthermore, these results also provide further evidence that the 
attenuation and enhancement of lectin binding seen is not simply a result of 
dilution of one lipid, glycolipid or ganglioside by another. For example, for 
tetanus toxin, simply diluting the GD3 with GM2 or GM3 has no effect on binding, 
whereas GD3 plus GM1 leads to a significantly enhanced signal. The same 
argument can be made for serum A reactivity with GM1:GD1a complex. If GM1 is 
instead ‘diluted’ with GD3 or GQ1b, or GD1a with GM3, GM3, GD3, GT1b or 
GQ1b, no binding results. Likewise, the inhibitory effect of GM1 on GD3 binding 
by siglec-7 is not replicated by dilution of GD3 with GM3.  Chapter 4  Results     141 
 
 
 
 
Figure 4.4 - Complex attenuated, complex independent and complex enhanced binding 
Three distinct patterns of lectin-carbohydrate interaction have been demonstrated, both for GM1-
series and GD3-series complexes. With complex attenuated binding, the lectin is able to interact 
with either GM1 or GD3 in isolation, but when a GM1:GD3 or GM1:GD1a complex is formed 
binding is prevented, possibly because the binding site is now cryptic. In complex independent 
binding, the lectin-carbohydrate interaction is unaffected by the presence or absence of a second 
partnering glycolipid. For complex enhanced binding, the GM1:GD3 or GM1:GD1a complex is 
bound, with no significant reactivity seen for either component ganglioside in isolation. 
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5  Anti-ganglioside and glycoplipid complex 
antibodies in a cohort of Guillain Barré 
syndrome patients 
5.1 Introduction 
The previously described observations provided the background and extra 
impetus to screen a large cohort of sera from GBS patients against a spectrum of 
ganglioside complex antigens using the PVDF glycoarray. Opportunistic studies 
using locally obtained samples on an ad hoc basis had further demonstrated that 
both complex enhanced and attenuated patterns of binding could be seen 
(Figure 5.1). 
 
Figure 5.1 - Complex attenuated and enhanced binding in neuropathy sera 
Binding of IgM antibodies in sera from a patient with multifocal motor neuropathy (MMN, A) follows 
a complex attenuated pattern. Binding is detected towards GM1 in isolation, but is not seen with 
GM1:GD1a complex, similar to the pattern of binding described for the monoclonal antibody DG1 in 
chapter 1. In contrast, sera from a patient with acute motor axonal neuropathy (AMAN, B) 
demonstrates enhanced binding to the GM1:GD1a complex by IgG as compared with GM1 and 
GD1a in isolation. 
A large cohort of GBS associated sera, with parallel clinical data, were available 
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Combined with the PVDF glycoarray, this provided the opportunity to screen a 
large number of sera against a large number of complex antigens. In the simplest 
terms, this allowed us to address the hypothesis that potential antigenic targets 
in GBS had been previously overlooked because the combinatorial aspect had 
either been overlooked entirely, or, more recently, only addressed for a limited 
number of complexes (Kaida et al., 2004;Kaida et al., 2006;Kaida et al., 2007), 
given the constraints of the ELISA system used. In addition to addressing many of 
the apparent serological-pathological inconsistencies as detailed in the 
introduction and further highlighted in chapter 3 above, this part of the study 
also has the capability to further develop some of the potential clinical 
applications of GBS immunology. 
As mentioned, the diagnosis of GBS is largely a clinical one, supported by 
cerebrospinal fluid analysis and nerve conduction studies, both of which may 
also be normal, especially early in the disease course (Asbury & Cornblath, 
1990;van der Meche et al., 2001). Likewise, current immunological assays in 
clinical use for the detection of anti-ganglioside antibodies are more often 
negative than positive in the disease. Therefore, if a more sensitive and specific 
immunological test could be derived, based on the PVDF glycoarray, this has the 
potential to refine and improve the diagnostic process. Furthermore, predicting 
prognosis and severity of GBS early in the disease can be difficult, although a 
recently derived clinical scoring system has been shown to be accurate predictor 
of the requirement for mechanical ventilation, one of the most feared 
complications (Walgaard et al., 2010). In addition, previous analysis of GSC 
antibodies using ELISA has demonstrated a significant association between the 
presence of GD1a:GD1b and/or GD1b:GT1b complex antibodies and severe 
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was postulated that the fine specificity and more distinct patterns of antibody 
response revealed by the PVDF array might be better correlated with such 
important clinical parameters. Chapter 5  Results     145 
 
 
5.2 Results 
5.2.1 Patient cohort 
5.2.1.1  Patients 
The patients in this cohort had previously participated in a clinical trial 
investigating methylprednisolone as an add-on to IVIg treatment in 225 GBS 
patients. (van Koningsveld et al., 2004) Inclusion criteria were fulfilment of the 
NINDS diagnostic criteria for GBS, (Asbury & Cornblath, 1990) being unable to 
walk unaided ten metres across an open space (GBS disability score 3 or more) 
and onset of weakness within two weeks before randomization. Exclusion 
criteria were age below six years, previous GBS, known severe allergic reaction 
to properly matched blood products, pregnancy, known selective IgA deficiency, 
previous steroid therapy, severe concurrent disease, inability to attend follow-
up, or contraindications for corticosteroid treatment. Approval was granted by 
an ethical standards committee on human experimentation for the study 
mentioned above. Written informed consent was received from all patients. To 
be included in the current study sufficient amounts of pre-treatment serum had 
to be available to perform the combinatorial glycoarray. Twenty samples were 
obtained from healthy controls in parallel with collection of the GBS associated 
sera, and a further 54 from healthy controls at the University of Glasgow and 
Southern General Hospital, Glasgow.  
5.2.1.2  Clinical data 
Baseline characteristics (age, gender), preceding diarrhoea or symptoms of an 
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disability score, and sensory deficit at study entry were collected prospectively. 
The GBS disability score is a widely accepted scale to assess functional status of 
GBS patients, ranging from zero (normal) to six (death). (Hughes et al., 1978) 
Serological screening was performed to determine recent infections with 
Campylobacter jejuni, cytomegalovirus (CMV), Epstein-Barr virus (EBV), and 
Mycoplasma pneumonia. The serum samples used were obtained within four 
weeks from onset of weakness and before start of treatment.  
Clinical data was available for 180 of 181 patients (99.4%). 103 were male 
(57.2%) and 77 female (42.8%). The mean age of patients was 52.6 years (range 7 
to 89). Electrophysiological data was available for 149 out of 181 patients 
(82.3%). The majority were classified either as AIDP (56, 37.6%) or equivocal (85, 
57.0%). Only 4 patients had electrophysiology consistent with the axonal variant 
AMAN (Figure 5.2). 
 
Figure 5.2 - Electrophysiological categorisation of disease subtype 
Electrophysiological data was available for 149 patients in the cohort. The majority were classified 
as equivocal on this basis. 56, or 37.6%, were electrically confirmed as AIDP, with only 4 (2.7%) 
classified as AMAN. 
Severity scores were recorded at a number of time points, using the GBS 
disability score. Data is shown for the severity score at randomisation (day 0), 
day 9, week 4, week 8, week 26 (Table 5.1). Chapter 5  Results     147 
 
 
GBS Disability Score  Day 0  Day 9  Week 4  Week 8  Week 26 
0  healthy  0  0  2  11  40 
1 
minor symptoms, 
capable of running  0  3  32  59  79 
2 
able to walk 10 m 
unassisted, but unable 
to run 
0  18  60  45  26 
3 
able to walk 10m over 
open space with help  46  45  16  20  11 
4 
bedridden or chair 
bound  126  81  47  29  10 
5 
needs ventilator at 
least for part of day  8  33  21  10  0 
6  dead  0  0  2  2  5 
Table 5.1 - GBS disability score at selected time points 
Over the course of their disease, 41 patients (22.8%) required mechanical 
ventilation at some point. There were 5 deaths (2.8%). 
There was a preceding history of upper respiratory tract infection (URTI) in 65 
patients (36.1%), and diarrhoea in 49(27.2%). Campylobacter jejuni, 
cytomegalovirus and Mycoplasma pneumoniae serology was positive in 50, 24 and 
11 patients (27.8, 13.3 and 6.1%) respectively. 93 (51.7%) had cranial nerve 
deficits during follow up, and 17 (9.4%) had bulbar involvement. A further 
breakdown of the cranial nerves affected is given in Table 5.2. 
Cranial Nerve  Number Affected  Percentage 
Optic  0  0.0 
Oculomotor  6  3.3 
Trochlear  3  1.7 
Abducens  5  2.8 
Trigeminal  9  5.0 
Facial  53  29.4 
Glossopharyngeal / Vagus  16  8.9 
Accessory  9  5.0 
Hypoglossal  4  2.2 
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5.2.2 Target selection 
The choice of glycolipids to use in this assay was directed by three parameters; 
the detection of the molecule in peripheral nervous system (PNS) myelin or 
axonal extracts, previous reports of neuropathy sera reactivity against the 
glycolipid, and the availability of the glycolipid, either commercially or via 
collaboration with other investigators. An initial screen using a 10x10 array 
consisting of sulfatide, galactocerebroside, GM1, LM1, GD3, GD1a, GD1b, GT1a, 
GT1b, and GQ1b and the resulting 45 1:1 complexes was performed by Dr 
Kathryn Brennan. Following the success of this initial screen, a larger, 28x10 
array composed of the single glycolipids listed below (Table 5.3), and the 1:1 
complexes of these not already tested, was performed by me. The results of 
these two screens were then combined before the final analysis was performed. 
Overall, 19 single glycolipids and 162 1:1 complexes were investigated, giving 
181 different target antigens in total 
 
1  Sphingomyelin 
2  Phosphatidylserine 
3  Gb4Cer / globoside 
4  ceramide trihexoside (CTH) 
5  Sulfated glucuronyl paragloboside (SGPG) 
6  GM2 
7  GM3 
8  GD2 
9  Asialo-GM1 
10  Galactocerebroside 
11  LM1 
12  GM1 
13  GD1a 
14  GD1b 
15  GD3 
16  GQ1b 
17  GT1b 
18  Sulfatide 
Table 5.3 - Single glycolipids used in the 28x10 PVDF glycoarray 
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5.2.3 Validation of intra- and inter assay variation for sera 
The inter- and intra-assay coefficients of variation for a 10x10 PVDF glycoarray 
were previously calculated at 4.1% and 8.6% respectively, using an anti-GM1 
monoclonal antibody. Using serum positive for GA1 and GA1:sulfatide complex, 
the intra-assay coefficients of variation using the larger grid and neuropathy sera 
were calculated as 12.3% and 14.1% for these two antigens, from nine 28x10 
arrays produced and processed over a 3 month period, representative of the 
time taken to process the 255 serum samples.  
5.2.4 Summary array data 
Overall, serum from 113 GBS patients (62.4%) versus 11 controls (14.9%) showed 
IgG binding to one or more target antigen (p<0.001, Χ
2), defined as a visible 
spot, in a location corresponding to applied antigen, with a corrected arbitrary 
intensity greater than zero following background subtraction. There are 
theoretical reasons for suspecting IgG to be the pathogenic entity in GBS and 
other subclass reactivities were not sought. Only 39 of the 181 sera were 
positive on a standard, contemporaneous GM1, GD1a, and GQ1b ELISA (Kuijf et 
al., 2005), and all but one of these samples was also positive on the array. 
This gives a sensitivity of 62.4% and a specificity of 85.1% for the test as a whole. 
The global likelihood ratios for the test are therefore calculated to be 4.2 
(positive) and 0.4 (negative). Reactivity towards 176 different single antigens 
and complexes was seen with serum from GBS patients (97.2%), whereas control 
sera was only seen to bind to 31 (17.1%) of the 181 different antigens across 
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By this definition (a visible spot with a corrected arbitrary intensity greater than 
zero following background subtraction), the glycolipid complex element of the 
array increased the number of positive GBS sera by 14.2% of the total (from 97 
to 113). If the cut off for definition of a positive spot is increased, the 
contribution of complex-only positive sera to the total increases. At a cut-off of 
8000 arbitrary units, complex-only positive GBS sera form 48.9% of the 88 
positives. With this cut off, sensitivity is reduced to 48.6%, while specificity is 
improved at 91.9%. The positive and negative likelihood ratios with this 
threshold are therefore 6.0 and 0.6 respectively.  The receiver operating 
characteristic for the test is improved when complexes antigens are also 
included, assessed across a range of threshold intensity values (Figure 5.3). 
 
Figure 5.3 - Receiver operator characteristics for the glycoarray 
The receiver operator curve demonstrates the performance of the test as a specific criterion is 
altered. In this example, the criterion varied for each curve is the intensity cut off used to define a 
positive spot, which was assessed over a range for 0 to 128,000 arbitrary units. The further the 
curve extends from the diagonal dashed line (representing a test no better than random guessing), 
and the closer towards the ideal test of 100% sensitivity and specificity represented by the point a 
the leftmost and top most corner of the graph (0,1), the better. As can be seen, including 
complexes on the array (blue line) means the test outperforms an array with single glycolipids only 
(pink line) across the whole range of threshold values assessed. Chapter 5  Results     151 
 
 
Furthermore, even when disease associated sera were positive for binding to one 
or more single glycolipid, they often bound to complexes consisting of two 
separate glycolipids, neither of which they bound in isolation (absolute complex 
dependent binding). Some 79 (43.6%) of the disease associated sera showed this 
pattern, as compared to only 3 (4.1%) of the control sera (p<0.0001, Fisher’s 
Exact Test), adding a further level of complexity to the fine specificity of these 
antibodies. Phosphatidylserine and sulfatide most often contributed to 
complexes bound in this way, yet examples were seen with all of the different 
glycolipids across the array (Figure 5.4). 
 
Figure 5.4 - Contribution of single glycolipids to antigens bound in an absolute complex 
dependent manner 
Across the 181 different disease associated sera screened on the array, binding to 1:1 
heterodimeric complexes in the absolute absence of binding to the component glycolipids in 
isolation was observed 828 times (as some sera demonstrated multiple examples of this 
phenomenon). All glycolipids were seen to contribute to the complexes in such circumstances, with 
phosphatidylserine (pulled out slice) and sulfatide performing this role most often. 
Using multiple Fisher’s Exact tests without correction for multiple comparisons 
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controls (Fisher’s Exact Test, α=0.05, uncorrected). When Bonferroni’s 
correction was applied to account for multiple comparisons, and the family error 
rate maintained at 0.05, 17 spots (Table 5.4 below) remained significantly 
associated with GBS versus controls (corrected individual α<0.0003). 
Antigen  GBS+  GBS-  CON+  CON-  Sensitivity(%)  Specificity(%)  LR+  LR- 
PS:Sulfatide  67  114  5  69  37.02  93.24  5.48  0.68 
SM:Sulfatide  62  119  5  69  34.25  93.24  5.07  0.71 
SGPG:Sulfatide  57  124  2  72  31.49  97.30  11.65  0.70 
Sulfatide  55  126  5  69  30.39  93.24  4.50  0.75 
PS:SGPG  52  129  5  69  28.73  93.24  4.25  0.76 
CTH :Sulfatide  49  132  3  71  27.07  95.95  6.68  0.76 
SGPG  45  136  3  71  24.86  95.95  6.13  0.78 
GD2:Sulfatide  36  145  2  72  19.89  97.30  7.36  0.82 
GA1:Sulfatide  32  149  0  74  17.68  100.00    0.82 
Sulfatide :GT1a  32  149  0  74  17.68  100.00    0.82 
PS:GM1  26  155  0  74  14.36  100.00    0.86 
Sulfatide :GalC  26  155  0  74  14.36  100.00    0.86 
Sulfatide :GD1b  26  155  0  74  14.36  100.00    0.86 
PS:Asialo-GM1  25  156  0  74  13.81  100.00    0.86 
Sulfatide :GM1  25  156  0  74  13.81  100.00    0.86 
PS:GD1b  24  157  0  74  13.26  100.00    0.87 
SGPG:GM1  24  157  0  74  13.26  100.00    0.87 
Table 5.4 - Antigens on the PVDF glycoarray significantly associated with binding by GBS 
as compared with control sera 
GBS+ : Number of GBS sera exhibiting binding to the antigen. GBS- : Number of GBS sera not 
binding to the antigen. CON+ : Number of control sera exhibiting binding to the antigen. CON- : 
Number of control sera not binding to the antigen. LR+ : Likelihood ratio positive. LR- : Likelihood 
ratio negative. PS : phosphatidylserine. SM – sphingomyelin. GA1 – asialo-GM1. 
The data above does not make use of the intensity readings, merely whether a 
particular spot was present or absent on each membrane assayed. Further 
analysis, taken into account the intensity data, was performed subsequently, as 
part of the cluster analysis process, and is described in greater detail in 
subsequent sections. Figure 5.5 shows individual value plots for the 17 
statistically significant antigen associations listed in Table 5.4. As can be seen, 
all of these antigens contain one or more of SGPG, phosphatidylserine (PS) or 
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Figure 5.5 - Individual value plots for the 17 antigen spots significantly associated with GBS 
(A) SGPG series complexes. (B) Phosphatidylserine series complexes. (C) Sulfatide series 
complexes. Chapter 5  Results     154 
 
 
5.2.4.1  SGPG and SGPG-series complexes 
Analysis of the different patterns of SGPG and SGPG: phosphatidylserine (PS) 
binding between patients and controls reveals an interesting difference. When 
comparing the intensity values for SGPG with those for SGPG:PS, the majority of 
GBS patients have antibodies which bind to the former at least as well as the 
latter, and some show an increment. In contrast, the one control with high 
intensity binding towards SGPG alone (AI=42943) is strongly inhibited from 
binding SGPG in the SGPG:PS complex (AI=3946). Changes of this magnitude, in 
this direction, were not seen with patient samples (Figure 5.6), and these 
different patterns are maintained when the sum of individual binding intensities 
to PS and SGPG is used as the baseline for comparison with PS:SGPG complex 
binding (Figure 5.7).  
Nevertheless, of the 60 GBS sera which demonstrated binding to either SGPG, 
PS:SGPG or both, 28 showed PS complex attenuated binding for SGPG, and 32 
showed a complex enhanced binding pattern. Of the ‘complex attenuated’ sera, 
4 had complex binding intensities within the margin of error of the assay (<14.1% 
different, as compared with the sum of PS and SGPG intensities) as did 5 of the 
‘complex enhanced sera’. These should probably be labelled complex 
independent on this basis.  
The magnitude of this change ranged from absolute (8 sera with binding only 
detected to SGPG in isolation, 13 binding PS:SGPG but not SGPG or PS alone) to 
minimal, as below (Table 5.5 and Table 5.6). 
Similar to the patterns of binding seen with siglecs, monoclonal antibodies and 
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different types of SGPG binding patterns within the sera of GBS patients and 
controls, namely complex attenuated, complex independent, and complex 
enhanced. As sera were only assessed in duplicate in one experiment statistical 
methods were not able to be applied to define these patterns. Instead, as 
above, the reproducibility/variability in the PVDF array was used to define the 
margin of difference chosen to define complex attenuation, enhancement and 
independence. 
 
Figure 5.6 - The relationship between SGPG and PS:SGPG complex binding within the same 
sera 
In GBS associated sera (A), the majority of sera bind SGPG and PS:SGPG with similar intensity 
values, or show a ‘complex enhanced’ effect for PS:SGPG over SGPG alone. In contrast, the only 
serum in the control group with high intensity binding to SGPG demonstrates a dramatic ‘complex 
attenuated’ fall in signal with PS:SGPG (B, black line). Chapter 5  Results     156 
 
 
 
Figure 5.7 - The relationship between SGPG, PS and PS:SGPG complex binding within the 
same sera 
When the sum of the individual phosphatidylserine and SGPG binding intensities is used as the 
baseline for comparison with binding to PS:SGPG complex, little difference is seen as compared 
with using an SGPG only baseline.  Chapter 5  Results     157 
 
 
 
Arbitrary Intensity     
SGPG  PS  PS+SGPG  PS:SGPG  Absolute 
attenuation 
Relative 
attenuation (%) 
8849  0  8849  0  8849  0.0 
3362  0  3362  0  3362  0.0 
2317  0  2317  0  2317  0.0 
2051  1188  3239  0  3239  0.0 
1850  0  1850  0  1850  0.0 
1084  0  1084  0  1084  0.0 
1031  0  1031  0  1031  0.0 
618  0  618  0  618  0.0 
8970  0  8970  546  8424  6.1 
9951  0  9951  1472  8479  14.8 
2331  0  2331  559  1772  24.0 
20332  3966  24298  6250  18048  25.7 
5214  2190  7404  1943  5461  26.2 
0  15623  15623  5159  10464  33.0 
6217  2729  8946  3861  5085  43.2 
6158  3419  9577  4214  5363  44.0 
0  14836  14836  7189  7647  48.5 
4834  0  4834  2416  2418  50.0 
5362  0  5362  2691  2671  50.2 
1383  0  1383  768  615  55.5 
20290  0  20290  11673  8617  57.5 
1398  0  1398  852  546  60.9 
37591  4179  41770  32216  9554  77.1 
45682  484  46166  39539  6627  85.6 
23608  0  23608  21012  2596  89.0 
3217  608  3825  3485  340  91.1 
35727  0  35727  33278  2449  93.1 
53313  0  53313  50009  3304  93.8 
Table 5.5 - GBS sera with phosphatidylserine complex attenuated SGPG binding 
The 28 SGPG binding sera showing lower binding intensities for PS:SGPG, arranged in 
descending order by degree of attenuation. Relative attenuation is defined as the binding intensity 
for PS:SGPG expressed as a percentage of the sum of SGPG and PS binding intensity 
(PS+SGPG). Serum results in orange fall within the margin of error for the test. Chapter 5  Results     158 
 
 
 
Arbitrary Intensity 
     
SGPG  PS  PS+SGPG  PS:SGPG  Absolute 
enhancement 
Relative 
enhancement (%) 
0  0  0  20869  20869  INF 
0  0  0  16617  16617  INF 
0  0  0  10417  10417  INF 
0  0  0  8578  8578  INF 
0  0  0  8117  8117  INF 
0  0  0  3661  3661  INF 
0  0  0  3478  3478  INF 
0  0  0  2119  2119  INF 
0  0  0  1805  1805  INF 
0  0  0  1751  1751  INF 
0  0  0  1104  1104  INF 
0  0  0  227  227  INF 
0  0  0  95  95  INF 
876  0  876  13581  12705  1550.3 
644  1177  1821  18657  16836  1024.5 
3051  1517  4568  32675  28107  715.3 
1402  0  1402  7544  6142  538.1 
6119  0  6119  29911  23792  488.8 
4006  0  4006  13891  9885  346.8 
2194  1765  3959  11793  7834  297.9 
3113  0  3113  8786  5673  282.2 
845  0  845  2217  1372  262.4 
7770  0  7770  11911  4141  153.3 
3704  1415  5119  7798  2679  152.3 
3210  0  3210  4822  1612  150.2 
5188  0  5188  7738  2550  149.2 
30352  0  30352  36754  6402  121.1 
14512  0  14512  16614  2102  114.5 
1174  0  1174  1314  140  111.9 
3261  0  3261  3642  381  111.7 
6182  0  6182  6618  436  107.1 
8949  351  9300  9407  107  101.2 
Table 5.6 - GBS sera with phosphatidylserine complex enhanced SGPG binding 
The 32 SGPG binding sera showing higher binding intensities for PS:SGPG, arranged in 
descending order by degree of enhancement. Relative enhancement is defined as the binding 
intensity for PS:SGPG expressed as a percentage of the sum of SGPG binding intensity. Serum 
results in orange fall within the margin of error for the test. (INF = infinite) 
5.2.4.2  Sulfatide and sulfatide-series complexes 
Anti-sulfatide and sulfatide containing complex antibodies form the largest 
group of antibodies found to be statistically associated with GBS, making up 11 Chapter 5  Results     159 
 
 
of the 17 in total. By studying the graph above (Figure 5.5C), it can be 
appreciated that for a number of sulfatide complexes (with asialo-GM1(GA1), 
galactocerebroside(GalC), GM1, GD1b and GT1a) no binding at all is observed in 
controls, whereas a range of intensity readings are seen with patient’s sera, 
some approaching the highest values recorded across the whole of the array and 
sample series. For complexes of sulfatide with GD2 and CTH, a range of intensity 
readings were returned following assay with GBS sera, and 2 or 3 control sera 
exhibited binding towards the lower end of the intensity range. In contrast, non-
complexed sulfatide and sulfatide:PS complexes returned generally lower 
intensity readings, and each were also bound by 5 negative control sera, the 
joint highest number for any of the spots on the array. Sulfatide complexes with 
sphingomyelin and SGPG fall somewhere between these two extremes. 
Looking at sulfatide:GA1 in more detail, of the 32 GBS sera which bound this 
complex, 17 also bound non-complexed GA1, 22 bound non-complexed sulfatide, 
and 13 bound both GA1 and sulfatide outwith complexes. However, in 28 out of 
32 cases binding to the complex was enhanced as compared with the sum of 
intensities of the two component glycolipids. When the 33 further sera which 
bound sulfatide but not sulfatide:GA1 are also included (and are therefore by 
definition complex attenuated), 28/65 which bind sulfatide and/or GA1 
individually display complex enhanced binding to GA1:sulfatide. None of the sera 
bind GA1 alone without either also binding sulfatide or sulfatide:GA1. Once 
again, the binding pattern in control sera is different. Binding to sulfatide was 
observed in 5 control sera, 2 of which also bound GA1. No control sera bound 
GA1 without also binding sulfatide.  Of the five, none we also able to recognise 
the sulfatide:GA1 complex, and hence all five showed absolute complex 
attenuated binding in this respect (Figure 5.8). This difference just fails to reach Chapter 5  Results     160 
 
 
statistical significance (p=0.07, Fisher’s Exact test for 2x2 contingency table, 
Table 5.7), largely because of the small numbers of control sera binding any of 
GA1, sulfatide, or the GA1:sulfatide GSC. 
  GA1+sulfatide v. GA1:sulfatide 
  Enhanced  Attenuated 
GBS  28  37 
Controls  0  5 
Table 5.7 - 2x2 contingency table for GA1 and sulfatide single versus complex binding 
 
 
Figure 5.8 - Contrast in binding patterns between GBS and control sera towards single 
sulfatide and GA1 as compared with sulfatide:GA1 complex 
In GBS (A), many of the sera show impressively enhanced binding towards sulfatide:GA1 complex 
as compared with the sum of intensities for sulfatide and GA1 in isolation (sulfatide+GA1 above). In 
the two most extreme cases the intensity is seen to increment from 3000 and 4000 to over 100000 
(black circle and red square). In contrast, all 5 of the control sera (B), show an absolute complex 
attenuated pattern with respect to the same targets. The most marked example here (black circle) 
falls from an arbitrary intensity of over 20000 to 0. Chapter 5  Results     161 
 
 
5.2.5 Cluster analysis of GBS array data 
Cluster analysis was performed using a variety of approaches by Dr Gabriella 
Kalna, a biomedical statistician with a specialist interest in microarray analysis, 
based at the Beatson Institute, Garscube Estate, Glasgow. In addition, she 
employed ANOVA analysis of log transformed intensity data including testing for 
independence and Bonferroni correction for multiple comparisons. This approach 
yielded 9 glycolipid and glycolipid complex antigens with significantly increased 
binding intensities for GBS as compared to control sera. These 9 are a subset of 
the 17 significantly associated antigens identified by the binary analysis 
described in section 5.2.4 above. Furthermore, this subset of 9 includes all 4 of 
the antibody targets discussed in further detail, namely SGPG and SGPG:PS 
(5.2.4.1), and sulfatide and sulfatide:GA1(5.2.4.2). Output from this statistical 
analysis for these nine targets is shown in Table 5.8.       
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5.2.5.1  Cluster analysis data 
Table 5.8 – ANOVA analysis of log transformed intensity data 
ANOVA analysis of log transformed intensity data from the PDVF glycoarray analysis of 181 GBS associated sera and 74 control sera revealed 9 glycolipid and 
glycolipid complex array antigens significantly associated with disease versus controls, following Bonferroni correction for multiple comparisons.   
 
GBS  Controls 
Antigen 
Uncorrected p-
value 
(GBS vs. 
controls) 
Bonferroni 
(p-value) 
(GBS vs. controls) 
stepup 
(p-value) 
(GBS vs. 
controls) 
Fold-Change 
(GBS vs. 
controls) 
Mean 
Spot 
Intensity 
SD 
Maximum 
Spot 
Intensity 
Mean 
Spot 
Intensity 
SD 
Maximum 
Spot 
Intensity 
SGPG:Sulfatide  1.26x10
-06  2.28x10
-04  1.70x10
-04  10.23  3.72  5.63  15.21  0.37  2.21  14.04 
PS:Sulfatide  1.88x10
-06  3.41x10
-04  1.70x10
-04  11.36  4.36  5.83  14.57  0.86  3.21  13.88 
Sphingomyelin:Sulfatide  7.48x10
-06  1.35x10
-03  4.51x10
-04  9.17  3.98  5.70  15.82  0.79  2.96  13.39 
CTH :Sulfatide  2.82x10
-05  5.11x10
-03  1.28x10
-03  7.03  3.25  5.50  16.51  0.44  2.17  12.15 
SGPG  5.54x10
-05  1.00x10
-02  2.01x10
-03  6.21  3.02  5.34  15.70  0.39  2.19  15.39 
PS:SGPG  7.95x10
-05  1.44x10
-02  2.24x10
-03  6.95  3.56  5.71  15.61  0.76  2.84  11.95 
Sulfatide  8.66x10
-05  1.57x10
-02  2.24x10
-03  5.78  3.31  5.12  14.32  0.78  2.93  13.98 
Sulfatide :GT1a  1.08x10
-04  1.96x10
-02  2.45x10
-03  6.11  2.61  5.70  16.99  0  0  0 
Asialo-GM1:Sulfatide  1.24x10
-04  2.24x10-
02  2.49x10
-03  6.00  2.58  5.70  16.90  0  0  0      163 
 
5.2.5.2  Cluster analysis heatmaps 
The intensity values generated were then used to produce heatmaps. Prior to 
any clustering it can be appreciated that the frequency and distribution of 
positive spots, and intensity of binding, is greater in the disease sera as 
compared with controls (Figure 5.9A). In advance of clustering, sera with no 
detectable binding were excluded. These were membranes where none of the 
antigen spots generated a signal intensity greater than zero following 
background correction. Both GBS and control sera were included in the 
clustering process. Several techniques, including covariance as shown, were then 
used for cluster analysis. This revealed a number of distinct populations of sera 
(Figure 5.9B). The vertical tramlines enclose sulfatide and 5 sulfatide containing 
complexes, demonstrating the high prevalence, and frequent co-existence in the 
same serum, of binding to all of these antigens in positive sera. Lesser numbers 
of sera can be seen to bind to a number of LM1, SGPG, GA1, GM1, GD1a and 
GT1b containing complexes, as labelled on the heatmap. A proportion of these 
sera also bind promiscuously to antigens in the other groups (Figure 5.9B).    
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Figure 5.9 - Heatmap analysis of glycoarray intensity data 
(A) Heatmap of GBS versus control sera probed arrays. This array was produced prior to any 
clustering, and shows all of the 255 sera analysed. On this heatmap, individual sera are listed on 
the x-axis, and the 181 different antigens probed run along the y-axis. The presence of a spot 
above the light green background indicates detectable binding, with the intensity given by the 
colour, as shown below the heatmap, bright red being the most intense. GBS samples are shown 
to the left of the vertical line, controls to the right. (B) Heatmap following removal of negative sera 
and covariance clustering. Both GBS and control sera are included. On this heatmap, the x and y 
axis are inverted as compared to (A), and the order of samples and antigens has been 
systematically altered to reveal patterns of binding.  
5.2.6 Disease associations 
The array intensity data was subsequently compared with the clinical database 
to identify any associations between the presence of specific antibodies and 
disease subtype (by electrophysiological criteria), disease severity, preceding 
infection, cranial nerve and/or bulbar involvement, the presence of sensory 
signs on examination, and the requirement for mechanical ventilation. Analysis 
of Variance (ANOVA) was used to statistically assess the significance of any 
clinical-serological associations, and Mann-Whitney and t-tests were additionally 
used if large numbers of zero results were present, to ensure ANOVA was robust 
against violations of model assumptions (non-normality). Both Bonferroni (more 
stringent) and step up (less stringent) techniques were used to correct for 
multiple comparisons.  
5.2.6.1  Disease subtype 
The analysis of antibody associations with AIDP as compared with AMAN was 
confounded by the small number of electrically conformed AMAN cases (4) and 
the large number of equivocal cases. Even so, in confirmed AIDP as compared to 
AMAN cases, 14 antigen spot intensities (GM1 and 13 GM1 containing complexes) 
were significantly decreased in AIDP following Bonferroni correction (Table 5.9). Chapter 5  Results     167 
 
 
When equivocal cases were combined with the AIDP group, all but one 
(sulfatide:GM1) of these associations remained statistically significant.  
 
Antigen  p-value 
(AIDP vs. AMAN) 
Bonferroni 
(AIDP vs. AMAN) 
Stepup 
(AIDP vs. AMAN) 
Fold-
Change(AIDP 
vs. AMAN) 
Globoside:GM1  2.54x10
-12  5.16x10
-10  5.16x10
-10  -871.59 
CTH :GM1  1.54x10
-11  3.13x10
-09  1.57x10
-09  -1784.65 
GD2:GM1  6.21x10
-09  1.26x10
-06  4.20x10
-07  -1045.65 
Asialo-GM1:GM1  2.57x10
-08  5.22x10
-06  1.31x10
-06  -1200.98 
Sphingomyelin:GM1  8.47x10
-08  1.72x10
-05  3.44x10
-06  -1210.83 
GalC:GM1  1.23x10
-07  2.50x10
-05  3.91x10
-06  -1882.68 
GM1  1.35x10
-07  2.73x10
-05  3.91x10
-06  -2279.72 
GM1:GD1b  2.42x10
-07  4.91x10
-05  6.14x10
-06  -1669.89 
GM1:GT1a  8.71x10
-07  1.77x10
-04  1.97x10
-05  -1505.36 
GM2:GM1  4.48x10
-06  9.10x10
-04  9.10x10
-05  -283.45 
GM1:GD3  9.23x10
-06  1.87x10
-03  1.70x10
-04  -481.57 
Phosphatidylserine:GM1  1.30x10
-05  2.63x10
-03  2.19x10
-04  -2225.63 
SGPG:GM1  2.79x10
-05  5.66x10
-03  4.35x10
-04  -706.20 
Sulfatide :GM1  1.37x10
-04  2.78x10
-02  1.98x10
-03  -1201.88 
 
Table 5.9 - Disease subtype antigen associations 
14 antigens (GM1 and 13 GM1 containing complexes) were significantly associated with the AMAN 
variant of GBS, as compared with electrically confirmed AIDP. The negative values in the fold 
change column indicate that binding to these antigens was down-regulated in AIDP as compared 
with AMAN. 
5.2.6.2  Disease severity and requirement for mechanical ventilation 
Nine antigen spot intensities (Table 5.10) were found to be significantly 
associated with more severe disease (GBS disability score >3), but only at the 
time of randomisation, including GA1 and three GA1 containing complexes. 
Likewise, three GA1 complex antigens (CTH :GA1, Globoside:GA1 and SGPG:GA1) 
were statistically significantly associated with the requirement for mechanical 
ventilation at any time, but only following the less stringent stepup correction 
for multiple comparisons. Chapter 5  Results     168 
 
 
 
Antigen  p-value 
(Day 0) 
Bonferroni 
(Day 0) 
Bonferroni 
(Day 6) 
Bonferroni 
(Week 4) 
Bonferroni 
(Week 8) 
Bonferroni 
(Week 26) 
CTH :GA1*  1.16x10
-05  2.36x10
-03  1  1  1  1 
Globoside:GA1*  1.70x10
-05  3.45x10
-03  1  1  1  1 
PS:GalC  3.12x10
-05  6.34x10
-03  1  1  1  1 
GA1:GalC  1.26x10
-04  2.56x10
-02  1  1  1  1 
Globoside:GD3  1.31x10
-04  2.66x10
-02  1  1  1  1 
GD2:GD3  1.31x10
-04  2.66x10
-02  1  1  1  1 
GA1  1.74x10
-04  3.52x10
-02  1  1  1  1 
GD3:GT1b  1.79x10
-04  3.64x10
-02  1  1  1  1 
GalC:GQ1b  2.18x10
-04  4.43x10
-02  1  1  1  1 
 
Table 5.10 - Antigens associated with disease severity 
The nine antigens listed are statistically significantly associated with severe disease (GBS 
disability score >3), but only at the point of randomisation (day 0). At other assessed time 
points, this association is not seen.  
 
* Antigen also significantly associated with the requirement for mechanical ventilation.  
 
5.2.6.3  Preceding infection 
GM1, four GM1 containing complexes, and GT1a:sulfatide complex all returned 
significantly higher spot intensities when a preceding diarrhoeal illness, as 
opposed to no preceding illness, was reported (Table 5.11). When campylobacter 
serology was positive (Table 5.12), nine GD1a containing spots returned 
significantly higher intensities, and three GM1 containing complexes are also 
represented if the less stringent correction is applied. 
 
Antigen  p-value(diarrhoea 
vs. neither) 
Bonferroni  Stepup 
Fold-Change 
(diarrhoea vs. 
neither) 
Sulfatide :GM1  2.58x10
-05  5.23x10
-03  4.26x10
-03  19.72 
Sulfatide :GT1a  4.91x10
-05  9.97x10
-03  4.26x10
-03  22.81 
GalC:GM1  6.43x10
-05  1.31x10
-02  4.26x10
-03  9.15 
Asialo-GM1:GM1  8.66x10
-05  1.76x10
-02  4.26x10
-03  7.02 
CTH :GM1  1.05x10
-04  2.13x10
-02  4.26x10
-03  5.56 
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Antigen  p-value 
(C.jejuni vs. none)  Bonferroni  Stepup  Fold-Change 
(C.jejuni vs. none) 
GD1a:GT1b  1.62x10
-06  3.29x10
-04  3.29x10
-04  6.42 
GD3:GD1a  1.30x10
-05  2.64x10
-03  1.32x10
-03  4.86 
Sulfatide :GD1a  3.16x10
-05  6.41x10
-03  1.99x10
-03  7.41 
GalC:GD1a  4.34x10
-05  8.80x10
-03  1.99x10
-03  5.30 
GM2:GD1a  5.79x10
-05  1.18x10
-02  1.99x10
-03  3.53 
GD1a  5.88x10
-05  1.19x10
-02  1.99x10
-03  5.08 
GD1a:GQ1b  7.62x10
-05  1.55x10
-02  2.21x10
-03  3.76 
GD2:GD1a  2.00x10
-04  4.07x10
-02  5.09x10
-03  4.09 
CTH :GD1a  2.32x10
-04  4.71x10
-02  5.24x10
-03  3.52 
 
Table 5.12 - Identified infection and antigens detected 
The only significant differences found were between cases where Campylobacter jejuni infection 
was detected as compared with no detected infection. In the former cases, antibodies directed 
against the nine antigens listed above were more prevalent. The presence of GD1a, GD3, and 
GQ1b in this list is in keeping with the fact that C.jejuni with α2,3 monofunctional-sialyltransferase 
activity display GM1 and GD1a like surface lipooligosaccharide, and those strains with α2,3 and 
α2,8 bifunctional-sialyltransferase activity display mimics of GD3, GT1a and GQ1b ganglioside. 
5.2.6.4  Presence of cranial nerve deficits, bulbar impairment or sensory 
involvement 
Sulfatide:GM1 and sulfatide:GT1a complex responses alone were significantly 
negatively associated with cranial nerve deficits at any time during follow up 
(Table 5.13). A number of complexes all containing one or more of GM1, GA1 
and GT1a were negatively associated with sensory deficit at both randomisation 
and week 4 (Table 5.14). No antigens were significantly associated with bulbar 
impairment. 
 
Antigen 
p-value  
(cranial nerve deficit 
present v. absent) 
Bonferroni  Stepup 
Fold-Change 
(present vs. 
absent) 
Sulfatide :GM1  5.97x10
-05  1.21x10
-02  3.03x10
-03  -8.49 
Sulfatide :GT1a  2.06x10
-04  4.17x10
-02  8.35x10
-03  -8.68 
 
Table 5.13 - Association with cranial nerve deficit 
Only two antigens, sulfatide:GM1 and sulfatide:GT1a complexes, were significantly associated 
with cranial nerve deficits at any time during follow up. The correlation in this case was 
negative. 
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Antigen 
p-value 
(sensory deficit 
present vs. absent) 
Bonferroni  Stepup 
Fold-
Change(present 
vs. absent) 
GM3:GM1  2.84x10
-05  5.77x10
-03  5.77x10
-03  -5.66 
GD2:GM1  6.05x10
-05  0.01  6.14x10
-03  -4.18 
GalC:GM1  1.45x10
-04  0.03  9.11x10
-03  -4.99 
GM1:GD1b  2.52x10
-04  0.05  9.11x10
-03  -4.76 
GA1:Sulfatide  2.85x10
-04  0.06  9.11x10
-03  -8.41 
GM1  2.96x10
-04  0.06  9.11x10
-03  -4.85 
Sulfatide :GM1  3.14x10
-04  0.06  9.11x10
-03  -7.09 
Phosphatidylserine:GM1  4.94x10
-04  0.10  0.01  -6.23 
GM2:GM1  8.69x10
-04  0.18  0.02  -3.35 
Sulfatide :GT1a  1.02x10
-03  0.21  0.02  -7.03 
GM1:GD1a  1.25x10
-03  0.25  0.02  -4.28 
Phosphatidylserine:GA1  1.25x10
-03  0.25  0.02  -5.11 
GM1:GT1a  1.39x10
-03  0.28  0.02  -4.11 
GM2:Asialo-GM1  1.73x10
-03  0.35  0.03  -2.83 
Sphingomyelin:GM1  2.00x10
-03  0.41  0.03  -3.40 
GalC:GT1a  2.81x10
-03  0.57  0.04  -3.79 
 
Table 5.14 - Antigens negatively correlated with sensory disturbance 
The above antigens were negatively correlated with the presence of sensory deficit. As might be 
expected, there is a degree of overlap with the antigens associated with the pure motor, axonal 
GBS variant AMAN (Table 5.9). 
5.2.7 Low frequency antibodies 
Of the 181 antigens screened, 78 were bound by IgG antibodies found in less 
than 10 of the GBS sera, 38 of these were bound by 4 or fewer, and 22 antigens 
were recognised by only 1 or 2 sera (Figure 5.10).  None of these 78 antigens 
were additionally bound by IgG antibodies in any of the 74 control sera. 
Individually, despite uniquely being found in GBS sera, none of these antibody-
antigen associations reached statistical significance as compared with control 
sera, given their low frequency. By way of comparison, the complex with the 
highest p value still reaching significance in the ANOVA intensity analysis 
(GA1:sulfatide) was bound by 32 GBS and no control sera. From the alternative 
perspective, certain GBS sera display very specifically targeted binding patterns 
- 13 sera showed binding against 1 or 2 complexes only (as demonstrated in Chapter 5  Results     171 
 
 
Figure 5.11). Increasing the intensity threshold to define a positive spot to 1000 
or 8000 arbitrary units likewise increases the number of sera showing this degree 
of targeted binding to 24 and 31, respectively. By way of comparison, (Figure 
5.12) shows examples of GBS sera displaying more promiscuous binding to 
multiple different antigens.  
 
Figure 5.10 - Example of complex antigen bound by only one serum tested 
The red circle indicates GD2:GD3 complex, bound only by this serum of the 181 tested. Chapter 5  Results     172 
 
 
 
Figure 5.11 - GBS sera with highly specific binding patterns 
Each membrane (A-E) represents the IgG binding pattern of one GBS serum.                             
Key: (1)Sphingomyelin, (2)Phosphatidylserine, (3)Globoside, (4)CTH, (5)SGPG, (6)GM2, (7)GM3, 
(8)GD2, (9)Asialo-GM1, (10)GalC, (11)LM1, (12)GM1, (13)GD1a, (14)GD1b, (15)GD3, (16)GQ1b, 
(17)GT1b, (18)Sulfatide. Chapter 5  Results     173 
 
 
 
Figure 5.12 - GBS sera with more promiscuous binding patterns 
Each membrane (A-E) represents the IgG binding pattern of one GBS serum.                             
Key: (1)Sphingomyelin, (2)Phosphatidylserine, (3)Globoside, (4)CTH, (5)SGPG, (6)GM2, (7)GM3, 
(8)GD2, (9)Asialo-GM1, (10)GalC, (11)LM1, (12)GM1, (13)GD1a, (14)GD1b, (15)GD3, (16)GQ1b, 
(17)GT1b, (18)Sulfatide. Chapter 5  Results     174 
 
 
5.3 Discussion 
The combinatorial glycoarray technique and the experimental results described 
in this chapter have substantially increased the number of glycolipid antibody 
specificities significantly associated with GBS, particularly with respect to AIDP. 
Use of the array increases the glycolipid antibody detection rate as compared to 
ELISA, and the inclusion of glycolipid complexes increases this yet further. 
Rather than identifying a single specificity, however, 176 different targets were 
bound by IgG present in the 113 disease associated sera with detectable anti-
glycolipid and glycolipid complex antibodies. Some complexes were bound by 
only a few sera, with 8 complexes being recognised by IgG antibodies in one 
serum each (Figure 5.10). Given their very low frequency these associations do 
not reach statistical significance. Of course, this does not mean that these 
antibodies do not have clinical and pathological significance in the individual in 
which they are found, which could be demonstrated by in vivo binding assays or 
functional readouts. However, to show statistically significant associations for an 
antibody with a frequency of 1/181 in disease, 3440 control sera would need to 
be analysed and found to be negative (Table 5.15), even when the effects of 
multiple comparisons are discounted. This is clearly not practical even using the 
PVDF glycoarray technique.  Chapter 5  Results     175 
 
 
 
  Disease  Control  Total 
Positive  1  0  1 
Negative  180  3440  3620 
Total  181  3440  3621 
Table 5.15 - Contingency table required for significance with disease frequency of 1 in 181 
To meet statistical significance for antibodies detected with a frequency of 1 in 181 in disease, 
3440 control samples would need to be analysed and found negative for the antibody in question. 
The above contingency table generates a p value of 0.049986 using Fisher’s Exact test, without 
any correction for multiple comparisons. 
These observations notwithstanding, the controls used in this part of the study 
remain its weakest link. Aside from the fact that lesser numbers of controls were 
able to be obtained compared with disease samples, an argument can be made 
that control samples should be taken from post-infectious patients who do not 
go on to develop GBS. Ideally, the samples should be taken at the same time 
point following infection as the disease sera. Again, this is practically difficult 
(and not attempted in previous serological studies of GBS) in a large part 
because patients with uncomplicated gastroenteritis or upper respiratory tract 
infections rarely seek medical attention and virtually never have blood samples 
taken 10 to 14 days later. In order to obtain these samples, therefore, a specific 
targeting and recruitment of such patients would be necessary. Nevertheless, 
this is likely to prove important in future to ensure that a non-specific, post 
infectious, antibody response is not being inadvertently and unnecessarily 
further investigated. Similarly, these antibodies may simply arise as 
epiphenomena during nerve damage, or be non-specifically elevated in states of 
inflammation. Therefore, it would also be rewarding to investigate control sera 
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inflammatory/autoimmune conditions not involving the peripheral nervous 
system. 
Also, disconcertingly, it may be that there is no single antibody specificity in 
AIDP, and rather that the response has a highly variable fine specificity towards 
many different glycolipids and complexes. Alternatively, it may simply be that 
the correct panel of target antigens and complexes is yet to be selected for 
analysis, and in addition to the vast range of fine specificities, one as yet 
undiscovered dominant antibody specificity exists in AIDP. It may even be that 
multimeric antigen structures, containing three or more glycolipids, and even 
including proteins, are important targets. The inconsistency of the antibody 
binding pattern seen may reflect the variability of the presentation of GBS, and 
in this regard the association of certain clinical features with particular antibody 
specificities is interesting. The fact that there are only significant associations 
for severity early in the disease course may mean that the antibodies detected 
have influence on the initial injurious process but are less relevant to the 
subsequent recovery phase. 
Even so, experiments such as this do not prove a pathological role for the large 
number of different antibodies detected. Nonetheless, evidence is beginning to 
accumulate of the pathogenic potential of anti-ganglioside complex antibodies. 
Work using serum samples with anti-GM1:GD1a reactivity shows that a 
proportion of these sera have the potential to induce neuromuscular blockade, 
as assessed by electrophysiological measurements in ex vivo murine muscle 
preparations (J. Plomp, unpublished observations). Dissecting out the effect of 
the presumed critical pathological monoclonal component from polyclonal sera 
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study of AIDP pathogenesis must pay attention to the myriad of fine specificities 
demonstrated by this study. It is clearly possible, as has already demonstrated 
for GM1 antibodies attenuated or enhanced by GD1a (Greenshields et al., 2009), 
that the complex enhanced GA1:sulfatide antibodies found in GBS sera will 
behave entirely differently in vivo as compared with the complex attenuated 
GA1:sulfatide antibodies that were occasionally also found in control sera.  
The Node of Ranvier has recently been demonstrated as a site for anti-
ganglioside and complement mediated damage (McGonigal et al., 2010). In this 
context, the fact that the majority of antibodies significantly associated with 
GBS in this study bind sulfatide containing glycolipid complexes (such as 
GA1:sulfatide) is intriguing. This myelin associated sulfated glycolipid is enriched 
at the paranodal loops, where it is responsible for the proper localisation and 
clustering of K
+- and Na
+ -channels, and of the axonal adhesion molecule Caspr. 
Mice lacking galactocerebroside and sulfatide (UDP-galactose:ceramide 
galactosyltransferase-knockout - CGT
-/-), or sulfatide alone (cerebroside 
sulfotransferase-knockout - CST
-/-), exhibit a decrease in Na
+ and K
+ channel 
clustering, altered nodal length, and abnormal localization
 of K
+ channels, with 
contactin widely and abnormally distributed along the internode (Ishibashi et 
al., 2002). Furthermore, sulfatide is required for the stabilisation of axon-myelin 
interactions, where it promotes the formation of neurofascin-155 containing 
lipid rafts (Schafer et al., 2004).  As such, anti-sulfatide complex antibody 
mediated injury at this location could be envisaged to result in a process of 
demyelination, the pathological hallmark of AIDP. The next step will therefore 
be to reproducibly generate monoclonal antibodies with the same sulfatide 
complex activity as those found in human AIDP sera, and investigate their 
pathogenic effects in vivo. 178 
6  The immune response to GSC containing 
liposomes 
6.1 Introduction 
Ganglioside complex immunisation experiments were envisaged and designed to 
address two main areas. Firstly, the ability or otherwise to generate serum 
responses to ganglioside complexes in different mice could provide further 
indirect evidence of the presence of ganglioside complexes within the 
membranes of these experimental animals. It is already known that normal mice 
littermates (subsequently referred to as GM2 WT mice) are tolerant following 
immunisation with single ganglioside containing liposomes or Campylobacter 
jejuni derived lipooligosaccharide, but that robust IgG responses are seen in GM2 
KO animals lacking longer chain gangliosides (Goodyear et al., 1999;Bowes et 
al., 2002). If GM2 WT mice proved tolerant of GSC injections also, this would 
suggest that the tolerogenic effect was due to the presence of similar GSC 
structures within the animal, whereas a serum response being observed when 
none is seen with single ganglioside injections would suggest the opposite. 
Likewise, the ability to investigate GD3s
-/- mice, which lack b-series but have a 
full complement of a-series gangliosides, allows investigation of the antibody 
response when only one member of the GSC heterodimer is systemically 
expressed in the immunised animal via the use of a-series:b-series complexes as 
immunogens.   
The experiments described in this chapter also address some of the questions 
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already been shown, both in experiments performed as earlier components of 
this study (using mAbs generated from animals injected with single ganglioside 
containing liposomes, 3.2.4) and from small clinical series (Kuijf et al., 2007), 
that GSC responses can arise in response to injection with single ganglioside 
containing liposomes or infection with bacteria displaying only one type of 
ganglioside mimic on their cell surface. Whether the converse is true (that 
immunisation with GSCs can induce antibodies against single gangliosides) 
remains to be seen. These single time point assessments also provide only 
limited information, whereas investigating serum responses at multiple time 
points allows greater insight into the dynamics and maturation of the anti-
ganglioside immune response. 
In addition to developing a greater understanding of the ‘mechanics’ of the GSC 
antibody response, the other aim was to generate a predictable and 
reproducible immune response which could be subsequently exploited to 
generate αGSC monoclonal antibody producing hybridoma cell lines. This is 
discussed further in the next chapter (7 - Cloning and characterisation of anti-
GSC antibodies, page 201). Chapter 6  Results     180 
 
 
6.2 Results 
These experiments were commenced before the results of the PVDF glycoarray 
analysis of Western European AIDP sera were available, and as such 
immunisations concentrated on complexes of GM1:GD1a and GD1a:GD1b, 2 of 
the 3 most common targets for GSC antibodies in the largest Japanese series yet 
published (Kaida et al., 2007). Furthermore, these gangliosides are widely, and 
relatively cheaply, available. The GD1a:GD1a antigen is also suitable for use in 
the GD3s
-/- immunisation experiments described above, as these mice over-
express GD1a but do not produce GD1b. 
6.2.1 GM1:GD1a liposomes 
Initial experiments were performed using GM1:GD1a ganglioside complex 
containing liposomes without ova, and without a priming stage or any alum 
adjuvant. Instead, 3 intravenous (iv) injections 7 days apart were performed 
using both GM2 WT and GM2 KO animals. In two separate experiments of 3 
animals per group each, no αGM1:GD1a IgM or IgG response was seen using 
ganglioside ELISA up to and including day 35. Follow up experiments involved 
changing the injection route to intraperitoneal (ip) but otherwise maintaining 
the same protocol. Again no response was seen with 2 independent experiments.  
In order to assess whether it was simply the protocol that was failing to drive 
antibody production, rather than of the use of GSC antigens themselves, a 
previously successful protocol (Bowes et al., 2002) was employed. This is the 
same as described in section 2.2.7, apart from the fact the booster iv injections 
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of ova in alum adjuvant at day 0, followed by 3 injections of IP ganglioside 
liposomes containing ova (see 2.2.6). 
6.2.1.1  ELISA analysis  
As can be seen (Figure 6.1), using this protocol both IgM and IgG responses can 
be seen, as detected by ganglioside complex ELISA performed as previously 
described (2.2.2). In GM2 WT and GM2 KO animals, anti-GM1:GD1a IgM 
antibodies can be first detected at day 14. In the GM2 WT animals the OD 
reading plateaus and subsequently declines slightly at days 21 and 28, whereas it 
continues to rise in the GM2 KO group (Figure 6.1A). This analysis is once again 
complicated by the very high, non-specific background ODs seen in methanol 
only coated negative control wells with IgM antibodies.  
The differences between the groups in terms of IgG response was much more 
clear cut, and binding to the control wells was not seen with these secondary 
antibodies. GM2 WT animals essentially failed to mount any IgG GSC whatsoever 
by day 28, whereas long chain ganglioside null GM2 KO mice had detectable 
αGSC IgG at day 21 and a rising titre at reassessment 7 days later. As the large 
standard deviation error bars suggest, even the antibody response seen with 
different mice of the same genotype (and indeed same sex and litter) showed a 
marked degree of variability, with some GM2 KO mice developing high titres of, 
and others barely detectable, αGSC antibodies. 
 Chapter 6  Results     182 
 
 
 
Figure 6.1 - Anti-GSC antibody response following GM1:GD1a immunisation 
An IgM response was detected using anti-ganglioside ELISA at day 14 in both GM2 KO and WT 
animals (A). The OD continued to rise through days 21 and 28 in GM2 KO, but not GM2 WT mice. 
IgG responses (B) lagged behind IgM by 7 to 14 days in GM2 KO mice, and no detectable αGSC 
activity whatsoever was seen in GM2 WT animals. The graph depicts results from one independent 
experiment with n=5 per group, and is representative of results obtained in two further independent 
experiments. 
6.2.1.2  PVDF glycoarray analysis 
As only very small volumes of sera could be collected from mice at each time 
point, ELISA analysis was only able to be performed against a limited panel of 
antigens and negative controls, even when half-area ELISA plates were used. 
This means that although GM1:GD1a antibodies were detected, it is not possible 
to establish from the ELISA studies the finer specificity of the induced antibody 
response, particularly in terms of its complex dependent or independent nature. 
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required for a pair of ELISA wells, this technique provided a practical method of 
assessing the complex dependent nature of this response. A standard PVDF array 
layout of gangliosides and 1:1 complexes, as shown previously in Figure 3.6, was 
used. 
None of the sera from GM2 WT animals had detectable anti-ganglioside 
antibodies as assessed by this method, even when using HRP conjugated IgM 
specific secondary antibodies, and conflicting with the ELISA analysis discussed 
in 6.2.1.1 above. In contrast, all of the GM2 KO mouse sera with detectable IgG 
or IgM GM1:GD1a reactivity on ELISA also displayed αGSC binding on PVDF array. 
However, the finer specificity of this response was again variable, particularly 
for IgG antibodies (Figure 6.2).The IgG subclass was not assessed. 
In general, the GM2 KO IgM response was more consistently complex 
independent than the IgG response, the latter showing a spectrum of complex 
independent to strikingly complex dependent binding.  Intriguingly, in those 
animals showing the most complex specific IgG binding pattern (Figure 6.2, 1+2), 
the antigen bound with the highest intensity was GM2:GD1a, rather than the 
GM1:GD1a complex used as the immunogen. This was the case in several animals 
across three separate experiments using freshly prepared GM1:GD1a liposomes 
and contemporaneously prepared and printed PDVF arrays. In any case, 
predominant GM1:GD1a complex binding was not seen, although all of the sera 
binding GM2:GD1a bound GM1:GD1a at a lower signal intensity. Chapter 6  Results     184 
 
 
 
Figure 6.2 - PVDF array analysis of sera from GM1:GD1a immunised GM2 KO mice 
The above figure shows examples of paired testing of day 28 serum samples from GM2 KO mice 
over 3 independent experiments, illustrative of the different antibody responses seen. The IgM 
response (left hand panels) is broad and complex independent in most GM2 KO animals, showing 
binding to a range of different gangliosides (including GM1, GD1a, GT1a, GT1b and to a lesser 
extent GD1b) in a largely complex independent fashion. This is not stereotyped, with distinct 
differences in the IgM antibodies detected in different animals which have undergone the same 
immunisation schedule. Above, mouse 3 has faint IgM binding to GD1a and GD1a-series 
complexes only, mouse 1 demonstrates a greater GD1a and series signal, in addition to complex 
independent GT1a and GT1b binding. Sera from mice 2 and 4 bind even more promiscuously to 
include GM1 and GD1b-series complexes to a greater and lesser extent. The right hand panels 
show the associated IgG responses from the same animals at the same time point. As can be 
seen, the IgG antibodies present have a narrower specificity, largely being confined to GD1a-series 
binding except for (3) which also demonstrates faint GT1a-series reactivity. As can be seen in (1) 
and especially (2), the complex specific nature of the binding was occasionally striking, but 
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6.2.2 GD1a : GD1b liposomes 
Subsequent experiments were carried out using GD1a:GD1b complex containing 
liposomes as immunogens. The refined protocol described above was used, with 
3 ip injections followed by 3 iv injections of ova containing liposomes following 
an initial ip priming injection of ova-alum. In these experiments, 3 different 
genotypes of mouse were used – GM2 WT, GM2 KO, and GD3s
-/-, the latter of 
which lack b-series gangliosides but have increased concentrations of a-series 
gangliosides.  
6.2.2.1  ELISA analysis 
Similarly to the result seen with GM1:GD1a liposomes, the injection of 
GD1a:GD1b containing liposomes in GM2 WT failed to result in a detectable IgG 
response, even when sera from day 35 was analysed. In contrast to the ELISA 
result in the prior experiment, however, no IgM response was seen either. In 
both GM2 KO and GD3s
-/- groups IgM and IgG responses were seen, although the 
rise in titre lagged about 7 days behind that seen with the previous antigen 
(Figure 6.3). 
In both the GM2 KO and GD3s
-/- groups, anti-GD1a:GD1b IgM and IgG antibodies 
were first detected on day 21. The OD for IgM continued to rise over the next 14 
days, and there was much less non-specific background staining seen with the 
GD1a:GD1a antigen as compared with GM1:GD1a.  As the IgG titre appeared to 
have plateau’d between days 21 and 28, the mice were rebled 7 days later. At 
this point there had been a significant further increase in the IgG OD, despite 
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between GD3s
-/- and GM2 KO titres was found at any time point, as assessed by 
multiple, 2 sample, 2 tailed, T-tests. 
 
Figure 6.3 - Anti-GSC antibody response following GD1a:GD1b immunisation 
The IgM (A) and IgG (B) response following GD1a:GD1ab immunisation, as assessed by 
ganglioside ELISA, is shown. No significant difference between GM2 KO and GD3s
-/- is seen using 
this method. The above results come from one experiment with n=4 per group. These patterns are 
representative of three further experiments, although the absolute ODs varied significantly. 
Likewise, the variation in response between mice of the same genotype within the same 
experiment was again large, as illustrated by the large error bars shown above. Results for the 
GM2 KO group are not shown, as these animals failed to produce a detectable IgM or IgG 
response even at day 35. 
6.2.2.2  PVDF glycoarray analysis 
Once again, the PDVF array was required to investigate the finer specificity of 
the immune response. In essence, GM2 KO mice generated a complex 
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GD3s KO mice produced a similar GD1b response but a highly discrepant GD1a 
response (Figure 6.4). All membranes shown below are examples of the IgG 
response. 
 
Figure 6.4 – The different complex response of GD1a:GD1b immunisation between GM2 KO 
and GD2s KO mice 
(A) shows the typical response seen in GM2 KO animals which was largely stereotyped, 
generating antibodies against both GD1a and GD1b antigens in a complex independent manner. 
Additionally some GT1b and patchy GQ1b series binding was occasionally observed. In GD3s KO 
animals the response was somewhat more diverse (B-D). Here, when an antibody response was 
generated GD1b binding was invariable seen, but GD1a binding was variable, either being 
completely absent (B), much reduced compared with GD1b (C) or equivalent (D). Again these 
discrepancies were seen even with age and sex matched mice from the same litter injected with 
liposomes from the same batches at the same time and intervals.  
The differences in GD1a series response between the two genotypes is quantified 
in (Figure 6.5), where the GD1a series average intensity level is reported as a 
percentage of the GD1b series average signal intensity reading.  Chapter 6  Results     188 
 
 
 
Figure 6.5 - Differing responses of GM2 KO and GD3s KO mice to immunisation with 
GD1a:GD1b liposomes 
By comparing the average signal intensity of the GD1a responses as a proportion of the GD1b 
response between the different genotypes it can be seen that the GD1a series reactivity of GD3s 
KO mice is reduced (n=4, *p=0.023, two tailed, two sided T-test). On average, the GD1a signal is 
50.9% of the GD1b signal in these mice. However, as shown by the error bar, there is a 
considerable variation, with some animals demonstrating nearly equivalent GD1a and GD1b 
reactivity. This is the norm in GM2 KO mice, where additionally some animals show increased 
GD1a versus GD1b binding.  
6.2.3 Sphingomyelin complex response 
As the cohort of Dutch GBS associated disease sera were assayed for anti-GSC 
complex activity and the results analysed it became increasingly clear that a 
proportion of human cases contained antibodies directed towards sphingomyelin 
containing complexes. In fact, 88 of 181 sera tested contained sphingomyelin 
complex binding antibodies (Chapter 5 above). This raised the possibility that, 
instead of the sphingomyelin simply being an inert carrier lipid for the 
gangliosides in the liposomes, there may have been additional ganglioside-
sphingomyelin complexes present in these liposomes. If this was the case then 
there would also be the potential for these complexes to act as distinct antigens 
stimulating a different sphingomyelin-ganglioside complex specific immune 
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Sera from 36 mice previously immunised under previously described conditions 
with both GM1:GD1a and GD1a:GD1b liposomes were available in sufficient 
quantities to allow further analysis. These were drawn from all three mouse 
strains studied. A new, 7x7 grid was devised for these experiments. This 
contained all of the different lipids and gangliosides used to create the 
liposomes, as shown (Figure 6.6). 
 
Figure 6.6 - Layout for 7x7 grid 
The limited panel above was used to look for additional complex in the sera of mice immunised 
with ganglioside complex liposomes additionally containing sphingomyelin (SM), cholesterol (chol), 
and dicetylphosphate (DCP). As previously, the single lipids are spotted in the leftmost column and 
uppermost row, with the complexes in the squares to the right and below derived by combining the 
row and column headings. 
Serum samples from 13 GM2 KO and 5 WT mice immunised with GM1:GD1a, plus 
7 GD3s KO, 6 GM2 KO and 4 WT immunised with GD1a:GD1b, were analysed. All 
sera were prepared at 1 in 100 dilution and binding detected with HRP 
conjugated anti-mouse IgG at 1 in 30000 using the standard PVDF array protocol. 
6.2.3.1  GM1:GD1a immunisations 
Of the 13 GM2 KO sera analysed, IgG in 7/13 (53.8%) bound to sphingomyelin 
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commonly this was GD1a:sphingomyelin (GD1a:SM, seen in all 7 positives), but 3 
additionally bound GM1:SM and 1 GD1b:SM. Five of these 7 bound the complex in 
the context of more general GD1a series binding (Figure 6.7 A+B), with various 
minor degrees of complex modulation, whereas in 2 sera more dramatic 
sphingomyelin-complex enhanced binding was seen (Figure 6.7 C+D) . 
Quantification of the difference between the sum of binding intensities for GD1a 
and sphingomyelin in isolation compared with the intensity of GD1a:SM complex 
binding shows the majority of the sera (5 of the 7 positives) had antibodies with 
complex enhanced binding patterns. Of the remaining two, one showed a small 
complex attenuation (serum B) and one showed no change (‘complex 
independent’, serum F). This is graphically represented in Figure 6.7F.  Chapter 6  Results     191 
 
 
 
Figure 6.7 - Sphingomyelin complex IgG reactivity following GM1:GD1a immunisation 
In the majority of GM2 KO mice showing sphingomyelin complex reactivity following GM1:GD1a 
liposome immunisation, this occurred in the context of more generalised GD1a-series (A) or GD1a 
and GM1-series (B) binding. In two mice, however, GD1a:SM complex reactivity was observed in 
the absence of anything but very low level binding to the component lipid structures in isolation 
(C+D). (E) shows the absence of binding following immunisation of a GM2 WT / littermate control. 
The value plot (F) shows the difference between the sum of binding intensities for GD1a and 
sphingomyelin in isolation (GD1a+SM) compared with the intensity seen for GD1a:SM complex, 
confirming that complex enhanced binding is seen with serum C in particular. Sera A to D in the 
graph correspond to the arrays above. Arrays for E to G are not shown.  Chapter 6  Results     192 
 
 
6.2.3.2  GD1a:GD1b immunisations 
Proportionally more of the GD1a:GD1b immunised animals had IgG antibodies 
binding Sphingomyelin-complexes, as compared with GM1:GD1a immunised mice. 
Five of the 7 GD3s KO mice displayed such binding, as did all 6 of the GM2 KOs. 
Once again, none of the four WT animals raised anti-sphingomyelin complex 
responses (identical membrane appearances to that already shown in Figure 
6.7E). 
Likewise, the complex specific nature of the GM2 KO response was again 
variable. This ranged from generalised GD1b-series binding, sometimes with 
additional GD1a-series binding, to very complex specific patterns, including 
exclusive GD1b:SM complex binding. Similarly, GD3s KO mice also showed a 
variable response, but in contrast never had detectable SM:GD1a complex 
binding antibodies. The range of responses seen is depicted in Figure 6.8. Here 
the sphingomyelin complex responses are compared between GM2 KO and GD3s 
KO mice, following immunisation with GD1a:GD1b liposomes. Both groups show a 
spectrum of binding patterns, which have a degree of overlap. Some GM2 KO 
animals generated antibodies with GD1b series binding which was markedly 
enhanced in the presence of certain additional lipids, such as cholesterol, 
dicetylphosphate (DCP) and particularly sphingomyelin (SM) (Figure 6.8A). This 
was sometimes critically dependent on the exact partnering lipid, with 
sphingomyelin containing ganglioside complexes alone being bound (Figure 6.8B) 
by some sera. In other examples both GD1a:SM and GD1b:SM complexes were 
recognised (Figure 6.8C,D), again without detectable binding to any of the 
component lipids in isolation. In further animals a more complex independent 
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(Figure 6.8E) or both GD1a and GD1b series (Figure 6.8F) reactivity. In both of 
these cases greater and lesser degrees of cholesterol:SM complex binding is 
additionally detected. 
Similar patterns were seen in a number of GD3s KO mice, although in contrast to 
the GM2 KO group, no GD1a:SM complex binding was ever observed. Some 
antibodies (Figure 6.8G) bound almost exclusively to GD1b:sphingomyelin 
complexes. Others (Figure 6.8H, I, J, K) additionally displayed GD1b:DCP 
complex binding, sometimes with an additional, weaker GD1b:cholesterol signal. 
Most intriguingly, only two sera from GD3s KO mice did not have GD1b:SM 
binding antibodies and one of these instead had complex specific αGD1a:GD1b 
IgG reactivity (Figure 6.8L). This serum had not previously been tested on PVDF 
array as it had proved negative for GD1a:GD1b binding on ELISA. Chapter 6  Results     194 
 
 
 
Figure 6.8 - Sphingomyelin complex reactivity following GD1a:GD1b immunisation 
The sphingomyelin complex responses are compared between GM2 KO (left column) and GD3s 
KO mice (right column), following immunisation with GD1a:GD1b liposomes. Each membrane 
represents a the total IgG response in serum from a single animal. Chapter 6  Results     195 
 
 
6.3 Discussion 
The most consistently observed result described in the preceding section is the 
lack of an IgG response directed towards either gangliosides or ganglioside 
complexes in wild type mice. Neither the complex independent or complex 
enhanced responses seen in both GM2 KO and GD3s KO animals were ever 
observed in wild types, using identical immunisation protocols and liposome 
preparations. Particularly given the relatively frequent detection of complex 
specific antibodies following GM1:GD1a injections in GM2 KO mice, the absence 
of this response in the WT implies tolerance to the GM1:GD1a antigen, 
suggesting it is recognised as self. It is possible, however, that the lack of a 
response in WT animals is simply a reflection of tolerance towards the individual 
gangliosides in isolation. This would require that the complex response in GM2 
KO was induced by non-complexed single gangliosides present in the injected 
liposomes. It is difficult to be sure based on the experiments performed whether 
this is the case, but logically it seems less likely. Furthermore, previous ELISA 
experiments using GM1:GD1a liposomes and the GM1 complex attenuated mAb 
DG1 (Figure 3.12) confirm that at least a proportion of the GM1 in GM1:GD1a is 
complexed, given the markedly reduced binding seen with these liposomes 
compared to GM1 only liposomes. This alternative explanation would therefore 
require the complexes known to be present not to have an immunogenic effect. 
This does not seem to be the case given the complex specific IgG response seen 
in at least a proportion of the GSC immunised GM2 KO mice.  
That the predominant complex response seen in a number of GM1:GD1a 
immunised GM2 KO mice is directed against GM2:GD1a is puzzling. GM1 and GM2 
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a number of possibilities. It might be that the GM1 used was contaminated by 
GM2, but this was not apparent when the GM1 preparation was run on TLC.  
Although this would not detect minor degrees of contamination it does confirm 
that the vast majority of the ganglioside present was indeed GM1, and therefore 
this could not be the sole reason for the observed response. It could additionally 
be that GM2:GD1a is for some reason more immunogenic that GM1:GD1a, and 
hence even minor contamination would result in the enhanced GM2:GD1a 
binding pattern seen. There is, however, no reason to suspect this based on 
previous single ganglioside work. Alternatively, GM1 could have been 
enzymatically converted to GM2 either in vitro prior to injection or in vivo 
following injection. This is the function of beta-galactosidase, present in 
lysosomes. However, when reserved portions of several batches of prepared 
GM1:GD1a liposomes were tested on liposome ELISA following injection they 
were still bound by the αGM1 positive control antibody DG2, suggesting that GM1 
remained, although not every batch was tested in this way, and this again does 
not rule out more minor degrees of enzymatic degradation in vitro. It was not 
possible to test for in vivo degradation. Another possibility is that the structure 
of GM1:GD1a complex present in the liposomes somehow differs from that on 
the PVDF array. For example, if the GM1:GD1a complex in the liposome forms 
with a different angle between to two component gangliosides as compared to 
that presented on PVDF, access of the antibody to its binding site may be 
impeded in the latter situation. Conversely, given the shorter chain length of 
GM2, this might provide better access to the GSC binding site on PVDF than GM1 
(Figure 6.9). 
In several sera collected following immunisation, a complex independent 
response was seen. This was an especially common pattern in GD1a:GD1b Chapter 6  Results     197 
 
 
immunised animals. Whether there is a complex specific component within the 
complex independent response has not been addressed by the above 
experiments. It was hoped that cloning individual B cells from these animals 
might further address this question, as detailed in the next chapter (7, Cloning 
and Characterisation of Anti-GSC Antibodies). 
 
Figure 6.9 - A hypothetical reason for enhanced binding to GM2:GD1a on PVDF despite 
immunisation with GM1:GD1a 
In the above example, the antibody is directed against a structure comprising of the internal sialic 
acids from both gangliosides and the N-acetylgalactosamine of GD1a. In the liposome (A), the 
paired gangliosides may be splayed apart, exposing the binding site. If the GM1:GD1a formed on 
the PVDF with a different angle between the two oligosaccharide chains, the terminal galactose of 
GM1 might sterically hinder and block the interaction.  Instead, as the GM2 molecule in a 
GM2:GD1a complex (C) lacks this terminal galactose (which does not form part of the binding site), 
binding is improved as the antibody is able to better access this binding site. Chapter 6  Results     198 
 
 
At a superficial level it is therefore apparent that immunisation with GSCs can 
additionally produce a response directed towards single gangliosides presented 
on PVDF. Of course, it is difficult to discount the possibility that this response is 
induced by non-complexed single gangliosides present within the injected 
liposomes. The fact that low level DG1 binding is seen towards GM1:GD1a 
liposomes in the previously described ganglioside ELISA experiments (Figure 
3.12) suggests that at least some GM1 remains non-complexed to GD1a in such 
liposomes. Another possibility is that the GSCs that are formed within the 
liposome membrane are broken apart before presentation to B cells. 
Interestingly in this regard, some GD3s
-/- animals injected with GD1a:GD1b 
containing liposomes generated a response against single GD1a (and GD1a series 
complexes) despite this ganglioside being present in increased quantities as 
compared with GD3s
+/+ mice. These mice are, however, tolerant of injection 
with GD1a-only liposomes, demonstrating that the response to GD1a in 
GD1a:GD1b liposomes differs from that to GD1a alone.  
The mechanisms involved in the immune response to glycolipid antigens are 
incompletely understood. Whether T-cell help and CD1 presentation is required 
is uncertain. Although the above described experiments were not designed to 
dissect out the finer mechanics of the glycolipid and glycolipid complex 
response, a number of comments can be made. When animals were injected 
with non-ova containing ganglioside complex liposomes, either iv or ip, no 
immune response was seen. Conversely, injections of ova-containing liposomes 
did result in a response. This has previously been seen as evidence of the 
requirement for T-cell help, although this evidence is indirect at best. It may 
alternatively be that the presence of the ova protein results in a generally more 
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non T-cell mediated pathways. CD1 molecules are involved in glycolipid 
presentation to T-cells (Porcelli & Modlin, 1999;Shamshiev et al., 2000;De Libero 
et al., 2002) and as previously discussed CD1a and CD1e polymorphisms were 
shown to be associated with modified risks of developing GBS in one study 
(Caporale et al., 2006). However, more recently, antibody responses to 
glycolipids in model carbohydrate systems have been shown to require CD4
+ T 
cells but not CD1 molecules or natural killer T (NKT) cells, IgG ganglioside 
responses have been generated in mice lacking CD1d, and a further study has not 
confirmed the association between GBS and CD1 polymorphisms (Kuijf et al., 
2008;Matsumoto et al., 2008). Likewise, although CD1 molecules are 
traditionally thought of presenting only one glycolipid molecule at a time, 
casting doubt on their ability to present glycolipid complex antigens, the binding 
pocket of CD1d in particular is large enough to potentially be able to 
accommodate two lipid tail chains concurrently. In fact, when glycolipids with 
shorter tails are bound by CD1 the remainder of the binding pocket has been 
shown to contain other ‘packing lipids’ (Cohen et al., 2009). Natural antibodies 
have also previously been linked with tolerance, autoimmune disease and 
transplant rejection (Holers, 2005;Shimizu et al., 2007). The presence of natural 
antibodies to self-glycolipids might either allow these antigens to be ‘mopped 
up’ before the adaptive immune response is activated (and thus maintain 
tolerance) or alternatively be a sign of intolerance to that particular target. 
None of the animals studied here ever had detectable anti-ganglioside complex 
antibodies prior to immunisation. Whether the initial rise and subsequent fall in 
IgM reactivity in wild-type mice following GM1:GD1a immunisation represents a 
‘spike’ in natural antibody production to detectable levels followed by a re-
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confounded by the very high levels of non-specific IgM binding seen in all animals 
following immunisation. 
Overall, the immunisation protocol resulted in a frequent, if inconsistent, 
antibody response, which could subsequently be utilised for the production of 
αGSC antibody producing hybridomas. Clearly, the animals used in this 
subsequent step would have to be carefully selected to ensure they had 
generated a robust antibody response, which had the potential to contain an 
αGSC monospecific component. 201 
7  Cloning and characterisation of anti-GSC 
antibodies 
7.1 Introduction 
The generation of a ganglioside complex specific monoclonal antibody was felt 
to be critical to further understand the pathogenic potential of this subtype of 
antibodies, their binding characteristics, and to allow an investigation of the 
tissue distribution of ganglioside complexes. Such antibodies could be used in 
surface plasmon resonance work, immunofluorescence binding studies, and ex 
vivo and in vivo pathological studies.  
The technique for creating monoclonal antibodies of defined specificities was 
developed in the 1970s (Kohler & Milstein, 1975). In essence, B cells are 
extracted from the spleens (and occasionally other sites) of immunised mice. 
These cells are then fused with myeloma cells using polyethylene glycol to 
render them immortal. The myeloma cells lack hypoxanthine-guanine-
phosphoribosyl transferase (HGPRT), a critical enzyme in the purine salvage 
pathway.  When de novo purine synthesis is also blocked using media containing 
aminopterin, the unfused cells die. In contrast, fused cells will have regained 
the HGPRT enzyme from the splenocytes, and can use this salvage pathway to 
synthesise purines. This media therefore selects out only the successfully fused 
cells for survival. In traditional liquid-media based techniques, the cells are 
plated out in multiple wells and the supernatants tested at intervals. Only those 
containing antibody of the required specificity are expanded and grown further. 
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positive wells and discarding negatives, until a pure growth which has originated 
from one cell is obtained.  
Modern techniques using semi-solid media rely on many of the same principles, 
but following fusion the cells are suspended in a semi-solid, aminopterin 
containing media. The resulting colonies should already be monoclonal, and can 
be picked individually and subsequently screened for antibody production. 
Further details of these techniques are given in chapter 2.  Chapter 7  Results     203 
 
 
7.2 Results  
Both liquid and semi-solid medium techniques were used in the selection and 
purification of monoclonal lines. 
7.2.1 Liquid medium selection 
Initial attempts were made using GM1:GD1a immunised animals and traditional 
liquid based selection media. Variations in the ratios of splenocytes to 653-
myleoma cells, the area of wells used for initial and subsequent cell growth (96 
well versus 24 well plates), and whether whole blood from other mice was used 
to feed the fusions, were tested in an attempt to optimise the protocol. A 
summary of the different experiments is given (Table 7.1). Although the 
methodology was refined and the number of first screen positive wells 
increased, this signal was lost when the wells were subsequently split and/or 
expanded. If this step could be omitted, and monoclonal wells produced from 
the outset, it was hoped that the cultures would have a better chance of 
continuing to produce the antibody required.  
7.2.2 Semi-solid medium selection 
The above was the rationale for moving to a semi-solid medium. Using this 
method, single colonies could be picked and once positives were indentified it 
would only be necessary to keep these cells growing, rather than moving to a 
cloning process involving limiting dilutions.  
In this protocol, following exposure to polyethylene glycol (PEG) to fuse the 
cells, they are returned to a recovery medium in a tissue culture flask for 24hrs Chapter 7  Results     204 
 
 
prior to mixing with the semi-solid selection medium and plating out. 
Unfortunately, in the initial experiment when the cells were resuspended after 
24hrs, copious, stringy clumps of cells were noted, suggesting substantial cell 
death. After 14 days of growth in the semi-solid medium, only a handful of very 
small, white colonies were visible to the naked eye, rather than to hundreds 
suggested in the literature accompanying the kit. After taking advice for the kit 
manufacturer’s technical department, it was decided to perform 3 further 
fusions, varying the recovery time post fusion. Zero, 24 and 48h periods were 
chosen. The results of these experiments are summarised in Table 7.2.       
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Immunogen  Mouse 
Strain 
Terminal OD (1 
in 100) 
Splenocytes 
(x10
7) 
Myeloma 
Cells (x10
7) 
Ratio 
(Spleen:Myeloma) 
Plates  Fed  Cells / 
well (x10
5) 
Positive Wells 
(1
st Screen) 
Positive Wells 
(2
nd Screen) 
GM1:GD1a  GM2 KO  0.522  2.7  0.27  10:1  6x96  Y  1.2  27  0 
GM1:GD1a  GM2 KO  0.158  11.5  0.945  ≈10:1  6x96  Y  5.0  3  0 
GM1:GD1a  GM2 KO  0.718  5.4  0.68  ≈10:1  6x96  Y  2.4  0 (infected)  - 
GM1:GD1a  GM2 KO  0.839  6.5  0.65  10:1  12x24  Y  2.5  0  - 
GM1:GD1a  GM2 KO  0.552  10.0  20.0  1:2  12x24  Y  10.5  0  - 
GM1:GD1a  GM2 KO  1.388  1.8  0.4  ≈5:1  6x96  N  0.3  0  0 
GM1:GD1a  GM2 KO  0.542  4.3  0.9  ≈5:1  6x96  N  0.8  2  0 
GM1:GD1a  GM2 KO  1.467 / 1.978 
(Pooled) 
10 + 8.5  25  1:1.35  6x96  N  2.0  3  0 
GD1a:GD1b  GD3s KO  2.34  11.9  2.4  5:1  6x96  N  2.9  4  0 
GM1:GD1a  GM2 KO  0.601  3.8  1.1  ≈4:1  3x96 
 
N  2.0  3  0 
GM1:GD1a  GM2 KO  0.954  7.8  2.1  ≈4:1  8x96  N  1.7  7  0 
GM1:GD1a  GM2 KO  1.266  8.4  2.1  ≈4:1  8x96  N  1.8  10  0 
GD1a:GD1b  GD3s KO  1.878  11.4 (+ bone 
marrow) 
 
2.5  4.5:1  6x96  N  2.8  26  0 
Table 7.1 - Summary of fusion experiments using liquid selection media       
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Table 7.2 - Summary of experiments using semi-solid selection media 
 
 
 
 
 
 
   
 
Immunogen  Mouse 
Strain 
Terminal OD 
(1 in 100) 
Splenocytes 
(x10
7) 
Myeloma Cells 
(x10
7) 
Recovery time 
(h) 
Colonies (14 
days) 
Growing wells 
(Day 21)  
Positive Wells 
(1
st Screen) 
Positive Wells 
(2
nd Screen) 
          24  not recorded  0     
GD1a:GD1b  GM2 KO  2.04  8.0  1.0  0  36  4  0   
GD1a:GD1b  GM2 KO  1.28  10.6 (+BM)  0.95  24  82  13  1  0 
GD1a:GD1b  GD3 KO / 
GM2 KO 
1.40 / 0.61 
(pooled) 
19.6 (+BM) 
(pooled)  1.8  48  67  29  3  0 Chapter 7  Results     207 
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7.3 Discussion 
The failure to generate a stable clone of myeloma cells producing anti-
ganglioside complex antibodies is a frustrating limitation to the further study of 
the potential pathogenic effects of such antibodies. The reasons for this failure 
have not been fully elucidated in the above experiments. A certain chance 
effect is at play, requiring that some of the limited proportion of splenocytes of 
the required antibody specificity fuse successfully with the immortal myeloma 
cells. The increasingly consistent observation of positive wells on the 1st post 
fusion ELISA screen suggests that this is not the sole problem. With this in mind, 
it had been initially postulated that non-antibody secreting clones in the wells 
were outgrowing the antibody secreting clones, resulting in a loss of antibody 
production. Furthermore, it was also speculated that attempts to clonally dilute 
the cells were stressing them and causing excessive cell death. The observation 
that initial positive wells obtained from plucked colonies in the semi-solid 
selection medium also lost their antibody secretion is counter to these 
hypotheses. It remains possible that the cells were overly sensitive to attempts 
to further expand them beyond the single tissue culture plate well stage, for 
reasons not established.  
653 myeloma cell lines were obtained from 2 further sources in case there had 
been a problem with the viability of the initially used line, but this made no 
dramatic difference to the outcome of the fusions. After the first two 
unsuccessful fusions, the viability and growth rate of the 653s pre-fusion was 
assiduously checked, and repeatedly found to be satisfactory. It may have been 
that exposure to PEG during the fusion was particularly toxic to the cells, but 
one might expect this to result in early, rather than delayed, cell death. Never Chapter 7  Results     208 
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the less, this was not systematically optimised, and attempts were simply made 
to follow the previously successful fusion protocol as closely as possible with 
respect to timings. 
Another possibility is that the products of the successful fusions (anti-GSC 
antibodies) are toxic to the cells producing them. This again seems unlikely as 
single ganglioside antibodies have previously been produced in this way. These 
antibodies are only structurally injurious in the nervous system in vivo, where 
their target antigen is much more highly expressed than compared with the 
haemopoietic system, and then only when also administered with a source of 
complement. However, GBS is (most usually) a monophasic disease and when 
ganglioside antibodies are detected in clinical cases their titre declines as the 
active disease process resolves, indicating that tolerance is re-established. This 
is generally felt to be due to immuno-regulatory mechanisms involving changes 
in the balance between pro- and anti-inflammatory cytokines and cells. Based on 
the speculation at the start of this paragraph, the possibility of self-toxicity of 
the anti-ganglioside antibodies to the cells producing them could be proposed as 
another potential mechanism for the re-establishment of tolerance.  
Future attempts to produce anti-GSC antibody secreting clones might then best 
begin with an optimisation of the PEG exposure time, and other components of 
the fusion process, in the first instance simply looking at the subsequent viability 
of the fused cells. Once this is completed, comparison could be made between 
the viability of cells in anti-GSC antibody producing and non-producing wells to 
look for any toxic effect of the antibodies themselves. Time and resource 
constraints precluded such assessments being undertaken and included herein. 209 
8  An active immunisation model of GBS 
8.1 Introduction 
As already discussed, although immune responses were successfully generated 
against ganglioside complexes (GSCs) expressed in liposomes, a stable clone of 
myeloma cells producing complex specific monoclonal antibodies was not 
produced in time to perform further studies assessing the nature and 
pathogenicity of αGSC antibodies and include the results in this thesis. Some 
limited studies involving assessment of the binding of neuropathy associated sera 
with apparent GSC specific binding patterns were undertaken, looking at 
immunoglobulin deposition in frozen sections of mouse diaphragm neuromuscular 
tissue (3.2.13). However, as reviewed in the above discussion section (3.3), such 
studies are restricted not only directly by the small amounts of sera available, 
limiting optimisation and repetition of the assay, but also by the knock on effect 
that with these limited resources only small frozen sections can be examined at 
all. As earlier investigation of the binding of the paired anti-GM1 monoclonal 
antibodies revealed there is (albeit indirect) evidence to suggest that GSC 
complexes may be disrupted in frozen, dead tissue. A potential alternative 
approach to investigate the in vivo effects of αGSC antibodies was made possible 
by the recent development of a new, transgenic, mouse line, created in house 
by Dr Denggao Yao.  
8.1.1 Background 
Although animal models of axonal neuropathy mediated by anti-ganglioside 
antibodies have been created in rabbits following repeated bovine brain Chapter 8  Results     210 
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ganglioside injections over long periods (Yuki et al., 2001), such models in mice 
are limited by the tolerance of wild type animals to ganglioside injections. These 
animals, which express a full range of gangliosides, fail to produce a robust 
immune (and in particular, IgG) response when repeatedly injected with 
gangliosides plus adjuvant administered in liposome form (Figure 8.1A), and as 
again demonstrated by experiments detailed in chapter 6 above. This hurdle can 
be overcome by using GalNAcT
-/- (also known as “GM2 KO”) mice. These mice 
produce no ganglioside beyond the block in the synthetic pathway resulting from 
the absence of the GalNAcT enzyme, and instead accumulate the shorter chain 
gangliosides GM3 and GD3. As they lack gangliosides of greater complexity, such 
as GQ1b for example, they are intolerant of immunisation with such antigens, 
and produce robust immune responses including high titres of anti-ganglioside 
IgG antibodies (Figure 8.1B)(Bowes et al., 2002). However, as these animals do 
not express the target molecule for this immune response, they do not develop 
neuronal injury and hence do not display a disease phenotype. As such, current 
mouse models of anti-ganglioside antibody mediated neuropathies rely on 
passive transfer of antibody produced in GM2 KO animals into GM2 WT animals, 
most usually (and reliably) via the intermediate step of creating a clone of 
myeloma cells producing a ganglioside antibody of defined specificity (Figure 
8.1C). Chapter 8  Results     211 
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Figure 8.1 – The current passive transfer model of anti-ganglioside mediated neuropathy in 
mice 
Wild type mice (A) are tolerant of immunisation with gangliosides, such as GQ1b (red triangles), 
failing to mount a robust IgG response despite repeated immunisations, as shown in the 
accompanying graph, taken from (Bowes et al., 2002). This can be overcome by using GalNAcT
-/- 
(GM2 KO) mice (B). These mice lack longer chain gangliosides, and produce a strong IgG 
response on repeat administration of such immunogens (IP GQ1b-liposomes on 3 occasions 2 
weeks apart in the example graph). However, given that they do not express the antigen, no 
disease phenotype ensues. Instead, a passive transfer of antibody from GM2 KO to GM2 WT 
animals is necessary, usually via the intermediate of antibody producing myeloma clone (C).  Chapter 8  Results     212 
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8.1.2 Development of a transgenic neurofilament promoter 
GalNAcT / GalNAcT
-/- mouse 
In an attempt to overcome this double step, and to assess the effect of 
gangliosides expressed solely within the nervous system, a transgenic mouse was 
created by Dr Denggao Yao. The approach taken was a tissue specific, axonal 
rescue of GalNAcT function in GM2 KO
 mouse, using the neurofilament light 
(NFL) promoter to drive axonal expression. In brief, the DNA for the GalNAcT 
gene was purified, fused to a Flag tag for detection of expression, and 
amplified. Activity of the enzyme was confirmed by insertion into a CMV 
promoter vector and transfection of GM3 only expressing melanoma cells, in 
which GM2 expression was subsequently detected by immunofluorescence 
microscopy using an anti-GM2 antibody (Figure 8.2A). Activity of the NFL 
promoter was confirmed by insertion of the transgene into a NFL promoter 
vector, and transfection of an NG108 neuroblastoma cell line. Detection of flag 
expression confirmed activity of the promoter (Figure 8.2B). The now verified 
vector was then microinjected into fertilised mouse ova, and by this technique 6 
transgenic germline transmitters were generated. However, as the transfection 
relied on GalNAcT
+/+ mice for success, these lines had to be crossed onto a GM2 
KO line such that systemic ganglioside expression was lost, leaving only that 
driven by the transgene under NFL control (Figure 8.2C). The resulting genotype 
is designated Tg(Nfl-GalNAcT)GalNAcT
-/-, subsequently referred to as NFL Tg.  Chapter 8  Results     213 
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Figure 8.2 - Development of the GM2-neurofilament light transgenic / GM2 KO mouse 
(A) Transfection of GM3 only expressing melanoma cells, with a strong CMV promoter, results in 
GM2 expression, as detected by immunofluorescence using a GM2 antibody (green = anti-GM2, 
red = anti-flag). This demonstrates that the inserted DNA results in the production of an active 
enzyme. (B) Using a different vector, transfection of neuroblastoma cells confirms that the 
neurofilament light (NFL) promoter is active, as evidenced by detectable flag expression, again 
using immunofluorescence (green = anti-flag, blue = DAPI). These experiments were performed 
and pictures kindly supplied by Dr Denggao Yao. (C) Following successful microinjection into the 
fertilised ova of wild type mice, the germline transmitting founders needed to be crossed onto the 
GM2 KO genotype to give an axon specific rescue. In the above diagram, the red shading 
represents gangliosides more complex (i.e. of longer chain length) than GM3 and GD3. GM2 KO 
mice contain no complex gangliosides, whereas WT mice express such gangliosides systemically. 
In the transgenic WT, the effect of the ‘native’ GalNAcT gene and enzyme would be expected to 
dwarf that of the transgene. By crossing the GM2 WT/NFL-GM2-Tg with a GM2 KO, the native 
gene can be removed, resulting in complex ganglioside expression confined solely to the axons, 
under the control of the NFL promoter. The resulting genotype is designated Tg(Nfl-
GalNAcT)GalNAcT
-/-, subsequently referred to as NFL Tg.   Chapter 8  Results     214 
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The transgenic animals were initially tested for axonal ganglioside expression 
using fluorescently labelled cholera toxin B-subunit and anti-GM1 mAb (DG2), 
but no binding was detected. However, when a different mAb with a different 
ganglioside binding profile was used, binding was detected in the neuromuscular 
tissue of these mice. The antibody used was MOG12, binding primarily to GT1b, 
but also to GD1a and GD1b (Figure 8.3).This immunofluorescent tissue analysis 
was carried out by Dr Kay Greenshields. As such, initial experiments to work up 
an active immunisation model of GBS in NFL Tg mice concentrated on anti-GT1b 
antibodies and GT1b as an immunogen (sections 8.2.1 to 8.2.3). When high 
performance thin layer chromatography (HP-TLC, Figure 8.4) (performed by 
Professor Koichi Furukawa at the Nagoya University School of Medicine, Nagoya, 
Japan) subsequently demonstrated that GM1 and GD1a expression had also been 
reconstituted, at least in the Ed2 line (one of the six transgenic lines resulting 
from the implantation and breeding programmes), a subsequent active 
immunisation protocol involving GM1:GD1a complex antigens was justified 
(section 8.2.4).  
 
Figure 8.3 - Immunofluorescent staining of neuromuscular tissue from the lumbricals of 
transgenic, knockout and wild type mice 
The MOG12 mAb (green) binds GT1b, GD1b and GD1a, whereas TRITC labelled alpha 
bungarotoxin (BTx, red) locates the post synaptic apparatus of the neuromuscular junction. As can 
be seen above (left panel), the presence of the transgene has restored binding by MOG12, as 
compared with the KO animal (centre panel, where only minor, presumably non-specific, 
background staining is seen), and to levels equivalent to that seen in wild types (right panel). This 
implies that the transgene has successfully rescued complex ganglioside synthesis in the axons. 
These experiments were performed and images kindly supplied by Dr Kay Greenshields. Chapter 8  Results     215 
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Figure 8.4 - HP-TLC using acidic glycolipid fractions extracted from transgenic, KO and WT 
mice brain 
The WT mouse (323) has strong bands corresponding to the gangliosides GD1a and GT1b, as well 
as slightly fainter bands representing GM1, GD1b, and other unidentified structures. In contrast, the 
KO mouse (242) has three strong bands only, corresponding to gangliosides accumulating behind 
the enzyme block – namely (from top to bottom); GM3, 9-O-acetyl GD3 and GD3. The identity of 
this central band has only recently been confirmed (Furukawa et al., 2008). Somewhat surprisingly, 
there appears to be a faint band at the level of GD1a in the KO lane. As can be seen, synthesis of 
more complex gangliosides has been rescued in the transgenic line Ed2 (mouse 395), indicated by 
the arrows above, from top to bottom representing GM1, GD1a, GD1b and GT1b. This analysis 
was performed and the image kindly provided by Professor Koichi Furukawa at the Nagoya 
University School of Medicine, Nagoya, Japan. Chapter 8  Results     216 
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8.2 Results 
In the development of the active immunisation model using the NFL Tg mouse 
and ganglioside antigens, an attempt was made to build up the level of 
complexity and test the validity of each component in the protocol individually 
before combining these together in the final protocol. In this way, initial 
experiments using the transgenics were performed using ex vivo preparations of 
neuromuscular tissue exposed to anti-ganglioside antibodies and complement, 
before passive transfer of the same antibodies was trialled in vivo. Subsequently 
immunisation experiments were performed, ultimately leading to disease 
induction, as discussed below. 
8.2.1 Ex vivo Model 
In these preliminary experiments, whole diaphragms along with a surrounding 
rim of costal tissue were quickly harvested from NFL Tg, WT and KO mice killed 
by a rising concentration of CO2, as per Home Office guidelines. This tissue was 
then kept alive by bathing in oxygenated, warmer Ringer’s solution (Figure 8.5, 
and see appendix), prior to application of MOG12 (or MOG16, a mAb obtained 
from the same fusion with a very similar ganglioside binding protocol), followed 
by normal human serum (NHS) as a source of complement.  
 
Figure 8.5 - Organ bath containing mouse diaphragm in Ringer's Chapter 8  Results     217 
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If the transgene had successfully sensitised the NMJs of the NFL Tg mouse to 
ganglioside mediated injury, one would expect to be able to detect 
immunoglobulin deposition, complement activation and neurofilament loss (as a 
marker of cytoskeletal degradation and neuronal injury), and this was indeed the 
case. Images from these experiments are shown in Figure 8.6. Panel A shows 
that IgG is deposited over the NMJs of neuromuscular tissue from NFL Tg animals 
exposed to anti-ganglioside antibody, and that these antibodies activate 
complement leading to MAC pore formation when NHS is provided. These 
appearances are similar to those seen with GM2 WT mice (Figure 8.6B), and in 
contrast to GM2 KO animals (Figure 8.6C) where no binding is seen. Likewise 
when Ringer’s medium is applied instead of the anti-ganglioside antibody, no 
binding is seen (Figure 8.6D-F).  
Quantification and statistical analysis of the above data confirms that all of IgG 
binding (Figure 8.7A), C3c (Figure 8.7B), and MAC pore deposition (Figure 8.7C) 
are significantly increased in NFL Tg and WT mice over controls (non parametric 
Mann-Whitney test for non normalised data, p<0.0001 for all comparisons). 
There is no statistically significant difference in IgG or C3c staining between WT 
and NFL Tg tissue, but MAC pore deposition is significantly increased in NFL Tg 
mice versus WT (p<0.0001). Intensity measurements are all given in arbitrary 
units. 
Neurofilament loss over the NMJ was additionally used as an indication of axonal 
injury, with comparison made between control and antibody treated. The 
neurofilament signal for GM2 KO tissue was unchanged regardless of whether 
Ringer’s alone (Con) or MOG16 (Ab) was applied (Figure 8.8A, Mann-Whitney, 
p=0.295). In contrast, in both GM2 WT (B) and NFL Tg tissue (C), the level of Chapter 8  Results     218 
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neurofilament staining was significantly decreased (p<0.0001) in tissue exposed 
to the antibody. There was no statistically significant difference in 
neurofilament staining between NFL Tg and GM2 WT either with (p=0.998), or 
without (p=0.276), antibody application. 
Similar results were seen with two different antibodies (MOG12 and MOG16) and 
two different transgenic lines (line 30 and Ed2). Chapter 8  Results     219 
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Figure 8.6 - Ex vivo application demonstrates the sensitivity of transgenic NMJs to anti-
ganglioside antibodies 
NFL Tg (A), GM2 WT (B), and GM2 KO (C) diaphragm exposed to MOG12 antibody followed by 
NHS as a source of complement. IgG, C3c, and MAC appear green in their respective panels and 
the neuromuscular junctions (NMJs) are labelled red with α-bungaratoxin. In the ethidium panels 
the NMJs are now green and the ethidium stain is red. One representative example of positive 
ethidium staining over an NMJ (A, two ethidium stained nuclei) and one example of negative 
ethidium staining (B, two NMJs with no associated ethidium staining) are shown. This latter 
appearance was typical of the ethidium pattern seen in all other experimental conditions, for which 
no additional representative images are shown.  
(D-F) are control diaphragm preparations exposed to Ringer’s medium alone rather than anti-
ganglioside antibody, but otherwise identically processed.. Chapter 8  Results     222 
 
 
2
2
2
 
 
Figure 8.7 - Quantification of ex vivo staining data 
Box plot showing the quantification of the above ex-vivo immunofluorescence experiments. IgG 
binding (A), C3c (B), and MAC pore deposition (C) levels are shown for all three different mouse 
strains used. Intensity measurements are all given in arbitrary units.* = outlying value Chapter 8  Results     223 
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Figure 8.8 - Neurofilament loss over the NMJ following ganglioside antibody and 
complement administration ex vivo 
Boxplot showing the staining intensity of neurofilament over the neuromuscular junction either with 
(Ab) or without (Con) the application of anti-GT1b antibody. A reduced intensity in the antibody 
treated tissue demonstrates neurofilament loss as a result of axonal damage. 
8.2.1.1  Perisynaptic Schwann cell injury 
In addition to assessing axonal injury by looking for loss of neurofilament staining 
as above, the ex vivo protocol also involved an assay of perisynaptic Schwann 
cell (pSc) injury, using an ethidium homodimer stain. It was assumed that, in 
NFL Tg tissue, such cells, lacking NFL expression, would also lack longer chain 
gangliosides and hence be resistant to ganglioside antibody and complement 
mediated damage. However, this was not the case. Counts of the number of 
dead pSCs per end plate (i.e. those whose nuclei stained with ethidium) 
revealed the opposite. WT tissue demonstrated levels of pSC death not elevated 
above KO and controls, whereas in NFL Tg tissue exposed to antibody and 
complement, dead pSC counts were significantly elevated (p<0.001, Table 8.1). Chapter 8  Results     224 
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  Number of Ethidium+ Cells / End Plate 
  0  1  2  3  4 
NFL TG Ab  144  34  24  3  1 
NFL TG Con  214  4  3  0  0 
WT Ab  103  1  0  0  0 
WT Con  202  3  1  1  0 
KO Ab  291  4  0  0  0 
KO Con  160  4  2  0  0 
Table 8.1 - Counts of ethidium positive cell nuclei per end plate by tissue type 
As can be seen, the counts of ethidium positive nuclei overlying the NMJs in NFL Tg mouse 
hemidiaphragm are substantially elevated above those in other tissues, and in controls. By 
consolidating these observations into two states (either ethidium positive cells present or absent for 
each end plate observed), chi squared analysis could be performed to show that these counts were 
statistically significantly elevated in NFL Tg tissue treated with MOG12 (or indeed MOG 16 in a 
separate experiment), as compared with all others (p<0.001 on both occasions). 
8.2.2 Passive transfer (αGT1b) 
8.2.2.1  Plethysmography 
Having demonstrated the restored sensitivity of NFL Tg mice (over GM2 KOs 
lacking the transgene) to ganglioside antibody mediated injury in an ex vivo 
setting, the next step was to confirm this in vivo. A passive transfer approach 
was used, involving the intra-peritoneal (ip) injection of MOG16 mAb, followed 
16h later by NHS as a source of complement. The functional consequence of 
axonal injury (muscle paralysis) can be assessed in vivo under these conditions 
by the use of whole body plethysmography. This assesses the function of the 
respiratory musculature, and in particular, the diaphragm, which is directly 
bathed in antibody (and NHS) following ip injection, and is therefore primarily 
affected in such a protocol. On contraction, this muscle reduces the 
intrathoracic pressure (by increasing the volume), resulting in a movement of air 
into the lungs. The volume of air moved in and out of the lungs with each breath 
is known as the tidal volume (TV), and is largely dependent on diaphragmatic 
function (not withstanding the effects of other accessory and abdominal muscles 
on respiration). In contrast, other measures of respiratory function, such as Chapter 8  Results     225 
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respiratory rate, may at first increase as an attempted compensation for 
reduced ventilation (i.e. reduced tidal volume) before falling again as 
exhaustion supervenes. As such, TV was chosen as the best indicator of 
diaphragmatic paralysis. Baseline TVs in humans, and other measures of 
respiratory function such as forced vital capacity (FVC), vary with such factors as 
height (primarily) and age, and are often measured as a “percentage of 
predicted” in disease processes. In mice, assessment of expected baseline 
respiratory function by similar methods is to my knowledge, and following an 
Pubmed search, not available, save for observed median values and ranges in 
different mouse strains (Reinhard et al., 2002;Schulz et al., 2002). In view of 
this, baseline TVs in each animal were normalised to 100%, and subsequent 
changes in TV related to this individually derived baseline. It was first checked 
that at baseline there were no differences in absolute tidal volume between the 
different strains by statistical analysis using General Linear Model (GLM) analysis 
of variance (ANOVA). No statistically significant differences were observed 
between any of the groups (KO v WT, p=1.000, KO v NFL Tg, p=0.518, WT v NFL 
Tg, p=1.000) after assessment of 14 GM2 KO, 13 NFL Tg and 8 GM2 WT mice, 
although the variability in TV appears less in WT as compared to other groups 
(Figure 8.9). 
However, after ip injection of antibody followed by NHS, the tidal volume (TV) 
in NFL Tg animals begins to fall at 30 minutes, becoming statistically lower than 
GM2 KO controls at t=60 and beyond, as assessed by multiple paired T-tests 
performed at each time point (Figure 8.10). An additional 2-way ANOVA with 
repeated measurements confirmed that both the time post complement 
injection and the mouse strain had significant influence on TV (p<0.0001 for 
both factors). In control animals (green trace, Figure 8.10), there is an initial Chapter 8  Results     226 
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increase in TV, followed by a slower fall back to baseline and below, although 
never dropping to the levels seen in the NFL Tg. Example plethysmography 
traces from control GM2 KO mice (Figure 8.10B) and NFL Tg mice (Figure 8.10C) 
90 minutes after complement injection show the deflections in the tracing, 
corresponding to pressure changes and hence air flow, are much more prominent 
in KO animals, and the fact that they are coloured indicates that the machine is 
recognising these as breathes. In the NFL Tg traces, a near flat line state is 
observed, and the absence of colour indicates these breaths are too small (or 
asymmetrical, or both) to be counted as true breathes by the software. 
   
Figure 8.9 - Baseline tidal volume 
No significant difference in baseline tidal volume was observed for any of the genotypes studied. Chapter 8  Results     227 
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Figure 8.10 - Whole body plethysmography following passive transfer of MOG16 anti-
ganglioside antibody 
(A) Change in tidal volume over time following passive transfer of MOG16 and NHS for NFL Tg 
(red) and GM2 KO (green) mice. B+C show example plethysmography traces from control GM2 
KO mice (B) and NFL Tg mice (C) 90 minutes after complement injection.  
8.2.2.2  Tissue analysis 
Following completion of the plethysmography, mice were culled, and their 
diaphragm muscles quickly harvested and snap frozen on dry ice. These were 
then analysed for immunoglobulin and complement deposition as before. This 
confirmed significantly increased IgG, C3c and MAC deposition over the NMJs of 
NFL Tg compared with GM2 KO animals, as expected (Figure 8.11, p<0.0001 
versus GM2 KO by Mann-Whitney, n=6 per group). Despite similar, or even 
increased, levels of IgG and C3c staining as compared with the ex vivo tissue 
(Figure 8.7), MAC intensity was reduced. Chapter 8  Results     228 
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Figure 8.11 - Immunoglobulin and complement deposition following passive transfer 
Boxplot quantification of  IgG (A), C3 (B), and MAC (C) detected over the neuromuscular junctions 
of NFL Tg and GM2 KO diaphragms. Significantly increased levels of all three are seen in the NFL 
Tg strain (all p<0.0001 versus GM2 KO by Mann-Whitney, n=6 per group) (*=outlier).  
8.2.3 Active immunisation (GT1b) 
Having established that the transgenic mice expressed long chain gangliosides 
(including GT1b) and that their neuromuscular tissue was sensitive to anti-GT1b 
ganglioside antibody mediated damage, the next step was to investigate their 
immune response to the same antigen, as a prelude to pursuing an active 
immunisation model. Chapter 8  Results     229 
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8.2.3.1  Immune response 
An immunisation protocol was used similar to that previously described for the 
assessment of the immune response towards GM1:GD1a and GD1a:GD1b 
complexes. GT1b containing liposomes were produced, and after priming with 
ova-alum ip (day 0), three ip injections of these ova-containing liposomes were 
administered on days 7, 14 and 21, followed by three intravenous (iv) injections 
on days 25, 26 and 27. Blood samples were initially taken on days 0, 14, 21, 28 
and 35. This first round of immunisations involved 4 animals in each genotype 
group, and revealed that a detectable IgG response was not seen until day 21. As 
such bleeds at earlier time points were subsequently omitted. 
Analysis of the anti-GT1b IgG response at these different time points shows that 
both GM2 KO and NFL Tg genotypes have detectable antibody from day 21, and 
that the OD measurement continues to rise through day 28 to day 35. There is no 
statistically significant difference in the levels between these two groups, 
although the average OD in the NFL Tg is slightly lower at day 21 and beyond. In 
contrast, the GM2 WT group has a response which does not significantly increase 
above baseline (Figure 8.12). The IgM response is less clear cut, with all three 
genotypes showing a progressive, but slight, increase in the corrected OD 
reading as time progresses (Figure 8.13). This is confounded by the fact that IgM 
binding to negative control wells also increases substantially over the same 
period, from 0.04 to 0.74 for some animals Chapter 8  Results     230 
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Figure 8.12 - The IgG response to GT1b immunisation in WT, KO and NFL Tg mice 
At 1 in 50 dilution in 1%BSA/PBS, a detectable antibody response in WT and NFL Tg mice towards 
the GT1b immunogen is first detected at day 21, and continues to rise beyond this point. In 
contrast, the antibody levels in GM2 WT mice does not rise significantly above baseline over the 
same period. (n=3 per group, statistical analysis by multiple two-tailed T-tests) 
 
Figure 8.13 - The IgM response to GT1b immunisation in WT, KO and NFL Tg mice 
The IgM response in the same animals is less clear cut, and potentially confounded by much 
higher signal generated in the negative control wells. When this is corrected for, all three genotypes 
show a trend to higher ODs as time progresses. Unlike the IgG response, this is also seen for the 
wild type mice, and except for the NFL Tg group, does not increase consistently from week to 
week. Chapter 8  Results     231 
 
 
2
3
1
 
8.2.3.2  Plethysmography 
Following the establishment of the pattern of immune response in the three 
groups, subsequent experiments were planned to assess the presence of a 
disease phenotype, pre- and post-complement injection, on day 35 of the 
protocol (7 days following the final iv boost). As shown above, there was no 
difference between any of the three mouse strain groups at baseline in terms of 
tidal volume (TV). There was also no statistical difference in absolute TV 
between the groups following immunisation, but before complement injection 
(as assessed by GLM ANOVA with Tukey correction, KO v WT, p=0.605, KO v NFL 
Tg, p=0.753, WT v NFL Tg, p=0.923). However, following an injection of 1ml of 
normal human serum ip as a source of complement, the TV fell more in the NFL 
Tg group, becoming statistically significant with respect to the KO control group 
30 minutes after injection, and with respect to the WT control group 60 minutes 
after injection (as assessed by multiple paired T-tests – again 2 way ANOVA with 
repeated measures was used to confirm that both the mouse strain and time 
point had a significant influence on TV). Slight falls in the measured TV in both 
the GM2 KO and GM2 WT groups were also observed, although there was no 
statistically significant difference between these two control groups (Figure 
8.14). Chapter 8  Results     232 
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Figure 8.14 - Plethysmography following active immunisation 
Although there was no significant difference in absolute tidal volume measurement between the 
three groups at baseline, or following the immunisation protocol, this measurement fell much more 
in the NFL Tg genotype following subsequent complement injection than in the two control groups 
(GM2 KO and GM2 WT). This difference became statistically significant (using multiple paired T-
tests) as compared with GM2 KO at 30 minutes and as compared to GM2 WT at 60 minutes. 
Following an initial rise in TV immediately after complement injection, this measurement also fell in 
the control groups over the next two hours, with no statistically significant difference in the 
magnitude of the fall between the two groups. 
8.2.3.3  Behavioural testing 
Groups of mice from each of the three strains were initially tested at baseline, 
and no statistically significant differences were seen in any of the parameters 
measured (as assessed by GLM-ANOVA with Tukey correction). For the balance 
bar, rotarod at fixed speed, and hindlimb reflex extension tests, all animals in 
each group achieved the maximum score, and these results are not shown 
further. Rotarod and grip strength tests were chosen for further analysis at later 
time points in the protocol, given the variable baseline of and time required to 
perform platform and open field tests (Figure 8.16 and Figure 8.17). Chapter 8  Results     233 
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Figure 8.15 - Baseline behavioural and strength testing 
On testing of six animals in each genotype group at baseline, when aged 6 to 10 weeks, no 
significant differences were observed for weight (A), forelimb grip strength (B), all limb grip strength 
(C), latency to platform (D), as well as hindlimb reflex extension pattern and balance bar time 
(results not shown). Large variability was seen in latency to platform time, and animals which 
performed similarly in other tests sometimes had very discrepant performances in this area. Chapter 8  Results     234 
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Figure 8.16 - Open field behaviour at baseline 
The same mice as in Figure 8.15 were investigated in a 1m
2, walled, open field area for 5 minutes 
each. Again, no significant differences were observed between any of the genotype groups prior to 
immunisation and complement injection. Latency to reach the outer squares (A), total number of 
squares entered (B), and rearing and grooming counts (C), were recorded. 
Following the immunisation protocol, but before complement injection, no 
significant differences in rotarod performance or limb grip strength 
measurements were seen. Following the immunisation protocol and complement 
injection, there was a small but non-significant fall in latency to fall on the 
rotarod at static speed for NFL Tg mice (n=9) versus GM2 KO (n=10, p= 0.0587) 
and GM2 WT (n=8, p= 0.1340)( Figure 8.17A). There was a greater reduction in Chapter 8  Results     235 
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latency to fall from the accelerating rotarod, which was significantly different in 
the NFL Tg compared to GM2 WT control group (p= 0.0386) but not compared to 
the GM2 KO group (p= 0.1425,Figure 8.17B). No differences were seen in front 
limb or all limb grip strength before or after complement injection (data not 
shown). Statistical assessment was performed using GLM ANOVA with Tukey 
correction for multiple comparisons. 
 
Figure 8.17 - Rotarod testing 
At baseline and prior to NHS injection, all mice achieved maximum latency to fall with a static 
speed rotarod (A), and there were no significant differences between scores with the accelerating 
rotarod (B). Following NHS injection, NFL Tg mice fell from the rod after a shorter interval. The 
change was most pronounced with the accelerating rod, reaching statistical significance as 
compared with the GM2 WT group under this protocol only (*=p<0.05). Chapter 8  Results     236 
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8.2.3.4  Tissue analysis 
Following plethysmography and behavioural testing, diaphragm muscles were 
harvested and processed as for the passive transfer experiments. Although the 
intensity levels were much lower than seen with the ex vivo and passive transfer 
tissue (Figure 8.7 and Figure 8.11), there was still a significant increase in IgG 
staining in the NFL Tg tissue as compared with controls (both p<0.0001). C3 
complement component staining was even weaker and patchier, and the median 
signal intensity for all three strains was zero. However, MAC intensity in the NFL 
Tg tissue was significantly increased as compared to the GM2 KO and GM2 WT 
genotypes (P<0.0001). All statistical comparisons used the Mood Median test 
(given the non-parametric distribution of the data) with n=6 per group. Chapter 8  Results     237 
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Figure 8.18 - Immunoglobulin and complement deposition following active immunisation 
with GT1b-liposomes 
Although all fluorescent staining was considerably weaker following active immunisation, IgG (A) 
and MAC (B) intensities remained significantly elevated in the diaphragms of NFL Tg animals as 
compared with GM2 KO and GM2 WT controls. C3c levels were not significantly different between 
any of the groups. Intensity levels are given in arbitrary units, and statistical comparisons 
performed by the Mood Median test (n=6 per group). Chapter 8  Results     238 
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8.2.4 Active immunisation (GM1:GD1a complex) 
Having demonstrated the principle for a single ganglioside antigen in the form of 
GT1b above the next step taken was to attempt to apply a similar protocol to 
investigate the anti-ganglioside complex response in an active immunisation 
disease model. Although immunofluorescence staining using the initially 
generated neurofilament transgenic mouse line had failed to demonstrate GM1 
binding, subsequent HP-TLC analysis of brain tissue from the later produced 
‘Ed2’ line showed bands corresponding to both GM1 and GD1a. As GM1:GD1a 
complex antibodies were also the most frequently observed in series of GBS 
patients (Kaida et al., 2007) prior to the investigation of the Dutch cohort 
detailed above (p142, Ch5) this complex was chosen to be the immunogen for 
this experiment. 
8.2.4.1  Immune response 
For unexplained reasons, the first round of GM1:GD1a immunisations, in a group 
of 4 NFL Tg mice, failed to induce any detectable immune response in the form 
of either an anti-GM1:GD1a IgM or IgG titre. The initial suspicion was that these 
mice might be tolerant to such a challenge, in keeping with the response seen 
previously in GM2 WT mice. However, when this experiment was repeated with a 
further batch of 4 mice, detectable anti-GM1:GD1a IgG titres were observed at 
day 28 and beyond in all mice.  
Unfortunately, these mice were lost in an animal house mix up. Three mice in a 
subsequent batch died shortly after an iv boost injection and as such further 
analysis was not possible. My time in the laboratory came to an end before these 
experiments could be repeated. Chapter 8  Results     239 
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8.3 Discussion 
The successful transgenic, axonal specific rescue of ganglioside synthesis in GM2 
KO ganglioside deficient mice has allowed the development the first single 
animal active immunisation model of acute motor axonal neuropathy in mice, as 
described above. This model not only provides a useful tool to further 
investigate the pathogenesis of this condition and to assess potential therapeutic 
strategies, but also raises a number of questions of more general relevance. In 
particular, the observation that confirmed axon specific expression of long chain 
gangliosides fails to induce systemic tolerance is intriguing. Is it, as initially 
hypothesised, that absence of ganglioside expression in those immune system 
organs involved in tolerance is responsible for this finding? Alternatively, could 
the reduced level of nervous system ganglioside expression in the NFL Tg simply 
be below a critical threshold required to induce tolerance? Ganglioside 
composition and immunohistochemical analysis of various immune and non-
immune organs from NFL Tg and GM2 WT animals is planned to further 
investigate this. Instead, might the increased levels of GM3, 9-O-acetyl GD3 and 
GD3 present in NFL Tg mice be forming complexes with the reduced levels of 
longer chain gangliosides, which shield them from tolerogenic immune 
recognition but not from antibody attack in states of inflammation?  
Likewise, the observation that perisynaptic Schwann cells are sensitised to 
antibody attack in the transgenic animals ex vivo warrants further consideration. 
As these cells do not themselves synthesise neurofilament, they would be 
expected to remain ganglioside deficient in the NFL Tg mouse, and hence 
resistant to antibody and complement mediated cytotoxicity.  It may simply be 
that the cells are subject to bystander injury resulting from the disruption of the Chapter 8  Results     240 
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juxtaposed neuromuscular junction (NMJ). The fact that similar injury is not 
seen in wild type controls which also sustain NMJ injury argues against this 
possibility. Similarly, the possibility that the antibodies are binding to the 
increased levels of GM3, 9-O-acetyl GD3 and GD3 present in the transgenic 
animals is discounted by the absence of pSc injury in the GM2 KO. Ganglioside 
transfer between nearby cell membranes has previously been observed, at least 
under experimental conditions (Heffer-Lauc et al., 2005). This seems the most 
likely explanation, especially given the occasional immunofluorescent evidence 
of IgG binding to the pSc membranes. This suggests, however, that some 
difference in the way transferred gangliosides sit in the cell membrane renders 
them susceptible to antibody mediated attack, while endogenously produced 
membrane gangliosides are shielded from such recognition in WT animals. 
Different accessibility of endogenous and exogenously administered ganglioside 
has recently been demonstrated for tetanus toxin (TeNT HC). (Chen et al., 2009) 
That the axonal rescue of complex ganglioside expression sensitises the 
diaphragm to anti-ganglioside mediated injury and results in significant paralysis 
in NFL Tg mice following immunisation and complement administration is clear. 
In the absence of such gangliosides in GM2 KO mice, despite higher titres of anti-
ganglioside antibodies, only a small fall in tidal volume is seen. In GM2 WT mice 
without detectable antibody titres but with the target gangliosides normally 
expressed, again only a small fall in tidal volume is seen. The fact that a small 
fall in TV is seen in these mice is consistent with previous observations (Halstead 
S.K. et al., 2008) and can be attributed to a splinting effect from the 1-2ml of 
fluid injected into the abdominal cavity, as well as a settling and acclimatisation 
of the animals to the plethysmography chamber over time. These changes are 
not suggestive of a neuromuscular injury. Chapter 8  Results     241 
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Also in line with previous passive transfer experiments, however, an exogenous 
source of complement is required before the disease phenotype will develop. 
Even in the presence of sustained circulating antibody titres over days to weeks, 
diaphragmatic paralysis only develops when a complement source is injected ip. 
The restricted, local effect of the injected complement source may also explain 
why the wider neurological function of the mice is only mildly disturbed. Why 
such a source is required is not clear, and is an area for future study. It has been 
hypothesised that mouse complement has only a limited potency, and that 
complement regulators such as decay accelerating factor (DAF) and CD59 
(Halstead et al., 2004a) are protective, but this does not seem to be the full 
story. Other scientists in the group have recently observed that some ganglioside 
antibodies are rapidly removed from the cell membrane by an internalisation 
process (Fewou, unpublished observations), and if a similar process operates in 
vivo this may result in a further tier of protection against complement induced 
damage. It may therefore be that a second insult is required to initiate 
complement mediated nerve injury – along the lines of a two-hit hypothesis – 
and this second hit could potentially be one or more of the systemic 
inflammatory response to a septic state, a disruption of the blood nerve barrier, 
or interference with the antibody internalisation process.  
Even though performance on the rotarod was impaired in NFL Tg compared to 
GM2 WT following NHS injection, this is likely to be an indirect measure of 
respiratory embarrassment rather than a sign of more generalised neurological 
dysfunction in most cases, especially as no differences in grip strength were 
observed. Nevertheless, a small subset of animals did seem to develop more 
generalised paralysis following complement injection, although the reason for 
their apparent enhanced sensitivity is not at present known. Many more animals Chapter 8  Results     242 
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did not, and further experiments and modifications to the protocol will 
therefore involve an exploration of the mechanisms by which most 
neuromuscular tissue remains resistant to damage even in the presence of 
systemically produced, circulating antibodies which are apparently auto-
reactive.  
The effect of actively induced anti-ganglioside complex antibodies in the same 
model remains to be elucidated. Investigation of this aspect was unfortunately 
confounded by technical problems and time constraints. 243 
9  Conclusion 
9.1 Summary 
The work described in this thesis has advanced knowledge in the field of 
glycolipid complexes, particularly with respect to anti-glycolipid complex 
antibodies and their association with inflammatory neuropathies such as 
Guillain-Barré syndrome. Far from being an obscure quirk in the immunobiology 
of these diseases, ganglioside complexes have been shown to be of potentially 
much wider relevance, as evidenced by the observation of their influence on the 
interaction of other lectins (such as bacterial toxins and siglecs) with their 
carbohydrate targets. In the PVDF glycoarray, a methodology for efficiently 
assessing these interactions in vitro has been developed with substantial 
advantages over traditional ELISA and TLC techniques. When this technology was 
applied to a cohort of Western European GBS patients, a spectrum of previously 
undiscovered antibody specificities was found to be associated with the disease. 
Most impressively, the antibody detection rate in the AIDP variant was increased 
from 14.3% by ELISA to 62.5% using the glycoarray. Furthermore, a number of 
different antibody specificities correlated with particular clinical features, such 
as the presence or otherwise of sensory deficits, the disease severity and the 
requirement for mechanical ventilation. The single animal active immunisation 
disease model enabled by the neurofilament-light GalNAcT transgenic mouse 
shows that gangliosides expressed solely within the nervous system are not 
sufficient to engender immune tolerance. Immune tolerance, the process 
whereby the immune system does not respond to a particular (usually self or 
self-related) antigen can be central, peripheral or acquired. In the former, Chapter 9  Conclusion     244 
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developing lymphocytes which display a too great self-reactivity are deleted 
prior to their final maturation. Peripheral tolerance can occur if antigen 
presentation does not include the appropriate co-stimulatory molecules or by 
the action of regulatory components of the immune system, such as T reg cells, 
amongst other mechanisms. Acquired tolerance can occur if specific doses of 
antigen (usually very large or very small) are repeatedly administered, most 
notably via the oral route. Whatever the mechanism at play in GBS, the above 
observations support the hypothesis that differential expression of GSCs between 
the immune and nervous systems might allow escape of tolerance in the clinical 
disease.  
Given that only a fraction of people exposed to self-mimicking antigens on 
bacteria such as Campylobacter jejuni go on to generate a self-reactive immune 
response and GBS, and given that around 5% of GBS patients have a recurrence 
of their disease (at least 20 times more often than would be expected by chance 
alone), it seems that there must be some host factor at play which predisposes 
to a breakdown in tolerance. As previously discussed, this host factor has so far 
escaped detection. It is exciting to speculate, based on the observations in NFL 
Tg mice described above, that differences in ganglioside/glycolipid expression 
between the immune and nervous system compartments might allow tolerance 
to be evaded. There may even be disparity in ganglioside complex formation 
between sites were immune tolerance is regulated and the peripheral nerves. 
Alternatively, it could be that antibodies are generated which are not self 
reactive until existing nerve GSCs are disrupted and their target antigen is 
exposed.  Chapter 9  Conclusion     245 
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9.2 Weaknesses 
The are, of course, a number of weaknesses in the work here presented. The 
nature of the complex binding site and of the glycolipid-glycolipid interaction 
producing it have not been directly demonstrated, and as such the concepts 
shown in Figure 3.16 remain speculative. The discrepancy between ELISA, PVDF, 
TLC and indeed ex vivo binding patterns was consistently noted but not 
systematically investigated. The effects of changes in antigen density, the 
solvents used, pH, temperature and the presence of cations such as Ca
2+ were 
not assessed and could potentially explain these differences. GSC specific 
neuropathy associated sera were only occasionally available for ex vivo tissue 
binding studies, and then only in sufficient quantities to use in frozen section 
preparations. In this setting there is concern that any ganglioside complexes 
present might be disrupted as the tissue dies / is frozen.  
The uses of normalised intensity data in early mAb / PVDF studies might also be 
criticised. This was used only to try and minimise differences in the activity of 
the ECL+ and exposure time between assays performed on different days. This 
was felt acceptable when generating replicates to inform comparisons on the 
magnitude and direction of complex modulated binding. When comparisons 
between binding of different lectins to different arrays on different days were 
required this was abandoned and only absolute intensity values were used. Initial 
problems with measuring spot intensity accurately were noted, and on some 
occasions spots clearly more intense by eye would return lower values whereas 
low intensity spots with high background would be overestimated. This was 
largely addressed by appropriately applying the local background correction 
functionality of the ImageQuant/TotalLab software, however some difficulties Chapter 9  Conclusion     246 
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remained when there was significant overlap of neighbouring spots. In such 
circumstances automated background correction would take into account the 
neighbouring spot, leading to an erroneous reduction of reported intensity. This 
meant that a selective disabling of such correction, along with assiduous spot 
definition, was required. This not only made the process much less automated 
and efficient that it would otherwise have been, but additionally introduced a 
degree of subjectivity into spot / background assignment. To reduce the chance 
of bias being introduced into such assessments, digitised PVDF images were 
coded and the analyst blinded to the serum / lectin applied.  
Although inter- and intra- assay coefficient of variation measurements 
performed using the 10x10 array and mAbs were favourable, the performance of 
the larger 28x10 array was less impressive. This was only appreciated when the 
variation in the intensity of certain spots on the positive control sera array were 
compared over the 3 month period taken to process all 181 GBS sera and 74 
controls. In retrospect, optimisation of the larger array should have been 
undertaken prior to proceeding with the above analysis. Additionally, although 
an estimate of the sensitivity, specificity and likelihood ratio statistics of the 
test were calculated, this should ideally be confirmed on a second cohort of GBS 
serum samples. The inadequacy of the control samples in this component of the 
study has previously been discussed in 5.3 above. 
The immunisation data is arguably the weakest component of this study. 
Production of a GSC specific mAb was prioritised over further investigation of 
the nature of the GSC immune response. When major difficulties were 
encountered with the former, the latter aim did not really proceed. Although 
single ganglioside immunisations had been performed previously, and Chapter 9  Conclusion     247 
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observations in these studies could be drawn upon, the lack of a direct 
comparison between parallel immunisation with ganglioside A, ganglioside B and 
ganglioside complex A:B significantly limits the conclusions which can be drawn 
from this work. Likewise, reasons for the huge variability in response between 
different animals of the same genotype, age and sex to the same ganglioside 
complex liposome preparation were not investigated.  
9.3 Parallel developments 
Nevertheless, whilst this work was in progress a handful of other investigators 
have advanced understanding of the functional importance of glycolipid 
complexes using a variety of different approaches. These have proved both 
complimentary to and supportive of observations made in the course of this 
thesis. Researchers in Seattle have shown that GM2:GM3 complexes interact with 
CD82 and inhibit the growth and mobility of HCV29 cancer cells. This effect is 
much enhanced as compared to the effect of either ganglioside in combination, 
and rather than simply being a summative or multiplicative effect of the two 
separate gangliosides, the complex itself appears to be critically important. This 
was demonstrated by creating nanospheres in the presence of Ca
2+, whereby the 
effect of the complex was magnified as compared to aqueous solutions of the 
gangliosides. The authors also demonstrated the heterodimeric complexes form 
in solution in the presence of Ca
2+ using ion-spray mass spectrometry. 
Furthermore, they were able to generate a complex specific GM2:GM3 complex 
monoclonal antibody. The specificity of this was confirmed in all of TLC, ELISA 
and cell based systems (the latter involving exogenous gangliosides reinserted 
into ganglioside null cells). This antibody alone was effective in blocking the 
effect of GM2:GM3 complex on cell motility, whereas antibodies against GM2 and Chapter 9  Conclusion     248 
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GM3 alone where not, although a mixture of the two single-ganglioside specific 
antibodies was not tested in this regard. (Todeschini et al., 2008)  
Confirming the hypothesis stated in the discussion section of chapter 3 (and in 
particular, illustrated in figure 3.16A), Chen and colleagues have now 
demonstrated that the two binding sites of tetanus toxin can bind components of 
two different gangliosides. Furthermore, the observation of the complex 
enhanced effect of GM1:GD3 complexes on tetanus toxin is further supported by 
the demonstration that GM1 binds the ‘W’ pocket and GD3 the ‘R’ pocket of the 
toxin. This was shown initially in solid phase assays using mutated tetanus toxin 
lacking one or both of the binding domains. Interestingly, in cell-based systems 
using PC12 cells displaying endogenous GD1b, GT1b and GQ1b, no binding was 
seen with untreated cells. When these cells were depleted of endogenous 
ganglioside and then reloaded with either GT1b, GM1, GD3, or GM1 and GD3, 
binding was only seen with GT1b and GM1 plus GD3 together. Additionally, both 
binding sites of tetanus toxin were required for high affinity binding in all assays. 
(Chen et al., 2009) Although the gangliosides themselves do not necessarily have 
to form chemical bonds in such a system, these observations are clear evidence 
that components of two different glycolipids can form a functional receptor for 
one lectin molecule.  
In the field of GBS and anti-ganglioside antibodies, it has been previously 
recognised that anti-GD1b antibodies are associated with ataxia, but around 50% 
of those with GD1b-antibodes do not develop ataxia. Kusunoki and co-workers 
were able to show that this apparent inconsistency is explained by the ability or 
otherwise of GD1b antibodies to bind GD1b complexes. In the ataxia group, the 
addition of GD1a or GT1b to GD1b reduced binding significantly more than in the Chapter 9  Conclusion     249 
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non-ataxia group. Furthermore, all 8 of the non-ataxic sera additionally 
contained antibodies binding to other ganglioside complexes not containing 
GD1b, whereas only 2 of 9 ataxic sera had such antibodies. (Kaida et al., 2008) 
Once again, this is further evidence to support the assertion that the fine 
specificity of antibodies with respect to their complex enhanced or attenuated 
qualities has important pathogenic implications. 
Nevertheless, significant questions in this field remain unanswered. Although 
some lectins display consistent patterns of binding to GSCs throughout the range 
of immunoassays performed, many others do not. By extension, this casts doubt 
on whether these lectins and others interact with GSCs in the most important 
system of all, the living membrane. Indeed, evidence for the existence of GSCs 
in vivo remains limited and largely circumstantial, as above. With this in mind, a 
more detailed understanding of the nature and mechanism of glycolipid cis 
interactions is additionally lacking. The variability in binding of the same 
antibody in different solid phase systems highlights the potential pitfalls in 
concluding if an antibody binds exclusively to a GSC in an in vitro system, and 
also binds to tissue, that the tissue likewise contains the GSC (and vice versa).  
Whether even more complex multimers of glycolipids, with or without proteins 
and glycoproteins, can also influence lectin interactions and act as distinct 
antigenic targets themselves is also not known. As previously discussed, 
examining these increasingly complex structures multiplies the difficulty of the 
necessary experimentation and will require targeted rather than wide ranging 
screening type approaches.  Chapter 9  Conclusion     250 
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9.4 Future work 
The work described in this thesis thus contributes to the existing body of 
knowledge but also suggests further investigations, which may be usefully 
pursued in future. These form two distinct but complementary lines of enquiry. 
The first would address the intrinsic nature of glycolipids and glycolipid 
complexes in vivo and investigate their behaviour, location and turnover in the 
living membrane. It is clearly important for further understanding of lectin-
carbohydrate interactions in their many forms that this is understood in greater 
detail. As has been stated, relying on even apparently highly specific monoclonal 
antibodies for these studies is potentially flawed. Other methods might be more 
usefully utilised. Clearly, light microscopy lacks the resolution to delineate 
individual gangliosides or complexes thereof. Fluorescence related energy 
transfer (FRET) approaches are one possibility. In these techniques, energy 
omitted from one fluorophore excites another in close proximity (within ≈10nm) 
producing a signal. (Stryer & Haugland, 1967) Although such approaches require 
labelling of the molecules under study, potentially modifying their interactions, 
these studies can be performed in membranes, and do not involve antibodies. 
(Silvius & Nabi, 2006) However, this technology would rely on assessing either 
artificial bilayers or cells into which exogenously labelled gangliosides had been 
reintroduced. From the earlier discussion, it is apparent that endogenous and 
exogenous ganglioside in the cell membrane do not necessarily interact in the 
same way, potentially confounding such an approach. Another possibility would 
be to use a scanning probe microscopy method like atomic force microscopy 
(AFM) to map out the distribution of glycolipids in membrane systems. This 
technique employs a nanometre scale probe to map out the topography of cell Chapter 9  Conclusion     251 
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surfaces and lipid bilayers, and has previously been used to demonstrate the 
existence of lipid microdomains. (Connell & Smith, 2006)  
Aside from this, future work might also further investigate the generation and 
pathological importance of anti-glycolipid complexes in the inflammatory 
neuropathies. A major limitation in the work just described was the failure to 
generate a complex specific monoclonal antibody. Armed with such a reagent, 
and appropriate controls, multiple further experiments would be possible. Most 
simply, one could look for pathological readout in systems similar to those 
previously used – namely ex vivo neuromuscular tissue assessed by 
electrophysiology, fluorescent microscopy looking for cytoskeletal degradation, 
and by passive transfer into animals. Attempts to model anti-complex antibody 
mediated neuropathy by active immunisation were precluded by time constraints 
but could easily be revisited. It would also be informative to assess the binding 
pattern of complex antibodies in neuromuscular tissue. This might directly 
address the hypothesis that motor and sensory nerves have different sensitivity 
to differing antibodies because of their different ganglioside complex profiles, 
and might provide further insight into the mechanism by which self tolerance is 
overcome if immune tissue was additionally examined for the presence of 
binding to the same complexes. The caveats regarding the conclusion that 
binding of an apparent complex specific antibody in vivo equates to the 
presence of the complex in the living membrane of course remain.  
The mechanisms by which these antibodies are generated and the cells involved 
in this process have also not been investigated. B1 cells are present in the 
peritoneal cavity and associated with the production of natural antibody of the 
IgM subclass. Although it would not be expected that these cells themselves Chapter 9  Conclusion     252 
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produce pathogenic IgG GSC antibodies, they may be involved with the early 
immune response and have the potential to modify the future reactivity. Both B 
cells, notably in the marginal zone, and also dendritic cells, express CD1 
molecules and seem likely to be involved in the presentation of processed 
glycolipid antigens to T cells. The various contributions of these cell types to the 
glycolipid immune response remain to be conclusively demonstrated, as do the 
particular aberrations which must occur to lead to the dysimmune pathology in 
GBS. 
The majority of previous work in this field has focussed on ganglioside 
antibodies, yet the glycoarray analysis of a cohort of largely AIDP cases 
demonstrated the frequent presence of antibodies towards complexes of 
sulfatide and SGPG. Further investigation of these will likely require a 
modification of existing approaches. It seems likely that wild type mice will 
prove tolerant to sulfatide and sulfatide complex immunisations (although this 
remains to be demonstrated). Future studies may therefore need to utilise 
sulfatide deficient animals. (Fewou et al., 2010) Conversely, mice lack SGPG and 
previous studies of anti-SGPG neuropathies have used other animals, including 
cats. (Ilyas et al., 2008)  Chapter 9  Conclusion     253 
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Area for further investigation  Potential studies / Methods 
1. Biophysical properties of GSCs in membranes  FRET, AFM  
Ex vivo studies with GSC specific mAbs  
2. Distribution of GSCs in vivo 
FRET, AFM 
Ex vivo studies with GSC specific mAbs 
Obtain GSC specific disease associated sera in 
greater quantities than routinely available for 
pathogenic studies 
3. Interaction of GSCs with the immune system 
Cloning of GSC specific mAbs (including 
sulfatide complex antibodies) 
4. Pathological potential of αGSC antibodies 
Ex vivo studies with GSC specific mAbs  
Cloning of GSC specific mAbs (including 
sulfatide complex antibodies)  
Obtain GSC specific disease associated sera in 
greater quantities than routinely available for 
pathogenic studies 
5. Clinical serological associations 
Confirm association and define test 
characteristics of the glycoarray using a second 
cohort of GBS patients 
Include larger numbers of controls, ideally 
post-infectious, non-neuropathy inflammatory, 
and non-inflammatory neuropathy 
Table 9.1 - Summary of proposed future work 
 
It therefore seems likely that a combination of approaches will be required to 
identify and evaluate putative pathogenic antibodies in GBS, and in AIDP in 
particular (Table 9.1). However, a greater understanding of this pathological 
process would seem be one of the first crucial steps in advancing disease 
modifying treatment for these conditions. As yet, this has not changed 
significantly in over 20 years.       254 
 
2
5
4
 
Appendices 
1  Commonly used solutions 
PBS 
NaCl      80g 
KH2PO4    2g 
Na2HPO4.12H2O  29g 
KCl      2g 
 
Make up to 1000ml with dH2O. 
 
Dilute 1 in 10 to use. 
 
pH to 7.4. 
 
 
2%/1% BSA 
2g/1g bovine serum albumin 
100ml PBS 
 
 
OPD detection buffer 
14ml 0.1M Citrate (10.507g to 500ml dH2O) 
16ml 0.2M Na2HPO4 (14.196g to 500ml dH2O) 
30ml dH2O 
1x OPD tablet (Sigma) 
20µl H2O2 
 
 
OPD stop solution  
4M H2SO4 (54ml to 500ml dH2O, perform in hood, add acid slowly to water)      255 
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Orcinol   
0.1g orcinol 
97ml dH2O 
3ml H2SO4 (add last, slowly) 
 
 
Resorcinol 
2.5ml 2% resorcinol 
62.5µl 0.1M CuSO4 
2.427ml dH2O 
20ml HCl (add last) 
 
 
0.4% PIBM 
0.1g polyisobutlymethacrylate 
Dissolve in 1ml of chloroform 
Make up to 25ml with n-hexane 
 
 
Ringer’s medium 
NaCl      67.79g 
KCl      3.35g 
NaHCO3    19.32g 
NaH2PO4    1.19g    (or NaH2PO4.2H2O, 1.56g) 
Glucose    19.82g 
1M MgCl2    10ml 
 
Make up to 1000ml with dH2O. 
 
Dilute 1 in 10 to use, bubble with O2 and add 2ml 1M CaCl2 per 1000ml. 
 
pH to 7.4. 
 
 
20% / 10% complete medium 
500ml RPMI with L-glutamine 
100ml / 50ml foetal bovine serum 
10ml penicillin / streptomycin solution      256 
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2  Example array programme 
Layout for 10x10 grid 
                       
  34  36  38  40  42  44  46  48  50  52  54 
15  +  GM1  GM2  GM3  GD1a  GD1b  GD3  GT1a  GT1b  GQ1b  + 
17  GM1  -  1  2  3  4  5  6  7  8   
19  GM2  1  -  9  10  11  12  13  14  15   
21  GM3  2  9  -  16  17  18  19  20  21   
23  GD1a  3  10  16  -  22  23  24  25  26   
25  GD1b  4  11  17  22  -  27  28  29  30   
27  GD3  5  12  18  23  27  -  31  32  33   
29  GT1a  6  13  19  24  28  31  -  34  35   
31  GT1b  7  14  20  25  29  32  34  -  36   
33  GQ1b  8  15  21  26  30  33  35  36  -   
35  +                    + 
      257 
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Programme for first slide 
  Position x  Position y  Type  Width (x)  Height (y)  Volume  Vial 
1  15  34  Band  0.4  0.4  0.1  e3 : 47 
2  17  34  Band  0.4  0.4  0.1  a2 : 2 
3  19  34  Band  0.4  0.4  0.1  a3 : 3 
4  21  34  Band  0.4  0.4  0.1  a4 : 4 
5  23  34  Band  0.4  0.4  0.1  a5 : 5 
6  25  34  Band  0.4  0.4  0.1  a6 : 6 
7  27  34  Band  0.4  0.4  0.1  a7 : 7 
8  29  34  Band  0.4  0.4  0.1  a8 : 8 
9  31  34  Band  0.4  0.4  0.1  a9 : 9 
10  33  34  Band  0.4  0.4  0.1  a10 : 10 
11  35  34  Band  0.4  0.4  0.1  e3 : 47 
12  15  36  Band  0.4  0.4  0.1  a2 : 2 
13  17  36  Band  0.4  0.4  0.1  A1 : 1 
14  19  36  Band  0.4  0.4  0.1  a11 : 11 
15  21  36  Band  0.4  0.4  0.1  b1 : 12 
16  23  36  Band  0.4  0.4  0.1  b2 : 13 
17  25  36  Band  0.4  0.4  0.1  b3 : 14 
18  27  36  Band  0.4  0.4  0.1  b4 : 15 
19  29  36  Band  0.4  0.4  0.1  b5 : 16 
20  31  36  Band  0.4  0.4  0.1  b6 : 17 
21  33  36  Band  0.4  0.4  0.1  b7 : 18 
22  15  38  Band  0.4  0.4  0.1  a3 : 3 
23  17  38  Band  0.4  0.4  0.1  a11 : 11 
24  19  38  Band  0.4  0.4  0.1  A1 : 1 
25  21  38  Band  0.4  0.4  0.1  b8 : 19 
26  23  38  Band  0.4  0.4  0.1  b9 : 20 
27  25  38  Band  0.4  0.4  0.1  b10 : 21 
28  27  38  Band  0.4  0.4  0.1  b11 : 22 
29  29  38  Band  0.4  0.4  0.1  c1 : 23 
30  31  38  Band  0.4  0.4  0.1  c2 : 24 
31  33  38  Band  0.4  0.4  0.1  c3 : 25 
32  15  40  Band  0.4  0.4  0.1  a4 : 4 
33  17  40  Band  0.4  0.4  0.1  b1 : 12 
34  19  40  Band  0.4  0.4  0.1  b8 : 19 
35  21  40  Band  0.4  0.4  0.1  A1 : 1 
36  23  40  Band  0.4  0.4  0.1  c4 : 26 
37  25  40  Band  0.4  0.4  0.1  c5 : 27 
38  27  40  Band  0.4  0.4  0.1  c6 : 28 
39  29  40  Band  0.4  0.4  0.1  c7 : 29 
40  31  40  Band  0.4  0.4  0.1  c8 : 30 
41  33  40  Band  0.4  0.4  0.1  c9 : 31 
42  15  42  Band  0.4  0.4  0.1  a5 : 5 
43  17  42  Band  0.4  0.4  0.1  b2 : 13 
44  19  42  Band  0.4  0.4  0.1  b9 : 20 
45  21  42  Band  0.4  0.4  0.1  c4 : 26 
46  23  42  Band  0.4  0.4  0.1  A1 : 1 
47  25  42  Band  0.4  0.4  0.1  c10 : 32 
48  27  42  Band  0.4  0.4  0.1  c11 : 33 
49  29  42  Band  0.4  0.4  0.1  d1 : 34 
50  31  42  Band  0.4  0.4  0.1  d2 : 35 
51  33  42  Band  0.4  0.4  0.1  d3 : 36 
52  15  44  Band  0.4  0.4  0.1  a6 : 6      258 
 
2
5
8
 
53  17  44  Band  0.4  0.4  0.1  b3 : 14 
54  19  44  Band  0.4  0.4  0.1  b10 : 21 
55  21  44  Band  0.4  0.4  0.1  c5 : 27 
56  23  44  Band  0.4  0.4  0.1  c10 : 32 
57  25  44  Band  0.4  0.4  0.1  A1 : 1 
58  27  44  Band  0.4  0.4  0.1  d4 : 37 
59  29  44  Band  0.4  0.4  0.1  d5 : 38 
60  31  44  Band  0.4  0.4  0.1  d6 : 39 
61  33  44  Band  0.4  0.4  0.1  d7 : 40 
62  15  46  Band  0.4  0.4  0.1  a7 : 7 
63  17  46  Band  0.4  0.4  0.1  b4 : 15 
64  19  46  Band  0.4  0.4  0.1  b11 : 22 
65  21  46  Band  0.4  0.4  0.1  c6 : 28 
66  23  46  Band  0.4  0.4  0.1  c11 : 33 
67  25  46  Band  0.4  0.4  0.1  d4 : 37 
68  27  46  Band  0.4  0.4  0.1  A1 : 1 
69  29  46  Band  0.4  0.4  0.1  d8 : 41 
70  31  46  Band  0.4  0.4  0.1  d9 : 42 
71  33  46  Band  0.4  0.4  0.1  d10 : 43 
72  15  48  Band  0.4  0.4  0.1  a8 : 8 
73  17  48  Band  0.4  0.4  0.1  b5 : 16 
74  19  48  Band  0.4  0.4  0.1  c1 : 23 
75  21  48  Band  0.4  0.4  0.1  c7 : 29 
76  23  48  Band  0.4  0.4  0.1  d1 : 34 
77  25  48  Band  0.4  0.4  0.1  d5 : 38 
78  27  48  Band  0.4  0.4  0.1  d8 : 41 
79  29  48  Band  0.4  0.4  0.1  A1 : 1 
80  31  48  Band  0.4  0.4  0.1  d11 : 44 
81  33  48  Band  0.4  0.4  0.1  e1 : 45 
82  15  50  Band  0.4  0.4  0.1  a9 : 9 
83  17  50  Band  0.4  0.4  0.1  b6 : 17 
84  19  50  Band  0.4  0.4  0.1  c2 : 24 
85  21  50  Band  0.4  0.4  0.1  c8 : 30 
86  23  50  Band  0.4  0.4  0.1  d2 : 35 
87  25  50  Band  0.4  0.4  0.1  d6 : 39 
88  27  50  Band  0.4  0.4  0.1  d9 : 42 
89  29  50  Band  0.4  0.4  0.1  d11 : 44 
90  31  50  Band  0.4  0.4  0.1  A1 : 1 
91  33  50  Band  0.4  0.4  0.1  e2 : 46 
92  15  52  Band  0.4  0.4  0.1  a10 : 10 
93  17  52  Band  0.4  0.4  0.1  b7 : 18 
94  19  52  Band  0.4  0.4  0.1  c3 : 25 
95  21  52  Band  0.4  0.4  0.1  c9 : 31 
96  23  52  Band  0.4  0.4  0.1  d3 : 36 
97  25  52  Band  0.4  0.4  0.1  d7 : 40 
98  27  52  Band  0.4  0.4  0.1  d10 : 43 
99  29  52  Band  0.4  0.4  0.1  e1 : 45 
100  31  52  Band  0.4  0.4  0.1  e2 : 46 
101  33  52  Band  0.4  0.4  0.1  A1 : 1 
102  15  54  Band  0.4  0.4  0.1  e3 : 47 
103  35  54  Band  0.4  0.4  0.1  e3 : 47 
 
Subsequent slides produced by sequentially adding 31.4mm to x co-ordinates 5 times. Second 
column of six slides produced by adding 92mm to y co-ordinates of first six.      259 
 
2
5
9
 
Vial assignment 
A1 : 1  -  - (Methanol)   
A2 : 2    GM1  100µg/ml 
A3 : 3    GM2  100µg/ml 
A4 : 4    GM3  100µg/ml 
A5 : 5    GD1a  100µg/ml 
A6 : 6    GD1b  100µg/ml 
A7 : 7    GD3  100µg/ml 
A8 : 8    GT1a  100µg/ml 
A9 : 9    GT1b  100µg/ml 
A10 : 10    GQ1b  100µg/ml 
A11 : 11  1  GM1/GM2  100µg/ml 
B1 : 12  2  GM1/GM3  100µg/ml 
B2 : 13  3  GM1/GD1a  100µg/ml 
B3 : 14  4  GM1/GD1b  100µg/ml 
B4 : 15  5  GM1/GD3  100µg/ml 
B5 : 16  6  GM1/GT1a  100µg/ml 
B6 : 17  7  GM1/GT1b  100µg/ml 
B7 : 18  8  GM1/GQ1b  100µg/ml 
B8 : 19  9  GM2/GM3  100µg/ml 
B9 : 20  10  GM2/GD1a  100µg/ml 
B10 : 21  11  GM2/GD1b  100µg/ml 
B11 : 22  12  GM2/GD3  100µg/ml 
C1 : 23  13  GM2/GT1a  100µg/ml 
C2 : 24  14  GM2/GT1b  100µg/ml 
C3 : 25  15  GM2/GQ1b  100µg/ml 
C4 : 26  16  GM3/GD1a  100µg/ml 
C5 : 27  17  GM3/GD1b  100µg/ml 
C6 : 28  18  GM3/GD3  100µg/ml 
C7 : 29  19  GM3/GT1a  100µg/ml 
C8 : 30  20  GM3/GT1b  100µg/ml 
C9 : 31  21  GM3/GQ1b  100µg/ml 
C10 : 32  22  GD1a/GD1b  100µg/ml 
C11 : 33  23  GD1a/GD3  100µg/ml 
D1 : 34  24  GD1a/GT1a  100µg/ml 
D2 : 35  25  GD1a/GT1b  100µg/ml 
D3 : 36  26  GD1a/GQ1b  100µg/ml 
D4 : 37  27  GD1b/GD3  100µg/ml 
D5 : 38  28  GD1b/GT1a  100µg/ml 
D6 : 39  29  GD1b/GT1b  100µg/ml 
D7 : 40  30  GD1b/GQ1b  100µg/ml 
D8 : 41  31  GD3/GT1a  100µg/ml 
D9 : 42  32  GD3/GT1b  100µg/ml 
D10 : 43  33  GD3/GQ1b  100µg/ml 
D11 : 44  34  GT1a/GT1b  100µg/ml 
E1 : 45  35  GT1a/GQ1b  100µg/ml 
E2 : 46  36  GT1b/GQ1b  100µg/ml 
E3 : 47  +  + (Blue)   
      260 
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3  Antigens significantly associated with GBS 
using stepup correction 
Antigen  Bonferroni (p-
value) 
Stepup 
(p-value) 
Disease Mean  Control Mean 
Sulfatide :GalC  0.11  0.01  1.90  0 
Phosphatidylserine:GM1  0.11  0.01  2.06  0 
Sulfatide :GD1b  0.12  0.01  1.99  0 
Sulfatide :GM1  0.14  0.01  2.08  0 
Phosphatidylserine:Asialo-GM1  0.16  0.01  1.90  0 
GD2:Sulfatide  0.17  0.01  2.38  0.36 
SGPG:GM1  0.21  0.01  1.70  0 
Phosphatidylserine:GD1b  0.22  0.01  1.78  0 
GM1:LM1  0.60  0.03  1.57  0 
GM1  0.61  0.03  1.45  0 
GM1:GT1a  0.74  0.04  1.43  0 
SGPG:GD1b  0.93  0.04  1.22  0 
LM1:GD1b  1  0.04  1.41  0 
GM1:GD1b  1  0.04  1.34  0 
GM3:GD1b  1  0.04  1.29  0 
GD2:Asialo-GM1  1  0.04  1.29  0 
Phosphatidylserine  1  0.04  1.37  0.16 
Asialo-GM1:LM1  1  0.04  1.67  0.14 
Asialo-GM1:GM1  1  0.04  1.19  0 
GM1:GD1a  1  0.04  1.39  0 
GalC:GT1a  1  0.04  1.36  0 
Asialo-GM1:GD3  1  0.04  1.34  0 
GM1:GD3  1  0.04  1.25  0 
SGPG:GalC  1  0.04  1.16  0 
GM3:GM1  1  0.04  1.27  0 
Sphingomyelin:GM1  1  0.04  1.23  0 
Asialo-GM1:GD1a  1  0.04  1.27  0 
GD1b  1  0.04  1.20  0 
Phosphatidylserine:GalC  1  0.04  1.12  0 
LM1:GT1a  1  0.05  1.21  0 
GalC:GM1  1  0.05  1.22  0 
      261 
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4  Publications arising 
Combinatorial glycoarray. 
Rinaldi S, Brennan KM, Willison HJ. 
Methods in Molecular Biology. 2012 Jan 808:413-423.      262 
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Lipid arrays identify myelin-derived lipids and lipid 
complexes as prominent targets for oligoclonal band 
antibodies in multiple sclerosis. 
 
Brennan KM, Galban-Horcajo F, Rinaldi S, O'Leary CP, Goodyear CS, Kalna G, 
Arthur A, Elliot C, Barnett S, Linington C, Bennett JL, Owens GP, Willison HJ. 
 
Journal of Neuroimmonology. 2011 Sep 15;238(1-2):87-95      274 
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The GD1a glycan is a cellular receptor for adenoviruses 
causing epidemic keratoconjunctivitis. 
Nilsson EC, Storm RJ, Bauer J, Johansson SM, Lookene A, Ångström J, 
Hedenström M, Eriksson TL, Frängsmyr L, Rinaldi S, Willison HJ, Pedrosa 
Domellöf F, Stehle T, Arnberg N. 
Nature Medicine. 2011 Jan;17(1):105-9 
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Transgenic rescue of ganglioside expression in the 
peripheral nervous system of ganglioside-null mice 
facilitates an active immunisation model of acute motor 
axonal neuropathy 
Yao D, Rinaldi S, Greenshields K, McKinnon A, Fewou S, Furukawa K, Brophy PJ, 
Willison HJ. 
Journal of the Peripheral Nervous System 2010 (Abstract) 
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Title: 
TRANSGENIC RESCUE OF GANGLIOSIDE EXPRESSION IN THE PERIPHERAL 
NERVOUS SYSTEM OF GANGLIOSIDE-NULL MICE FACILITATES AN ACTIVE 
IMMUNISATION MODEL OF ACUTE MOTOR AXONAL NEUROPATHY  
 
Authors: 
Denggao Yao (1), Simon Rinaldi (1), Kay Greenshields (1), Allan McKinnon (1), Simon 
Fewou (1), Koichi Furukawa (2), Peter J. Brophy (3), Hugh J. Willison (1) 
 
Institution(s): 
(1) Division of Clinical Neurosciences, University of Glasgow, Glasgow, UK 
(2) Department of Biochemistry, Nagoya University School of Medicine, Nagoya, Japan 
(3) Centre for Neuroregeneration, University of Edinburgh, Edinburgh, UK 
 
Body of Abstract: 
In the motor axonal variant of Guillain-Barré syndrome (GBS) antibodies to complex gangliosides are 
frequently found. Evidence shows that these antibodies have pathogenic effects on the structure and 
function of the neuromuscular junction (NMJ) and nodes of Ranvier. Mouse models of this disease are 
confounded by the fact that wild type (WT) mice, expressing the normal complement of gangliosides, 
are immunologically tolerant when immunised with exogenous gangliosides. Conversely, N-
acetylgalactosaminyl-transferase knockout (GalNAcT
-/-) mice, lacking all complex gangliosides, 
produce high affinity antibody responses to complex ganglioside immunisation, but do not develop 
neuropathology as they lack the target antigen. Our current model therefore relies on passive 
immunisation into WT mice of anti-ganglioside antibody generated in GalNAcT
-/- mice. To overcome 
this double step, and assess the tolerogenic effect of gangliosides solely expressed in axons, we crossed 
a transgenic mouse expressing GalNAcT driven by an axonal neurofilament-light (NFL) promoter onto 
a GalNAcT
-/- background to create GalNAcT Tg/KO mice. Rescue of neuronal ganglioside expression 
was demonstrated by thin layer chromatography of brain glycolipid, and by immunofluorescence 
staining of neuromuscular tissue, using an anti-GT1b ganglioside antibody. The sensitivity of the 
transgenic NMJ to anti-GT1b antibody and complement mediated injury was first established using ex 
vivo preparations of hemidiaphragm. Antibody bound to the pre-synaptic membrane, fixed 
complement, and led to membrane attack complex deposition in GalNAcT Tg/KO and WT mice, but 
not in GalNAcT
-/- mice. In in vivo passive transfer studies with intra-peritoneal (IP) anti-GT1b antibody 
plus complement, GalNAcT Tg/KO mice developed respiratory failure, whereas GalNAcT
-/- mice did 
not. Furthermore, immunisation of transgenic animals with GT1b-liposomes produces a vigorous 
antibody response indistinguishable from that seen in GalNAcT
-/- mice, compared with a blunted 
response in WT mice. When provided with a source of complement delivered IP, GT1b immunised 
transgenic mice develop diaphragmatic paralysis. This model demonstrates that local axonal expression 
of ganglioside does not induce systemic immunological tolerance, and in doing so allows for the 
production of an active immunisation model of motor axonal GBS in a single mouse line, through the 
re-sensitisation of axons to antibody mediated injury. 
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Ganglioside complexes (GSCs) have been demonstrated as ligands for antibodies and 
lectins, including those found in the serum of Guillain-Barré syndrome patients. 
Investigating such reactivity using ELISA is problematic, principally because of the 
increased quantities of antigen and antisera required to accommodate the combinatorial 
dimension. To overcome this, we have developed a miniaturised system using a TLC 
autosampler to create matrices of 100 glycolipids and their 1:1 complexes in 100 nanolitre 
volumes on 20x20mm polyvinyl-difluoride (PVDF) membranes. These PVDF glycoarrays 
are then probed with a variety of different lectins, and binding detected by 
chemiluminescence and autoradiography. Using a prototypic anti-GM1 monoclonal 
antibody, the inter- and intra-assay coefficients of variation were calculated as 4.1% and 
8.6%, comparable with ELISA. We have demonstrated that the binding of neuropathy sera 
to glycolipids can be enhanced, attenuated, or unaffected by complexes, and that this 
phenomenon is observed for other carbohydrate binding proteins. Thus, a tetanus 
neurotoxin binding fragment binds GM1:GD3 (‘complex enhanced’) whilst failing to react 
with either component ganglioside alone. The immunomodulatory receptor siglec-7 
displays the reverse pattern, binding GD3 in isolation, but not when this ganglioside is 
complexed with GM1 (‘complex attenuated’). Conversely, the anti-disialosyl monoclonal 
antibody CGM3 reacts equally with all GD3 containing complexes (‘complex 
independent’). This complex independent pattern is also seen for cholera toxin B and 
GM1.  We have shown that the GSC reactivities of a pair of anti-GM1 monoclonal 
antibodies in vitro correlate with their pathological potential in vivo. One antibody is 
prevented from binding GM1 in solid phase assays and live neural tissue by the presence 
of a cis interaction between GM1 and GD1a, and is therefore ‘non-pathogenic’. 
Conversely, a second anti-GM1 antibody is able to bind GM1:GD1a complexes in assays 
and live tissue, and thereby exert pathogenic effects. Immunising GalNAcT
-/- mice (lacking 
all complex gangliosides) with GSC-containing unilamellar liposomes created by a freeze-
thaw-extrusion method can induce a complex independent IgM response which transforms 
to complex dependency on IgG class switching. These studies are advancing our 
knowledge of the immunological, pathological and clinical relevance of GSCs in 
autoimmune peripheral neuropathies and in other paradigms involving protein-
carbohydrate interactions.      314 
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